



(43) International Publication Date
20 July 2017 (20.07.2017)

(10) International Publication Number
WO 2017/121650 A1

- (51) **International Patent Classification:**
C07D 235/02 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4166 (2006.01)
- (21) **International Application Number:**
PCT/EP2017/025008
- (22) **International Filing Date:**
13 January 2017 (13.01.2017)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
16 151 015.1 13 January 2016 (13.01.2016) EP
- (71) **Applicant:** GRÜNENTHAL GMBH [DE/DE]; Ziegler-
strasse 6, 52078 Aachen (DE).
- (72) **Inventors:** KÜHNERT, Sven; Bachstrasse 62, 52355
Düren (DE). KOENIGS, René Michael; Frankenring 219,
41812 Erkelenz (DE). KLESS, Achim; Berensberger
Winkel 14, 52072 Aachen (DE). WEGERT, Anita; Fritz-
Erler-Ring 52, 52457 Aldenhoven (DE). RATCLIFFE,
Paul; Im Vennbahnbogen 20, 52076 Aachen (DE).
JOSTOCK, Ruth; Hostetstrasse 35, 52223 Stolberg (DE).
KOCH, Thomas; Frankenstr. 2, 52223 Stolberg (DE).
LINZ, Klaus; Nachtigallengrund 5, 53359 Rheinbach
(DE). SCHRÖDER, Wolfgang; Auf der Hörn 92, 52074
Aachen (DE).

(81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) **Title:** 8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES

(57) **Abstract:** The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in
medicine, particularly in the treatment of pain.



WO 2017/121650 A1

8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives

[0001] The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.

[0002] Opioid receptors are a group of Gi/o protein-coupled receptors which are widely distributed in the human body. The opioid receptors are currently subdivided into four major classes, i.e. the three classical opioid receptors mu-opioid (MOP) receptor, kappa-opioid (KOP) receptor, and delta-opioid (DOP) receptor as well as the opioid receptor-like (ORL-1) receptor, which was more recently discovered based on its high homology with said classical opioid receptors. After identification of the endogenous ligand of the ORL-1 receptor, known as nociceptin/orphanin FQ, a highly basic 17 amino acid peptide isolated from tissue extracts in 1995, the ORL-1 receptor was renamed "nociceptin opioid peptide receptor" and abbreviated as "NOP-receptor".

[0003] The classical opioid receptors (MOP, KOP and DOP) as well as the NOP receptor are widely distributed/expressed in the human body, including in the brain, the spinal cord, on peripheral sensory neurons and the intestinal tract, wherein the distribution pattern differs between the different receptor classes.

[0004] Nociceptin acts at the molecular and cellular level in very much the same way as opioids. However, its pharmacological effects sometimes differ from, and even oppose those of opioids. NOP-receptor activation translates into a complex pharmacology of pain modulation, which, depending on route of administration, pain model and species involved, leads to either pronociceptive or antinociceptive activity. Furthermore, the NOP receptor system is upregulated under conditions of chronic pain. Systemic administration of selective NOP receptor agonists was found to exert a potent and efficacious analgesia in non-human primate models of acute and inflammatory pain in the absence of side effects. The activation of NOP receptors has been demonstrated to be devoid of reinforcing effects but to inhibit opioid-mediated reward in rodents and non-human primates (Review: Schroeder et al, Br J Pharmacol 2014; 171 (16): 3777-3800, and references therein).

[0005] Besides the involvement of the NOP receptor in nociception, results from preclinical experiments suggest that NOP receptor agonists might be useful inter alia in the treatment of neuropsychiatric disorders (Witkin et al, Pharmacology & Therapeutics, 141 (2014) 283-299; Jenck et al., Proc. Natl. Acad. Sci. USA 94, 1997, 14854-14858). Remarkably, the DOP receptor is also implicated to modulate not only pain but also neuropsychiatric disorders (Mabrouk et al, 2014; Pradhan et al., 2011).

[0006] Strong opioids acting at the MOP receptor site are widely used to treat moderate to severe acute and chronic pain. However, the therapeutic window of strong opioids is limited by severe side effects such as nausea and vomiting, constipation, dizziness, somnolence, respiratory depression, physical dependence and abuse. Furthermore, it is known that MOP receptor agonists show only reduced effectiveness under conditions of chronic and neuropathic pain.

[0007] It is known that some of the above mentioned side-effects of strong opioids are mediated by activation of classic opioid-receptors within the central nervous system. Furthermore, peripheral opioid receptors, when activated, can inhibit transmission of nociceptive signals shown in both, clinical and animal studies (Gupta et al., 2001; Kalso et al., 2002; Stein et al., 2003; Zollner et al., 2008).

[0008] Thus, to avoid CNS-mediated adverse effects after systemic administration, one approach has been to provide peripherally restricted opioid receptor ligands that do not easily cross the blood-brain barrier and therefore distribute poorly to the central nervous system (see for instance WO 2015/192039). Such peripherally acting compounds might combine effective analgesia with limited side-effects.

[0009] Another approach has been to provide compounds which interact with both the NOP receptor and the MOP receptor. Such compounds have for instance been described in WO 2004/043967, WO 2012/013343 and WO 2009/118168.

[0010] A further approach has been to provide multi-opioid receptor analgesics that modulate more than one of the opioid receptor subtypes to provide additive or synergistic analgesia and/or reduced side effects like abuse liability or tolerance.


[0011] On the one hand, it would be desirable to provide analgesics that selectively act on the NOP receptor system but less pronounced on the classic opioid receptor system, especially MOP receptor system, whereas it would be desirable to distinguish between central nervous activity and peripheral nervous activity. On the other hand, it would be desirable to provide analgesics that act on the NOP receptor system and also to a balanced degree on the MOP receptor system, whereas it would be desirable to distinguish between central nervous activity and peripheral nervous activity.

[0012] There is a need for medicaments which are effective in the treatment of pain and which have advantages compared to the compounds of the prior art. Where possible, such medicaments should contain such a small dose of active ingredient that satisfactory pain therapy can be ensured without the occurrence of intolerable treatment-emergent adverse events.

[0013] It is an object of the invention to provide pharmacologically active compounds, preferably analgesics that have advantages compared to the prior art.

[0014] This object has been achieved by the subject-matter of the patent claims.

[0015] A first aspect of the invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives according to general formula (I)



wherein

R¹ and R² independently of one another mean

-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH₃, -CN and -CO₂CH₃;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH₃, -CN and -CO₂CH₃; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH₃, -CN and -CO₂CH₃; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted;

or

R¹ and R² together with the nitrogen atom to which they are attached form a ring and mean -(CH₂)₃₋₆-; -(CH₂)₂-O-(CH₂)₂-; or -(CH₂)₂-NR^A-(CH₂)₂-, wherein R^A means -H or -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br and -I;

preferably with the proviso that R¹ and R² do not simultaneously mean -H;

R³ means

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

R⁴ means

-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said -C₁-C₆-alkyl is optionally connected through -C(=O)-, -C(=O)O-, or -S(=O)₂-;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered cycloalkyl moiety is optionally optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH₂-, or -S(=O)₂-;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH₂-, or -S(=O)₂-;

a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6-14-membered aryl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH₂-, or -S(=O)₂-; or

a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5-14-membered heteroaryl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH₂-, or -S(=O)₂-;

R⁵ means


-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

a moiety according to general formula (X);



R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ independently of one another mean -H, -F, -Cl, -Br, -I, -OH, or -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

wherein "mono- or polysubstituted" means that one or more hydrogen atoms are replaced by a substituent independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -R²¹, -C(=O)R²¹, -C(=O)OR²¹, -C(=O)NR²¹R²², -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, =O, -OR²¹, -OC(=O)R²¹, -OC(=O)OR²¹, -OC(=O)NR²¹R²², -NO₂, -NR²¹R²², -NR²¹-(CH₂)₁₋₆-C(=O)R²², -NR²¹-(CH₂)₁₋₆-C(=O)OR²², -NR²³-(CH₂)₁₋₆-C(=O)NR²¹R²², -NR²¹C(=O)R²², -NR²¹C(=O)-OR²², -NR²³C(=O)NR²¹R²², -NR²¹S(=O)₂R²², -SR²¹, -S(=O)R²¹, -S(=O)₂R²¹, -S(=O)₂OR²¹, and -S(=O)₂NR²¹R²²;

wherein

R²¹, R²² and R²³ independently of one another mean

-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, and -O-C₁-C₆-alkyl;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, -C₁-C₆-alkyl and -O-C₁-C₆-alkyl;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently

of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, -C₁-C₆-alkyl and -O-C₁-C₆-alkyl;

a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, -C₁-C₆-alkyl and -O-C₁-C₆-alkyl;

a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, -C₁-C₆-alkyl and -O-C₁-C₆-alkyl;

or R²¹ and R²² within -C(=O)NR²¹R²², -OC(=O)NR²¹R²², -NR²¹R²², -NR²³-(CH₂)₁₋₆-C(=O)NR²¹R²², -NR²³C(=O)NR²¹R²², or -S(=O)₂NR²¹R²² together with the nitrogen atom to which they are attached form a ring and mean -(CH₂)₃₋₆-, -(CH₂)₂-O-(CH₂)₂-, or -(CH₂)₂-NR^B-(CH₂)₂-, wherein R^B means -H or -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br and -I;

or a physiologically acceptable salt thereof.

[0016] Preferably, aryl includes but is not limited to phenyl and naphthyl. Preferably, heteroaryl includes but is not limited to -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl. Preferably, cycloalkyl includes but is not limited to -cyclopropyl, -cyclobutyl, -cyclopentyl and -cyclohexyl. Preferably, heterocycloalkyl includes but is not limited to -aziridinyl, -azetidiny, -pyrrolidinyl, -piperidinyl, -piperazinyl, -morpholinyl, -sulfamorpholinyl, -oxiridinyl, -oxetanyl, -tetrahydropyranyl, and -pyranyl.

[0017] When a moiety is connected through an asymmetric group such as -C(=O)O- or -C(=O)O-CH₂-, said asymmetric group may be arranged in either direction. For example, when R⁴ is connected to the core structure through -C(=O)O-, the arrangement may be either R⁴-C(=O)O-core or core-C(=O)O-R⁴.

[0018] In preferred embodiments of the compound according to the invention, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ independently of one another mean -H, -F, -OH, or -C₁-C₆-alkyl; preferably -H.

[0019] In a preferred embodiment of the compound according to the invention, R¹ means -H; and R² means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R¹ means -H and R² means -CH₃.

[0020] In another preferred embodiment of the compound according to the invention, R¹ means -CH₃; and R² means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R¹ means -CH₃ and R² means -CH₃.

[0021] In still another preferred embodiment of the compound according to the invention, R¹ and R² together with the nitrogen atom to which they are attached form a ring and mean -(CH₂)₃₋₆-. Preferably, R¹ and R² together with the nitrogen atom to which they are attached form a ring and mean -(CH₂)₃-.

[0022] In yet another preferred embodiment,

- R¹ means -H or -CH₃; and
- R² means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is connected through -CH₂-, unsubstituted; preferably -CH₂-cycloalkyl, -CH₂-cyclobutyl or -CH₂-cyclopentyl; or R² means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through -CH₂-, unsubstituted; preferably -CH₂-oxetanyl or -CH₂-tetrahydrofuryl.

[0023] In a preferred embodiment of the compound according to the invention, R³ means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R³ means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with -OCH₃.

[0024] In another preferred embodiment of the compound according to the invention, R³ means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted, optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted. In a preferred embodiment, R³ means -phenyl unsubstituted, mono- or polysubstituted. More preferably, R³ means -phenyl unsubstituted, mono- or disubstituted with -F, -Cl, -CH₃, -CF₃, -OH, -OCH₃, -OCF₃ or -OCH₂OCH₃, preferably -F. In another preferred embodiment, R³ means -benzyl unsubstituted, mono- or polysubstituted. More preferably, R³ means -benzyl unsubstituted, mono- or disubstituted with -F, -Cl, -CH₃, -CF₃, -OH, -OCH₃, -OCF₃ or -OCH₂OCH₃, preferably -F.

[0025] In still another preferred embodiment of the compound according to the invention, R³ means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Preferably, R³ means -thienyl or -pyridinyl, in each case unsubstituted, mono- or polysubstituted. More preferably, R³ means -thienyl, -pyridinyl, -imidazolyl or benzimidazolyl, in each case unsubstituted or monosubstituted with -F, -Cl or -CH₃.

[0026] In a preferred embodiment of the compound according to the invention, R⁴ means -H.

[0027] In another preferred embodiment of the compound according to the invention, R⁴ means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R⁴ means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with a substituent selected from the group consisting of -F, -Cl, -Br, -I, -CN, -CF₃, -OH, -O-C₁-C₄-alkyl, -OCF₃, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -OC(=O)C₁-C₄-alkyl, -C(=O)C₁-C₄-alkyl, -C(=O)OH, -

$C(=O)OC_1-C_4$ -alkyl, $-C(=O)NH_2$, $-C(=O)NHC_1-C_4$ -alkyl, $-C(=O)NHC_1-C_4$ -alkylene-CN, $-C(=O)NHC_1-C_4$ -alkylene-O- C_1-C_4 -alkyl, $-C(=O)N(C_1-C_4-alkyl)_2$, $-S(=O)C_1-C_4$ -alkyl, and $-S(=O)_2C_1-C_4$ -alkyl; or with $-C(=O)NR^{21}R^{22}$ wherein R^{21} and R^{22} together with the nitrogen atom to which they are attached form a ring and mean $-(CH_2)_{3-6}$ -, $-(CH_2)_2-O-(CH_2)_2$ -, or $-(CH_2)_2-NR^B-(CH_2)_2$ -, wherein R^B means -H or $-C_1-C_6$ -alkyl; or with $-C(=O)NH$ -3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with -F, -Cl, -Br, -I, -CN, or -OH; or with $-C(=O)NH$ -3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with -F, -Cl, -Br, -I, -CN, or -OH. More preferably, R^4 means $-C_1-C_6$ -alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with -O- C_1-C_4 -alkyl or $-C(=O)N(C_1-C_4-alkyl)_2$.

[0028] In still another preferred embodiment of the compound according to the invention, R^4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through $-C_1-C_6$ -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R^4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is connected through $-CH_2$ - or $-CH_2CH_2$ -. More preferably, R^4 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, $-C_1-C_4$ -alkyl, $-O-C_1-C_4$ -alkyl, $-C(=O)OH$, $-C(=O)OC_1-C_4$ -alkyl, $-C(=O)NH_2$, $-C(=O)NHC_1-C_4$ -alkyl, $-C(=O)N(C_1-C_4-alkyl)_2$, $-S(=O)C_1-C_4$ -alkyl and $-S(=O)_2C_1-C_4$ -alkyl; wherein said 3-12-membered cycloalkyl moiety is connected through $-CH_2$ - or $-CH_2CH_2$ -.

[0029] In a preferred embodiment of the compound according to the invention, R^4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through $-C_1-C_6$ -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R^4 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through $-CH_2$ - or $-CH_2CH_2$ -. More preferably, R^4 means -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, $-C_1-C_4$ -alkyl, $-O-C_1-C_4$ -alkyl, $-C(=O)OH$, $-C(=O)OC_1-C_4$ -alkyl, $-C(=O)NH_2$, $-C(=O)NHC_1-C_4$ -alkyl, $-C(=O)N(C_1-C_4-alkyl)_2$, $-S(=O)C_1-C_4$ -alkyl and $-S(=O)_2C_1-C_4$ -alkyl; wherein said -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl is connected through $-CH_2$ - or $-CH_2CH_2$ -.

[0030] In yet another preferred embodiment of the compound according to the invention, R^4 means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is connected through $-C_1-C_6$ -alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R^4 means -phenyl, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through $-CH_2$ - or $-CH_2CH_2$ -. More preferably, R^4 means -phenyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, $-C_1-C_4$ -alkyl, $-O-C_1-C_4$ -alkyl, $-C(=O)OH$, $-C(=O)OC_1-C_4$ -alkyl, $-C(=O)NH_2$, -

$\text{C(=O)NHC}_1\text{-C}_4\text{-alkyl}$, $\text{-C(=O)N(C}_1\text{-C}_4\text{-alkyl)}_2$, $\text{-S(=O)C}_1\text{-C}_4\text{-alkyl}$ and $\text{-S(=O)}_2\text{C}_1\text{-C}_4\text{-alkyl}$; wherein said -phenyl is connected through $\text{-CH}_2\text{-}$ or $\text{-CH}_2\text{CH}_2\text{-}$.

[0031] In a further preferred embodiment of the compound according to the invention, R^4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through $\text{-C}_1\text{-C}_6\text{-alkylene-}$, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R^4 means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through $\text{-CH}_2\text{-}$ or $\text{-CH}_2\text{CH}_2\text{-}$. More preferably, R^4 means -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, $\text{-C}_1\text{-C}_4\text{-alkyl}$, $\text{-O-C}_1\text{-C}_4\text{-alkyl}$, -C(=O)OH , $\text{-C(=O)OC}_1\text{-C}_4\text{-alkyl}$, -C(=O)NH_2 , $\text{-C(=O)NHC}_1\text{-C}_4\text{-alkyl}$, $\text{-C(=O)N(C}_1\text{-C}_4\text{-alkyl)}_2$, $\text{-S(=O)C}_1\text{-C}_4\text{-alkyl}$ and $\text{-S(=O)}_2\text{C}_1\text{-C}_4\text{-alkyl}$; wherein said -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl is connected through $\text{-CH}_2\text{-}$ or $\text{-CH}_2\text{CH}_2\text{-}$.

[0032] In a preferred embodiment of the compound according to the invention, R^5 means -H.

[0033] In another preferred embodiment of the compound according to the invention, R^5 means $\text{-C}_1\text{-C}_6\text{-alkyl}$, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, $\text{-O-C}_1\text{-C}_4\text{-alkyl}$, $\text{-O-(CH}_2\text{CH}_2\text{-O)}_{1-30}\text{-H}$, $\text{-O-(CH}_2\text{CH}_2\text{-O)}_{1-30}\text{-CH}_3$, -C(=O)OH , $\text{-C(=O)OC}_1\text{-C}_4\text{-alkyl}$, -C(=O)NH_2 , $\text{-C(=O)NHC}_1\text{-C}_4\text{-alkyl}$, $\text{-C(=O)N(C}_1\text{-C}_4\text{-alkyl)}_2$, $\text{-S(=O)C}_1\text{-C}_4\text{-alkyl}$ and $\text{-S(=O)}_2\text{C}_1\text{-C}_4\text{-alkyl}$. Preferably, R^5 means $\text{-C}_1\text{-C}_6\text{-alkyl}$, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with -F, -Cl, -Br, -I, -CN, -OH, $\text{-O-C}_1\text{-C}_4\text{-alkyl}$, $\text{-O-(CH}_2\text{CH}_2\text{-O)}_{1-30}\text{-H}$, $\text{-O-(CH}_2\text{CH}_2\text{-O)}_{1-30}\text{-CH}_3$, -C(=O)NH_2 , $\text{-C(=O)NHC}_1\text{-C}_4\text{-alkyl}$, $\text{-C(=O)N(C}_1\text{-C}_4\text{-alkyl)}_2$, $\text{-S(=O)C}_1\text{-C}_4\text{-alkyl}$ or $\text{-S(=O)}_2\text{C}_1\text{-C}_4\text{-alkyl}$.

[0034] More preferably,

- (i) R^5 means $\text{-C}_1\text{-C}_6\text{-alkyl}$, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with -F, -Cl, -Br, -I, -CN, -OH, $\text{-O-C}_1\text{-C}_4\text{-alkyl}$, $\text{-O-(CH}_2\text{CH}_2\text{-O)}_{1-30}\text{-H}$, $\text{-O-(CH}_2\text{CH}_2\text{-O)}_{1-30}\text{-CH}_3$, $\text{-S(=O)C}_1\text{-C}_4\text{-alkyl}$ or $\text{-S(=O)}_2\text{C}_1\text{-C}_4\text{-alkyl}$; or
- (ii) R^5 means $\text{-C}_3\text{-C}_6\text{-alkyl}$, linear or branched, saturated or unsaturated, monosubstituted with -C(=O)NH_2 , $\text{-C(=O)NHC}_1\text{-C}_4\text{-alkyl}$, or $\text{-C(=O)N(C}_1\text{-C}_4\text{-alkyl)}_2$.

[0035] In another preferred embodiment of the compound according to the invention, R^5 means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, $\text{-C}_1\text{-C}_4\text{-alkyl}$, $\text{-O-C}_1\text{-C}_4\text{-alkyl}$, $\text{-C}_1\text{-C}_4\text{-alkyl-OH}$, $\text{-O-(CH}_2\text{CH}_2\text{-O)}_{1-30}\text{-H}$, $\text{-O-(CH}_2\text{CH}_2\text{-O)}_{1-30}\text{-CH}_3$, -C(=O)OH , $\text{-C(=O)C}_1\text{-C}_4\text{-alkyl}$, $\text{-C(=O)OC}_1\text{-C}_4\text{-alkyl}$, -C(=O)NH_2 , $\text{-C(=O)NHC}_1\text{-C}_4\text{-alkyl}$, $\text{-C(=O)N(C}_1\text{-C}_4\text{-alkyl)}_2$, -NH_2 , $\text{-NHC}_1\text{-C}_4\text{-alkyl}$, $\text{N(C}_1\text{-C}_4\text{-alkyl)}_2$, $\text{-NHC(=O)-C}_1\text{-C}_4\text{-alkyl}$, $\text{-N(C}_1\text{-C}_4\text{-alkyl)C(=O)C}_1\text{-C}_4\text{-alkyl}$, $\text{-S(=O)C}_1\text{-C}_4\text{-alkyl}$ and $\text{-S(=O)}_2\text{C}_1\text{-C}_4\text{-alkyl}$; wherein said 3-12-membered cycloalkyl moiety is optionally connected through $\text{-C}_1\text{-C}_6\text{-alkylene-}$, linear or branched, saturated or unsaturated, unsubstituted.

[0036] In a preferred embodiment of the compound according to the invention, R^5 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -C₁-C₄-alkyl-OH, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)C₁-C₄-alkyl, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -NH₂, -NHC₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)C(=O)C₁-C₄-alkyl, -S(=O)C₁-C₄-alkyl and -S(=O)₂C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted. Preferably, R^5 means -oxetanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -piperidiny, -piperaziny, -morpholiny or -thiomorpholiny, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl and -S(=O)₂C₁-C₄-alkyl; wherein said -oxetanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -piperidiny, -piperaziny, -morpholiny or -thiomorpholiny is connected through -CH₂- or -CH₂CH₂-.

[0037] In a preferred embodiment of the compound according to the invention, R^5 means

-H;


-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, =O, -OH, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)C₁-C₄-alkyl, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl, -S(=O)₂C₁-C₄-alkyl, -NH₂, -NH-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NH-S(=O)₂C₁-C₄-alkyl; or

3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, =O, -OH, -C₁-C₄-alkyl, -C₁-C₄-alkyl-OH, -NH₂, -NH-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NHS(=O)₂-C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)C₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl, -S(=O)₂C₁-C₄-alkyl, -phenyl, -C(=O)-phenyl, -C(=O)-pyridyl, -thiazolyl, -N-methyldiazolyl, -pyridyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or


3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, =O, -OH, -C₁-C₄-alkyl, -C₁-C₄-alkyl-OH, -NH₂, -NH-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NHS(=O)₂-C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)C₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl, -S(=O)₂C₁-C₄-alkyl, -phenyl, -C(=O)-phenyl, -C(=O)-pyridyl, -thiazolyl, -N-methyldiazolyl, -pyridyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered heterocycloalkyl

moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted.


[0038] In preferred embodiments, the compound according to the invention has a structure according to any of general formulas (II-A) to (VIII-C):




(II-A)




(II-B)




(II-C)




(III-A)




(III-B)













(III-C)




(IV-A)




(IV-B)






(VIII-A)



(VIII-B)



(VIII-C)

wherein in each case


















R¹, R², R³, R⁴, and R⁵ are defined as above,



















R^C means -H, -OH, -F, -CN or -C₁-C₄-alkyl; preferably -H or -OH;

R^D means -H or -F;

or a physiologically acceptable salt thereof.

[0039] Preferably, in the compounds according to general formula (I) or any of the compounds according to general formulas (II-A) to (VIII-C), R⁵ is selected from the group consisting of:

 <chem>CC(C)(O)CC</chem>	 <chem>CCCCl</chem>
 <chem>CCCCC(=O)OC</chem>	 <chem>H</chem>
 <chem>NC1CC2CC1C2</chem>	 <chem>CC(=O)NC1CC2CC1C2</chem>
 <chem>C1=CC=NC=C1N2CCCCC2</chem>	 <chem>OC1CCCOC1</chem>
 <chem>CC(C)CCN1CCCC1=O</chem>	 <chem>CC(C)CCN1CCCC1=S(=O)(=O)</chem>
 <chem>OC1CCCOC1</chem>	 <chem>OC1CCC(S(=O)(=O))CC1</chem>
 <chem>CC(=O)NC(C)CC</chem>	 <chem>CS(=O)(=O)NC(C)CC</chem>
 <chem>CC(C)CCN1C(=O)CCC1=O</chem>	 <chem>C1=CC=NC=C1N2CCCCC2</chem>
 <chem>C1=CC=NC=C1N2CCCCC2</chem>	 <chem>C1=CN=CN=C1N2CCCCC2</chem>

[0040] In a particularly preferred embodiment of the compound according to the invention

R¹ means -H or -CH₃;

R² means -C₁-C₆-alkyl, linear or branched, saturated, unsubstituted;

R³ means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -CH₃, -CH₂CH₃, -CH₂F, -CHF₂, -CF₃, -OCF₃, -OH, -OCH₃, -C(=O)NH₂, C(=O)NHCH₃, -C(=O)N(CH₃)₂, -NH₂, -NHCH₃, -N(CH₃)₂, -NHC(=O)CH₃, -CH₂OH, SOCH₃ and SO₂CH₃; or

R⁴ means

-H;

-C₁-C₆-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, =O, -S(=O)₂-C₁-C₄-alkyl and -O-C₁-C₄-alkyl;

3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl, wherein said 3-6-membered cycloalkyl is connected through -C₁-C₆-alkylene;

3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene-, unsubstituted or substituted with =O;

6-14-membered aryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl; wherein said 6-14-membered aryl is optionally connected through -C₁-C₆-alkylene- or -S(=O)₂-;

R⁵ means

-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, =O, -OH, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)C₁-C₄-alkyl, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl, -S(=O)₂C₁-C₄-alkyl, -NH₂, -NH-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NH-S(=O)₂C₁-C₄-alkyl; or

3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN,

=O, -OH, -C₁-C₄-alkyl, -NH₂, -NH-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NHS(=O)₂-C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)C₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl, -S(=O)₂C₁-C₄-alkyl, -phenyl, -C(=O)-phenyl, -C(=O)-pyridyl, -pyridyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; and

R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ mean -H.

[0041] In a particularly preferred embodiment of the compound according to the invention

R¹ means -H or -CH₃; and/or

R² means -C₁-C₆-alkyl, linear or branched, saturated, unsubstituted; preferably R² means -CH₃ or -CH₂CH₃; more preferably, R¹ and R² both mean -CH₃; and/or

R³ means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -CH₃, -CH₂CH₃, -CH₂F, -CHF₂, -CF₃, -OCF₃, -OH, -OCH₃, -C(=O)NH₂, C(=O)NHCH₃, -C(=O)N(CH₃)₂, -NH₂, -NHCH₃, -N(CH₃)₂, -NHC(=O)CH₃, -CH₂OH, SOCH₃ and SO₂CH₃; preferably, R³ means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with -F; more preferably, R³ means phenyl, unsubstituted; and/or

R⁴ means

-H;

-C₁-C₆-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl; or

3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl, wherein said 3-6-membered cycloalkyl is connected through -C₁-C₆-alkylene; preferably, R⁴ means 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl, wherein said 3-6-membered cycloalkyl is connected through -CH₂- or -CH₂CH₂-; more preferably, R⁴ means -cyclobutyl, unsubstituted or monosubstituted with -OH, wherein said -cyclobutyl is connected through -CH₂-;

R⁵ means

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -

C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl and -S(=O)₂C₁-C₄-alkyl; preferably, R⁵ means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with -F, -Cl, -Br, -I, -CN, -OH, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl or -S(=O)₂C₁-C₄-alkyl; or

3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl and -S(=O)₂C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; preferably, R⁵ means -oxetanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -piperidiny, -piperazinyl, -morpholinyl or -thiomorpholinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl and -S(=O)₂C₁-C₄-alkyl; wherein said -oxetanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -piperidiny, -piperazinyl, -morpholinyl or -thiomorpholinyl is connected through -CH₂- or -CH₂CH₂-; and

R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ mean -H.

[0042] Preferred compounds according to the invention are selected from the group consisting of:

SC_4001	CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyramide
SC_4002	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4003	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4004	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4005	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4006	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(2-methoxy-ethoxy)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4007	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4008	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4009	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4010	CIS-1-(Cyclobutyl-methyl)-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-

	diazaspiro[4.5]decan-2-one
SC_4011	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4012	CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile
SC_4013	CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methyl-butylamide
SC_4014	CIS-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile
SC_4017	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4018	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-methyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4021	CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4022	CIS-3-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile
SC_4024	CIS-2-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile
SC_4025	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(tetrahydro-pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4026	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4027	CIS-3-(3-Chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4028	CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyric acid methyl ester
SC_4029	CIS-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile
SC_4030	CIS-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile
SC_4031	CIS-3-Acetyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4032	CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4033	CIS-1-Acetyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4034	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

SC_4035	CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-1-(oxetan-3-yl-methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4036	CIS-8-Dimethylamino-1-(3-methoxy-propyl)-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4037	CIS-8-Dimethylamino-8-phenyl-1-(p-tolylsulfonyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4038	CIS-8-Dimethylamino-3-[(1,1-dioxo-thian-4-yl)-methyl]-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4039	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4040	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-tetrahydro-pyran-4-yl-1,3-diazaspiro[4.5]decan-2-one
SC_4041	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4042	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-tetrahydro-pyran-4-yl-1,3-diazaspiro[4.5]decan-2-one
SC_4043	CIS-1-[[8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]-cyclobutane-1-carbonitrile
SC_4044	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4045	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4046	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(1,1-dioxo-thian-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4047	CIS-8-Dimethylamino-3-(1,1-dioxo-thian-4-yl)-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4048	CIS-3-(1-Acetyl-piperidin-4-yl)-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4049	CIS-3-(1-Benzoyl-piperidin-4-yl)-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4050	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one
SC_4051	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4052	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(4-hydroxy-tetrahydro-pyran-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4053	CIS-3-[(1-Acetyl-piperidin-4-yl)-methyl]-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4054	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-piperidin-4-yl-1,3-diazaspiro[4.5]decan-2-one
SC_4055	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-hydroxy-2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4056	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one

SC_4057	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-phenyl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4058	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(piperidin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4059	CIS-3-(1-Benzoyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4060	CIS-8-Dimethylamino-8-phenyl-3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one
SC_4061	CIS-3-(1-Acetyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4062	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4063	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4064	CIS-3-[(1-Amino-cyclopropyl)-methyl]-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4066	CIS-8-Dimethylamino-1,3-bis(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4067	CIS-N-[1-[[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-cyclopropyl]-acetamide
SC_4068	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-[(1-pyrimidin-5-yl-piperidin-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
SC_4069	CIS-8-Dimethylamino-8-phenyl-3-[(1-pyrimidin-5-yl-piperidin-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
SC_4070	CIS-8-Dimethylamino-8-phenyl-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4071	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(3-hydroxy-oxetan-3-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4072	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[2-methyl-2-(2-oxo-pyrrolidin-1-yl)-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4073	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[2-(1,1-dioxo-[1,2]thiazolidin-2-yl)-2-methyl-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4074	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-(4-hydroxy-tetrahydro-pyran-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4075	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(4-hydroxy-1,1-dioxo-thian-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4076	CIS-3-[(1-Acetyl-piperidin-4-yl)-methyl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4077	CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4078	TRANS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4079	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-(4-hydroxy-1,1-dioxo-thian-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

SC_4080	CIS-8-Dimethylamino-8-phenyl-3-(1-phenyl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4081	CIS-N-[2-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-acetamide
SC_4082	CIS-N-[2-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-methanesulfonic acid amide
SC_4083	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-(3-hydroxy-oxetan-3-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4084	CIS-1-[2-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-pyrrolidine-2,5-dione
SC_4085	CIS-N-[2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-acetamide
SC_4086	CIS-N-[2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-methanesulfonic acid amide
SC_4087	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyridin-3-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4088	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-(2-methylsulfonyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4089	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyridin-4-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4090	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-methyl-2-(2-oxo-pyrrolidin-1-yl)-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4091	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methyl-2-methylsulfonyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4092	TRANS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methyl-2-methylsulfonyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4093	CIS-8-Dimethylamino-3-[2-(1,1-dioxo-[1,2]thiazolidin-2-yl)-2-methyl-propyl]-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4094	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-hydroxy-tetrahydropyran-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one
SC_4095	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4096	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyridazin-4-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4097	CIS-2-[8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide
SC_4098	TRANS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4099	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4100	CIS-1-(cyclopropylmethyl)-8-(3-fluorophenyl)-8-(methylamino)-3-(2-(methylsulfonyl)ethyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4101	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

SC_4102	CIS-8-(dimethylamino)-8-(3-fluorophenyl)-3-((4-hydroxy-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1-((1-hydroxycyclobutyl)methyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4103	CIS-8-(dimethylamino)-8-(3-fluorophenyl)-1-((1-hydroxycyclobutyl)methyl)-3-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4104	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-(3-fluorophenyl)-3-((4-hydroxy-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4105	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(oxetan-3-ylmethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4106	CIS-8-(dimethylamino)-8-phenyl-3-((S)-1-(thiophen-3-yl)propan-2-yl)-1,3-diazaspiro[4.5]decan-2-one
SC_4107	CIS-8-(dimethylamino)-8-phenyl-1,3-bis((1-(trifluoromethyl)cyclopropyl)methyl)-1,3-diazaspiro[4.5]decan-2-one
SC_4108	CIS-8-(dimethylamino)-1,3-bis((1-fluorocyclopropyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4109	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-((3-(hydroxymethyl)oxetan-3-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4110	CIS-3-((3-aminooxetan-3-yl)methyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one
SC_4111	CIS-1-((1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)methyl)cyclobutanecarbonitrile
SC_4112	CIS-3-(8-(dimethylamino)-1-((1-fluorocyclopropyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile
SC_5061	CIS-3-[8-(Ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile
SC_5062	CIS-3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethyl-propionitrile
SC_5063	CIS-2,2-Dimethyl-3-(8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-propionitrile
SC_5065	CIS-3-[8-(Ethyl-methyl-amino)-1-methyl-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile
SC_5068	CIS-3-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethyl-propionitrile
SC_5075	CIS-3-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile
SC_5080	TRANS-3-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile

and the physiologically acceptable salts thereof.

[0043] According to the invention, unless expressly stated otherwise, "-C₁-C₄-alkyl", "-C₁-C₆-alkyl" and any other alkyl residues can be linear or branched, saturated or unsaturated. Linear saturated alkyl includes methyl, ethyl, n-propyl, n-butyl, n-pentyl and n-hexyl. Examples of branched saturated alkyl include but are not limited to iso-propyl, sec-butyl, and tert-butyl. Examples of linear unsaturated alkyl include but are not limited to vinyl, propenyl, allyl, and propargyl.

[0044] According to the invention, unless expressly stated otherwise, "-C₁-C₄-alkyl", "-C₁-C₆-alkyl" and any other alkyl residues can be unsubstituted, mono- or polysubstituted. Examples of substituted alkyl include but are not limited to -CH₂CH₂OH, -CH₂CH₂OCH₃, -CH₂CH₂CH₂OCH₃, -CH₂CH₂S(=O)₂CH₃, -CH₂C(=O)NH₂, -C(CH₃)₂C(=O)NH₂, -CH₂C(CH₃)₂C(=O)NH₂, and -CH₂CH₂C(=O)N(CH₃)₂.

[0045] According to the invention, unless expressly stated otherwise, "-C₁-C₆-alkylene-", "-C₁-C₄-alkylene" and any other alkylene residue can be unsubstituted, mono- or polysubstituted. Examples of saturated alkylene include but are not limited to -CH₂-, -CH(CH₃)-, -C(CH₃)₂-, -CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂CH(CH₃)-, -CH(CH₃)-CH(CH₃)-, -C(CH₃)₂CH₂-, -CH₂C(CH₃)₂-, -CH(CH₃)C(CH₃)₂-, -C(CH₃)₂CH(CH₃)-, C(CH₃)₂C(CH₃)₂-, -CH₂CH₂CH₂-, and -C(CH₃)₂CH₂CH₂-. Examples of unsaturated alkylene include but are not limited to -CH=CH-, -C≡C-, -C(CH₃)=CH-, -CH=C(CH₃)-, -C(CH₃)=C(CH₃)-, -CH₂CH=CH-, -CH=CHCH₂-, -CH=CH-CH=CH-, and -CH=CH-C≡C-.

[0046] According to the invention, unless expressly stated otherwise, "-C₁-C₆-alkylene-", "-C₁-C₄-alkylene" and any other alkylene residue can be unsubstituted, mono- or polysubstituted. Examples of substituted -C₁-C₆-alkylene- include but are not limited to -CHF-, -CF₂-, -CHOH- and -C(=O)-.

[0047] According to the invention, moieties may be connected through -C₁-C₆-alkylene-, i.e. the moieties may not be directly bound to the core structure of compound according to general formula (I), but may be connected to the core structure of compound according to general formula (I) or its periphery through a -C₁-C₆-alkylene- linker.

[0048] According to the invention, "3-12-membered cycloalkyl moiety" means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring carbon atoms but no heteroatoms in the ring. Examples of preferred saturated 3-12-membered cycloalkyl moieties according to the invention include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, hydrindane, and decaline. Examples of preferred unsaturated 3-12-membered cycloalkyl moiety moieties according to the invention include but are not limited to cyclopropene, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, 1,3-cyclohexadiene, and 1,4-cyclohexadiene. The 3-12-membered cycloalkyl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 3 to 12 ring atoms of the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 3-12-membered heterocycloalkyl moieties include but are not limited to octahydro-1*H*-indol, decahydroquinoline, decahydroisoquinoline, octahydro-2*H*-benzo[b][1,4]oxazin, and decahydroquinoxalin, which in each case are connected through the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 6-14-membered aryl moieties include but are not limited to 2,3-dihydro-1*H*-indene and tetraline, which in each case are connected through the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl

moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 3-12-membered cycloalkyl moiety.

[0049] According to the invention, the 3-12-membered cycloalkyl moiety may optionally be connected through -C₁-C₆-alkylene-, i.e. the 3-12-membered cycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a -C₁-C₆-alkylene- linker. Examples include but are not limited to -CH₂-cyclopropyl, -CH₂-cyclobutyl, -CH₂-cyclopentyl, -CH₂-cyclohexyl, -CH₂CH₂-cyclopropyl, -CH₂CH₂-cyclobutyl, -CH₂CH₂-cyclopentyl, and -CH₂CH₂-cyclohexyl.

[0050] According to the invention, unless expressly stated otherwise, the 3-12-membered cycloalkyl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 3-12-membered cycloalkyl moieties include but are not limited to -CH₂-1-hydroxy-cyclobutyl.

[0051] According to the invention, "3-12-membered heterocycloalkyl moiety" means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas sulfur may be oxidized (S(=O) or (S(=O))₂), whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s). Examples of preferred saturated 3-12-membered heterocycloalkyl moieties according to the invention include but are not limited to aziridin, azetidine, pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, triazolidine, tetrazolidine, oxiran, oxetane, tetrahydrofurane, tetrahydropyrane, thiirane, thietane, tetrahydrothiophene, diazepane, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, morpholine, thiomorpholine. Examples of preferred unsaturated 3-12-membered heterocycloalkyl moiety moieties according to the invention include but are not limited to oxazoline, pyrazoline, imidazoline, isoxazoline, thiazoline, isothiazoline, and dihydropyran. The 3-12-membered heterocycloalkyl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 3 to 12 ring atoms of the 3-12-membered heterocycloalkyl moieties. Examples of 3-12-membered heterocycloalkyl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to octahydro-1*H*-indol, decahydroquinoline, decahydroisoquinoline, octahydro-2*H*-benzo[b][1,4]oxazin, and decahydroquinoxalin, which in each case are connected through the 3-12-membered heterocycloalkyl moiety. An examples of a 3-12-membered heterocycloalkyl moiety condensed with a 6-14-membered aryl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 3-12-membered heterocycloalkyl moiety. An example of a 3-12-membered heterocycloalkyl moiety condensed with a 5-14-membered heteroaryl moieties includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-*a*]pyrazine, which is connected through the 3-12-membered heterocycloalkyl moiety.

[0052] According to the invention, the 3-12-membered heterocycloalkyl moiety may optionally be connected through -C₁-C₆-alkylene-, i.e. the 3-12-membered heterocycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a -C₁-C₆-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 3-12-membered heterocycloalkyl moiety. Examples include but are not limited to -CH₂-oxetane, -CH₂-pyrrolidine, -CH₂-piperidine, -CH₂-morpholine, -CH₂CH₂-oxetane, -CH₂CH₂-pyrrolidine, -CH₂CH₂-piperidine, and -CH₂CH₂-morpholine.

[0053] According to the invention, unless expressly stated otherwise, the 3-12-membered heterocycloalkyl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 3-12-membered heterocycloalkyl moieties include but are not limited to 2-carboxamido-N-pyrrolidinyl-, 3,4-dihydroxy-N-pyrrolidinyl, 3-hydroxy-N-pyrimidinyl, 3,4-dihydroxy-N-pyrimidinyl, 3-oxo-N-piperazinyl, -tetrahydro-2H-thiopyranyl dioxide and thiomorpholinyl dioxide.

[0054] According to the invention, "6-14-membered aryl moiety" means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring carbon atoms but no heteroatoms in the ring. Examples of preferred 6-14-membered aryl moieties according to the invention include but are not limited to benzene, naphthalene, anthracene, and phenanthrene. The 6-14-membered aryl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties. Examples of 6-14-membered aryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 2,3-dihydro-1*H*-indene and tetraline, which in each case are connected through the 6-14-membered aryl moiety. An example of a 6-14-membered aryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 6-14-membered aryl moiety. Examples of 6-14-membered aryl moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxazine, which in each case are connected through the 6-14-membered aryl moiety.

[0055] According to the invention, the 6-14-membered aryl moiety may optionally be connected through -C₁-C₆-alkylene-, i.e. the 6-14-membered aryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a -C₁-C₆-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 6-14-membered aryl moiety. Examples include but are not limited to -CH₂-C₆H₅, -CH₂CH₂-C₆H₅ and -CH=CH-C₆H₅.


[0056] According to the invention, unless expressly stated otherwise, the 6-14-membered aryl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 6-14-membered aryl moieties include but are not limited to 2-fluorophenyl, 3-fluorophenyl, 2-methoxyphenyl and 3-methoxyphenyl.

[0057] According to the invention, "5-14-membered heteroaryl moiety" means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s). Examples of preferred 5-14-membered heteroaryl moieties according to the invention include but are not limited to pyrrole, pyrazole, imidazole, triazole, tetrazole, furane, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine, pyrazine, indolicine, 9H-chinoline, 1,8-naphthyridine, purine, imidazo[1,2-a]pyrazine, and pteridine. The 5-14-membered heteroaryl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties. Examples of 5-14-membered heteroaryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 5-14-membered heteroaryl moiety. An examples of a 5-14-membered heteroaryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 5-14-membered heteroaryl moiety. Examples of 5-14-membered heteroaryl moieties condensed with 6-14-membered aryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxazine, which in each case are connected through the 5-14-membered heteroaryl moiety.

[0058] According to the invention, the 5-14-membered heteroaryl moiety may optionally be connected through -C₁-C₆-alkylene-, i.e. the 5-14-membered heteroaryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a -C₁-C₆-alkylene- linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 5-14-membered heteroaryl moiety. Examples include but are not limited to -CH₂-oxazole, -CH₂-isoxazole, -CH₂-imidazole, -CH₂-pyridine, -CH₂-pyrimidine, -CH₂-pyridazine, -CH₂CH₂-oxazole, -CH₂CH₂-isoxazole, -CH₂CH₂-imidazole, -CH₂CH₂-pyridine, -CH₂CH₂-pyrimidine, and -CH₂CH₂-pyridazine.

[0059] According to the invention, unless expressly stated otherwise, the 5-14-membered heteroaryl moiety can be unsubstituted, mono- or polysubstituted. Examples of 5-14-membered heteroaryl moieties include but are not limited to 2-methoxy-4-pyridinyl, 2-methoxy-5-pyridinyl, 3-methoxy-4-pyridinyl, 3-methoxy-6-pyridinyl, 4-methoxy-2-pyridinyl, 2-methylsulfonyl-5-pyridinyl, 3-methylsulfonyl-6-pyridinyl, 3-methoxy-6-pyridazinyl, 2-nitrilo-5-pyrimidinyl, 4-hydroxy-2-pyrimidinyl, 4-methoxy-pyrimidinyl, and 2-methoxy-6-pyrazinyl.


[0060] Preferably, the compounds according to the invention have a structure according to general formula (I')



wherein R^1 to R^5 , R^{10} to R^{20} are defined as above, or a physiologically acceptable salt thereof.

[0061] In one preferred embodiment, the excess of the cis-isomer so designated is at least 50% de, more preferably at least 75% de, yet more preferably at least 90% de, most preferably at least 95% de and in particular at least 99% de.

[0062] Preferably, the compounds according to the invention have a structure according to general formula (IX)



wherein

R^C means -H or -OH;

R^3 means -phenyl or -3-fluorophenyl;

R^5 means

C_1 - C_6 -alkyl, linear or branched, saturated, unsubstituted or monosubstituted with -OH, -CN, -NH₂, -NHC(=O) C_1 - C_4 -alkyl, -NHS(=O)₂- C_1 - C_4 -alkyl, or -S(=O)₂- C_1 - C_4 -alkyl; or

3-6-membered heterocycloalkyl, saturated, unsubstituted or substituted with -OH; wherein said 3-6-membered heterocycloalkyl is optionally connected through -CH₂- or -(CH₂)₂;

or a physiologically acceptable salt thereof.

[0063] Preferably, the 3-6-membered heterocycloalkyl is selected from the group consisting of oxetanly, tetrahydrofuranly and tetrahydropyranyly.

[0064] In a preferred embodiment, the compounds according to the invention are in the form of the free bases.

[0065] In another preferred embodiment, the compounds according to the invention are in the form of the physiologically acceptable salts.

[0066] For the purposes of the description, a "salt" is to be understood as being any form of the compound in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution. The term is also to be understood as meaning complexes of the compound with other molecules and ions, in particular complexes which are associated via ionic interactions. Preferred salts are physiologically acceptable, in particular physiologically acceptable salts with anions or acids or also a salt formed with a physiologically acceptable acid.

[0067] Physiologically acceptable salts with anions or acids are salts of the particular compound in question with inorganic or organic acids which are physiologically acceptable, in particular when used in humans and/or mammals. Examples of physiologically acceptable salts of particular acids include but are not limited to salts of hydrochloric acid, sulfuric acid, and acetic acid.

[0068] The invention also includes isotopic isomers of a compound according to the invention, wherein at least one atom of the compound is replaced by an isotope of the respective atom which is different from the naturally predominantly occurring isotope, as well as any mixtures of isotopic isomers of such a compound. Preferred isotopes are ^2H (deuterium), ^3H (tritium), ^{13}C and ^{14}C .

[0069] Certain compounds according to the invention are useful for modulating a pharmacodynamic response from one or more opioid receptors (mu, delta, kappa, NOP/ORL-1) either centrally or peripherally, or both. The pharmacodynamic response may be attributed to the compound either stimulating (agonizing) or inhibiting (antagonizing) the one or more receptors. Certain compounds according to the invention may antagonize one opioid receptor, while also agonizing one or more other receptors. Compounds according to the invention having agonist activity may be either full agonists or partial agonists.

[0070] As used herein, compounds that bind to receptors and mimic the regulatory effects of endogenous ligands are defined as "agonists". Compounds that bind to a receptor but produce no regulatory effect, but rather block the binding of ligands to the receptor, are defined as "antagonists".

[0071] In certain embodiments, the compounds according to the invention are agonists at the mu opioid (MOP) and/or kappa opioid (KOP) and/or delta opioid (DOP) and/or nociceptin opioid (NOP/ORL-1) receptors.

[0072] The compounds according to the invention potentially bind to the MOP and/or KOP and/or DOP and/or NOP receptors.

[0073] The compounds according to the invention can be modulators at the MOP and/or KOP and/or DOP and/or NOP receptors, and therefore the compounds according to the invention can be used/administered to treat, ameliorate, or prevent pain.

[0074] In some embodiments, the compounds according to the invention are agonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are agonists of the MOP and/or KOP and/or DOP and/or NOP receptors.

[0075] In some embodiments, the compounds according to the invention are antagonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are antagonists of the MOP and/or KOP and/or DOP and/or NOP receptors.

[0076] In some embodiments, the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.

[0077] In some embodiments, the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.

[0078] In some embodiments, the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.

[0079] In some embodiments, the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.

[0080] In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

- have agonist activity at the NOP receptor, but no significant activity at the MOP receptor;
- have agonist activity at the NOP receptor, but no significant activity at the KOP receptor;
- have agonist activity at the NOP receptor, but no significant activity at the DOP receptor;
- have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
- have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
- have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.

[0081] In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the MOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

- have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the KOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the DOP receptor;
- can be regarded as opioid pan agonists, i.e. have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the DOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the KOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the DOP receptor; or
- have agonist activity at the NOP receptor as well as agonist activity at the MOP receptor, but no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.

[0082] In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

- have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the MOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor as well as agonist activity at the DOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the MOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the DOP receptor; or
- have agonist activity at the NOP receptor as well as agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor.

[0083] In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the

DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

- have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor;
- have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the KOP receptor; or
- have agonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor.

[0084] In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have selective agonist activity at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

- have agonist activity at the KOP receptor, but no significant activity at the MOP receptor;
- have agonist activity at the KOP receptor, but no significant activity at the NOP receptor;
- have agonist activity at the KOP receptor, but no significant activity at the DOP receptor;
- have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the NOP receptor;
- have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
- have agonist activity at the KOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the NOP receptor as well as no significant activity at the DOP receptor.

[0085] In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have agonist activity at the MOP receptor, agonist activity at the KOP receptor, and antagonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

- have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor;
- have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor as well as agonist activity at the NOP receptor;
- have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor as well as antagonist activity at the NOP receptor; or
- have agonist activity at the MOP receptor as well as agonist activity at the KOP receptor as well as antagonist activity at the DOP receptor, no significant activity at the NOP receptor.

[0086] In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

- have agonist activity at the NOP receptor, but no significant activity at the MOP receptor;
- have agonist activity at the NOP receptor, but no significant activity at the KOP receptor;
- have agonist activity at the NOP receptor, but no significant activity at the DOP receptor;
- have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
- have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
- have agonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.

[0087] In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have selective antagonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

- have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor;
- have antagonist activity at the NOP receptor, but no significant activity at the KOP receptor;
- have antagonist activity at the NOP receptor, but no significant activity at the DOP receptor;
- have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor;
- have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the DOP receptor; or
- have antagonist activity at the NOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor as well as no significant activity at the DOP receptor.

[0088] In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

- have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor;
- have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor;

- have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the KOP receptor; or
- have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor, but no significant activity at the MOP receptor as well as no significant activity at the KOP receptor.

[0089] For the purpose of the specification, "no significant activity" means that the activity (agonist/antagonist) of the given compound at this receptor is lower by a factor of 1000 or more compared to its activity (agonist/antagonist) at one or more of the other opioid receptors.

[0090] A further aspect of the invention relates to the compounds according to the invention as medicaments.

[0091] A further aspect of the invention relates to the compounds according to the invention for use in the treatment of pain. A further aspect of the invention relates to a method of treating pain comprising the administration of a pain alleviating amount of a compound according to the invention to a subject in need thereof, preferably to a human. The pain is preferably acute or chronic. The pain is preferably nociceptive or neuropathic.

[0092] A further aspect of the invention relates to the compounds according to the invention for use in the treatment of neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, and substance abuse/dependence. A further aspect of the invention relates to a method of treating any one of the aforementioned disorders, diseases or conditions comprising the administration of a therapeutically effective amount of a compound according to the invention to a subject in need thereof, preferably to a human.

[0093] Another aspect of the invention relates to a pharmaceutical composition which contains a physiologically acceptable carrier and at least one compound according to the invention.

[0094] Preferably, the composition according to the invention is solid, liquid or pasty; and/or contains the compound according to the invention in an amount of from 0.001 to 99 wt. %, preferably from 1.0 to 70 wt. %, based on the total weight of the composition.

[0095] The pharmaceutical composition according to the invention can optionally contain suitable additives and/or auxiliary substances and/or optionally further active ingredients.

[0096] Examples of suitable physiologically acceptable carriers, additives and/or auxiliary substances are fillers, solvents, diluents, colorings and/or binders. These substances are known to the person skilled in the art (see H. P. Fiedler, *Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete*, Editio Cantor Aulendorf).

[0097] The pharmaceutical composition according to the invention contains the compound according to the invention in an amount of preferably from 0.001 to 99 wt. %, more preferably from 0.1 to 90 wt. %, yet more

preferably from 0.5 to 80 wt. %, most preferably from 1.0 to 70 wt. % and in particular from 2.5 to 60 wt. %, based on the total weight of the pharmaceutical composition.

[0098] The pharmaceutical composition according to the invention is preferably for systemic, topical or local administration, preferably for oral administration.

[0099] Another aspect of the invention relates to a pharmaceutical dosage form which contains the pharmaceutical composition according to the invention.

[0100] In one preferred embodiment, the pharmaceutical dosage form according to the invention is produced for administration twice daily, for administration once daily or for administration less frequently than once daily. Administration is preferably systemic, in particular oral.

[0101] The pharmaceutical dosage form according to the invention can be administered, for example, as a liquid dosage form in the form of injection solutions, drops or juices, or as a semi-solid dosage form in the form of granules, tablets, pellets, patches, capsules, plasters/spray-on plasters or aerosols. The choice of auxiliary substances etc. and the amounts thereof to be used depend on whether the form of administration is to be administered orally, perorally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to the skin, the mucosa or into the eyes.

[0102] Pharmaceutical dosage forms in the form of tablets, dragees, capsules, granules, drops, juices and syrups are suitable for oral administration, and solutions, suspensions, readily reconstitutable dry preparations and also sprays are suitable for parenteral, topical and inhalatory administration. Compounds according to the invention in a depot, in dissolved form or in a plaster, optionally with the addition of agents promoting penetration through the skin, are suitable percutaneous administration preparations.


[0103] The amount of the compounds according to the invention to be administered to the patient varies in dependence on the weight of the patient, on the type of administration, on the indication and on the severity of the disease. Usually, from 0.00005 mg/kg to 50 mg/kg, preferably from 0.001 mg/kg to 10 mg/kg, of at least one compound according to the invention is administered.

[0104] Another aspect of the invention relates to a process for the preparation of the compounds according to the invention. Suitable processes for the synthesis of the compounds according to the invention are known in principle to the person skilled in the art.

[0105] Preferred synthesis routes are described below:

[0106] The compounds according to the invention can be obtained via different synthesis routes. Depending on the synthesis route, different intermediates are prepared and subsequently further reacted.


[0107] In a preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIa):



(IIIa)

wherein R¹, R² and R³ are defined as above.


[0108] In another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIb):



(IIIb)

wherein R¹, R² and R³ are defined as above and PG is a protecting group.

[0109] Preferably the protecting group is -p-methoxybenzyl. Therefore, in another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIc):



(IIIc)

wherein R¹, R² and R³ are defined as above.

[0110] As already indicated, in general formula (IIIc), the -p-methoxybenzyl moiety represents a protecting group which can be cleaved in the course of the synthesis route.

[0111] In yet another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of

- an intermediate according to general formula (IIIa) and according to general formula (IIIb); or
- an intermediate according to general formula (IIIa) and according to general formula (IIIc); or
- an intermediate according to general formula (IIIb) and according to general formula (IIIc); or
- an intermediate according to general formula (IIIa), according to general formula (IIIb) and according to general formula (IIIc).

[0112] The following examples further illustrate the invention but are not to be construed as limiting its scope.

[0113] **Examples**

[0114] „RT“ means room temperature (23 ± 7 °C), „M“ are indications of concentration in mol/l, „aq.“ means aqueous, „sat.“ means saturated, „sol.“ means solution, "conc." means concentrated.

[0115] Further abbreviations:

brine	saturated aqueous sodium chloride solution
CC	column chromatography
cHex	cyclohexane
DCM	dichloromethane
DIPEA	N,N-diisopropylethylamine
DMF	N,N-dimethylformamide
Et	Ethyl
ether	diethyl ether
EE	ethyl acetate
EtOAc	ethyl acetate
EtOH	ethanol
h	hour(s)
H ₂ O	water
HATU	O-(7-aza-benzotriazol-1-yl)-N,N,N',N'-tetramethyluroniumhexafluorophosphate
LDA	Lithium-di-isopropyl-amid
Me	Methyl
m/z	mass-to-charge ratio
MeOH	methanol
MeCN	acetonitrile
min	minutes
MS	mass spectrometry
NBS	N-bromo-succinimide
NEt ₃	triethylamine

PE	Petrol Ether (60-80°C)
RM	reaction mixture
RT	room temperature
T3P	2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide
tBME	tert-.butyl methyl ether
THF	tetrahydrofuran
v/v	volume to volume
w/w	weight to weight

[0116] The yields of the compounds prepared were not optimised. All temperatures are uncorrected.


[0117] All starting materials, which are not explicitly described, were either commercially available (the details of suppliers such as for example Acros, Aldrich, Bachem, Butt park, Enamine, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, Oakwood, etc. can be found in the Symyx® Available Chemicals Database of MDL, San Ramon, US or the SciFinder® Database of the ACS, Washington DC, US, respectively, for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database of Elsevier, Amsterdam, NL or the SciFinder® Database of the ACS, Washington DC, US, respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art.

[0118] The mixing ratios of solvents or eluents for chromatography are specified in v/v.

[0119] All the intermediate products and exemplary compounds were analytically characterised by mass spectrometry (MS, m/z for $[M+H]^+$). In addition ^1H -NMR and ^{13}C spectroscopy was carried out for all the exemplary compounds and selected intermediate products.


[0120] **Remark regarding stereochemistry**

[0121] **CIS** refers to the relative configuration of compounds described herein, in which both nitrogen atoms are drawn on the same face of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:



CIS configuration


[0122] **TRANS** refers to compounds, in which both nitrogen atoms are on opposite faces of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:



TRANS configuration

[0123] **Synthesis of Intermediates**

[0124] **Synthesis of INT-799: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0125] **Step 1: CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0126] NaOH (1.42 g, 35.5 mmol) was added to a solution of CIS-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-794**) (3 g, 7.09 mmol) in DMSO (90 mL) under argon atmosphere and the reaction mixture was stirred at 80°C for 30 min. ((1-(Bromomethyl)cyclobutoxy)methyl)benzene (5.4 g, 21.3 mmol) was added and stirring was continued for 2 days at 80°C. The reaction completion was monitored by TLC. The reaction mixture was diluted with water (500 mL) and extracted with diethyl ether (4x300 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (230-400mesh silica gel; 65-70% EtOAc in petroleum ether as eluent) to afford 2.5g (59%) of CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (TLC system: 10% MeOH in DCM; R_f: 0.8).

[0127] **Step 2: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0128] TFA (12mL) was added to CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (2.5 g, 4.18 mmol) at 0°C and the resulting mixture was stirred at 70°C for 6 h. The reaction completion was monitored by LCMS. The reaction mixture was concentrated under reduced pressure. To the residue sat. aq. NaHCO₃ was added (until pH 10) and the organic product was extracted with DCM (3x150mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (230-400mesh silica gel; 5% MeOH in DCM as eluent) to afford 500mg (33%) of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-799**) (TLC system: 10% MeOH in DCM; Rf: 0.5). [M+H]⁺ 358.2

[0129] **Synthesis of INT-951: CIS-1-[(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-methyl]-cyclobutane-1-carbonitrile**



[0130] **Step 1: 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile**

[0131] NaH (50% in mineral oil) (2.44 g, 50.89 mmol) was added to a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro [4.5]decan-2-one (**INT-975**) (5 g, 12.72 mmol) in DMF (100 mL) at 0°C portionwise over 10 min. 1-(Bromomethyl)cyclobutanecarbonitrile (4.4 g, 25.44 mmol) was added dropwise over 10 minutes at 0°C. The reaction mixture was allowed to stir at RT for 3 h, then quenched with water and the organic product was extracted with ethyl acetate (3x200mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 5g (crude) of 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane-carbonitrile as gummy brown liquid. The material was used for the next step without further purification.


[0132] **Step 2: 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarboxamide**

[0133] TFA (100mL) was added to 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile (5 g, 10.28 mmol) at 0°C and the reaction mixture at mixture was stirred at RT for 2 days. The reaction mixture was concentrated *in vacuo*. To the residue sat. aq. NaHCO₃ was added (until pH 10) and the organic product was extracted with dichloromethane (3x150mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 3.5g (crude) of 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl) cyclobutanecarboxamide. The material was used for the next step without further purification.

[0134] **Step 3: 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane carbonitrile**


[0135] Thionyl chloride (35 mL) was added to 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarboxamide (3.5 g, 9.11 mmol) at RT and the resulting mixture was stirred at reflux for 2h. The reaction mixture was concentrated *in vacuo*. To the residue sat. aq. NaHCO₃ was added (until pH 10) and the organic product was extracted with dichloromethane (3x150mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography to afford 1.3 g (34% after three steps) of CIS-1-[(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-methyl]-cyclobutane-1-carbonitrile (**INT-951**). [M+H]⁺ 367.2.

[0136] **Synthesis of INT-952: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one**



[0137] To a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-975**) (10 g, 25 mmol) in THF (500 mL) was added KOtBu (7.1 g, 63 mmol) at 50 °C. The reaction mixture was heated up to reflux, cyclobutylmethylbromide (11.3 g, 76 mmol) was added in one portion, and stirring was continued at reflux for 12 h. KOtBu (7.1 g) and cyclobutylmethylbromide (11.3 g) were added again. The reaction mixture was allowed to stir another 2 h at reflux, then cooled to RT, diluted with water (150 mL) and the layers partitioned. The aqueous layer was extracted with EtOAc (3x300 mL). The combined organic layers were dried over Na₂SO₄ and then concentrated *in vacuo*. The residue was filtered through a plug of silica gel using a DCM/MeOH (19/1 v/v) mixture. The filtrate was concentrated *in vacuo* and the resulting solid was recrystallized from hot ethanol to yield 7.8 g of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (**INT-952**). [M+H]⁺ 461.3.

[0138] **Synthesis of INT-953: CIS-1-(Cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0139] **Step 1: 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxo-1,3-diazaspiro[4.2.4.2]tetradecan-2-one**

[0140] To a stirred solution of 3-(4-methoxy-benzyl)-9,12-dioxo-1,3-diazaspiro[4.2.4.2]tetradecan-2-one (4 g, 12.04 mmol) in anhydrous DMF (60 ml) was added NaH (1.38 g, 60% dispersion in oil, 36.14 mmol) at RT. The reaction mixture was stirred for 10 min, bromomethylcyclobutane (3 ml, 26.5 mmol) was added dropwise and stirring was continued for 50 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was quenched with sat. aq. NH_4Cl (50 ml) and extracted with EtOAc (3x200ml). The combined organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The resulting residue was purified column chromatography (neutral aluminum oxide, EtOAc – petroleum ether (2:8)) to give 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxo-1,3-diazaspiro[4.2.4.2]tetradecan-2-one (2.4 g, 50%, white solid). TLC system: EtOAc – pet ether (6:4); R_f = 0.48.

[0141] **Step 2: 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diazaspiro[4.5]decane-2,8-dione**

[0142] To a stirred solution of 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxo-1,3-diazaspiro[4.2.4.2]tetradecan-2-one (1 g, 2.5 mmol) in MeOH (7 ml) was added 10% aq. HCl (8 ml) at 0°C. The reaction mixture was warmed up to RT and stirred for 16 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was quenched with sat. aq. NaHCO_3 (30 ml) and extracted with EtOAc (3x50ml). The combined organic phase was dried over Na_2SO_4 and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, 230-400 mesh, EtOAc – pet ether (1:3)→(3:7)) to give 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diazaspiro[4.5]decane-2,8-dione (650 mg, 73%, colorless viscous oil). TLC system: EtOAc – pet ether (6:4); R_f = 0.40.

[0143] **Step 3: 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile**

[0144] To a stirred solution of N-isobutyl-N-methylamine (1.34 ml, 11.23 mmol) and MeOH/H₂O (8 ml, 1:1, v/v) was added 4N aq. HCl (1.5 ml) and the reaction mixture was stirred for 10 min at 0°C (ice bath). A solution of 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione (1 g, 2.80 mmol) in MeOH (7 ml) and KCN (548 mg, 8.42 mmol) were added and the reaction mixture was stirred at 45°C for 20 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was diluted with water (30 ml), extracted with EtOAc (3x30ml), the combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure to give 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (1.3 g, viscous yellow oil). TLC system: EtOAc – pet ether (1:1); R_f = 0.45. The product was used for the next step without additional purification.


[0145] **Step 4: CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0146] A round bottom flask containing 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (1.3 g, 2.81 mmol) was cooled in an ice bath (~0°C) and a solution of phenylmagnesium bromide (26 ml, ~2M in THF) was added slowly at 0°C-5°C. The ice bath was removed and the reaction mixture was stirred for 30 min, then diluted with sat. aq. NH₄Cl (25 ml) and extracted with EtOAc (4x30 ml). The combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure to give pale yellow viscous oil. This residue was purified by column chromatography (silica gel, 230-400 mesh, eluent: EtOAc – pet ether (15:85) → (2:4)) to give CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (135 mg, 10%, white solid). TLC system: EtOAc – pet ether (1:1); R_f = 0.6

[0147] **Step 5: CIS-1-(Cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0148] A round bottom flask containing CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (130 mg, 0.25 mmol) was cooled in an ice bath and a mixture of TFA/CH₂Cl₂ (2.6 ml, 1:1, v/v) was added slowly at 0°C-5°C. The reaction mixture was warmed to RT and stirred for 20 h, then quenched with methanolic NH₃ (10ml, ~10% in MeOH) and concentrated under reduced pressure to give pale yellow viscous oil. This residue was purified twice by column chromatography (silica gel, 230-400 mesh, eluent: MeOH – CHCl₃ (1:99) → (2:98)) to give CIS-1-(cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-953**) (65 mg, 66%, white solid). TLC system: MeOH – CHCl₃ (5:95); R_f = 0.25; [M+H]⁺ 384.3

[0149] **Synthesis of INT-958: 4-Oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile**




[0150] **Step 1: Ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate**

[0151] KOtBu (57.0 g, 508.4 mmol) was added to the solution of 2-(pyridin-2-yl)acetonitrile (50.0 g, 423.7 mmol) and ethyl acrylate (89.0 g, 889.8 mmol) in THF (500 mL) at 0°C and stirred for 16 h at RT. The reaction mixture was quenched with sat. aq. NH₄Cl and extracted with EtOAc (2x500 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 68.0 g (60%; crude) of ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate as a brown liquid (TLC system: 50% ethyl acetate in petroleum ether; R_f: 0.65).

[0152] **Step 2: 4-Oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile**

[0153] A solution of ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate (68.0 g, 250.0 mmol) was added to a mixture of conc. aq. HCl and glacial acetic acid (170mL/510mL) at 0°C. The reaction mixture was heated to 100°C for 16 h. All volatiles were evaporated under reduced pressure. The residue was diluted with sat. aq. NaHCO₃ and extracted with ethyl acetate (3x300 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 44.0g (88%) of 4-oxo-1-(pyridin-2-yl)-cyclohexane-1-carbonitrile **INT-958** as a brown solid (TLC system: 50% ethyl acetate in pet ether; R_f: 0.45). [M+H]⁺ 201.1

[0154] **Synthesis of INT-961: 4-Dimethylamino-4-(pyridin-2-yl)-cyclohexan-1-one**



[0155] **Step 1: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile**

[0156] A solution of 4-oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile (**INT-958**) (44.0 g, 220.0 mmol), ethylene glycol (27.0 g, 440.0 mmol) and PTSA (4.2 g, 22.0 mmol) in toluene (450 mL) was heated to 120°C for 16 h using Dean Stark apparatus. All volatiles were evaporated under reduced pressure. The residue was diluted with sat. aq. NaHCO₃ and extracted with ethyl acetate (3x300 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 45.0 g (85%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile as a light brown solid (TLC system: 50% ethyl acetate in petroleum ether; R_f: 0.55).

[0157] **Step 2: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide**

[0158] Potassium carbonate (50.0 g, 368.84 mmol) and 30% aq. H₂O₂ (210.0 mL, 1844.2 mmol) were added to the solution of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile (45.0 g, 184.42 mmol) in DMSO (450 mL) at 0°C and the resulting mixture was stirred at RT for 14 h. The reaction mixture was diluted with water (1.5 L) and stirred for 1 h. The precipitated solid was separated by filtration, washed with water, petroleum ether and dried under reduced pressure to get 32.0 g (66%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide as a white solid. (TLC system: 10% MeOH in DCM R_f: 0.35).

[0159] **Step 3: methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate**

[0160] A mixture of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide (25.0 g, 95.41 mmol), sodium hypochlorite (5wt% aq. solution, 700 mL, 477.09 mmol) and KF-Al₂O₃ (125.0 g) in methanol (500 mL) was heated to 80°C for 16 h. The reaction mixture was filtered through celite and the solid residue was washed with methanol. The combined filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (3x500mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 18.0g (66%) of methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate as a light brown solid. (TLC system: 5% MeOH in DCM R_f: 0.52.)


[0161] **Step 4: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine**

[0162] A suspension of methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate (18.0 g, 61.64 mmol) in 10wt% aq. NaOH (200 mL) was heated to 100°C for 24 h. The reaction mixture was filtered through celite pad, the solid residue was washed with water and the combined filtrate was extracted with EtOAc (4x200 mL). The combined organic layer washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 12.5g (88%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine as a light brown semi-solid. (TLC system: 5% MeOH in DCM R_f: 0.22.).

[0163] **Step 5: 4-Dimethylamino-4-pyridin-2-yl-cyclohexan-1-one**

[0164] Sodium cyanoborohydride (13.7 g, 0.213 mol) was added portionwise to a solution of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine (12.5 g, 53.418 mmol) and 35wt%aq. formaldehyde (45 mL, 0.534 mol) in acetonitrile (130 mL) at 0 °C. The reaction mixture was warmed up to room temperature and stirred for 16 h. The reaction mixture was quenched with sat. aq. NH₄Cl and concentrated under reduced pressure. The residue was dissolved in water and extracted with EtOAc (3x200 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 10.5 g (72%) of 4-dimethylamino-4-pyridin-2-yl-cyclohexan-1-one (**INT-961**) as a light brown solid. (TLC system: 5% MeOH in DCM R_f: 0.32.). [M+H]⁺ 219.1

[0165] **Synthesis of INT-965: 4-Dimethylamino-4-phenyl-cyclohexan-1-one**



[0166] **Step 1: 8-(Dimethylamino)-1,4-dioxaspiro 4.5] decane-8-carbonitrile**

[0167] Dimethylamine hydrochloride (52 g, 0.645 mol) was added to the solution of 1,4-dioxaspiro-[4.5]-decan-8-one (35g, 0.224 mmol) in MeOH (35 mL) at RT under argon atmosphere. The solution was stirred for 10 min and 40wt% aq. dimethylamine (280 mL, 2.5 mol) and KCN (32 g, 0.492 mol) were sequentially added. The reaction mixture was stirred for 48 h at RT, then diluted with water (100mL) and extracted with EtOAc (2x200 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 44 g of 8-(dimethylamino)-1,4-dioxaspiro-[4.5]-decan-8-carbonitrile (93%) as a white solid.

[0168] **Step 2: N,N-dimethyl-8-phenyl-1,4-dioxaspiro [4.5] decan-8-amine**


[0169] 8-(Dimethylamino)-1,4-dioxaspiro[4.5]decan-8-carbonitrile (35 g, 0.167 mol) in THF (350 mL) was added to the solution of 3M phenylmagnesium bromide in diethyl ether (556 mL, 1.67 mol) dropwise at -10°C under argon atmosphere. The reaction mixture was stirred for 4 h at -10°C to 0°C and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0°C, diluted with sat. aq. NH₄Cl (1 L) and extracted with EtOAc (2x600 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 60 g of, N N-dimethyl-8-phenyl-1, 4-dioxaspiro-[4.5]-decan-8-amine as a liquid.

[0170] **Step 3: 4-(dimethylamino)-4-phenylcyclohexanone**

[0171] A solution of N,N-dimethyl-8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine (32 g, 0.123 mol) in 6N aq. HCl (320 mL) was stirred at 0°C for 2 h and then at RT for 18 h. The reaction completion was monitored by

TLC. The reaction mixture was extracted with DCM (2x150 mL). The aqueous layer was basified to pH 10 with solid NaOH and extracted with ethyl acetate (2x200mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The solid residue was washed with hexane and dried *in vacuo* to afford 7g of 4-dimethylamino-4-phenyl-cyclohexan-1-one (**INT-965**) (25% over 2 steps) as a brown solid. [M+H]⁺ 218.1

[0172] **Synthesis of INT-966: 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione**



[0173] **Step 1: 9,12-Dioxa-2,4-diazadispiro[4.2.4⁸.2⁵]]tetradecane-1,3-dione**

[0174] KCN (93.8 g, 1441.6 mmol) and (NH₄)₂CO₃ (271.8 g, 1729.9 mmol) were added to the solution of 1,4-dioxaspiro[4.5]decan-8-one (150 g, 961 mmol) in MeOH:H₂O (1:1 v/v) (1.92 L) at RT under argon atmosphere. The reaction mixture was stirred at 60°C for 16 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0°C, the precipitated solid was filtered off and dried *in vacuo* to afford 120 g (55%) of 9,12-dioxa-2,4-diazadispiro[4.2.4⁸.2⁵]]tetradecane-1,3-dione. The filtrate was extracted with DCM (2x1.5 L). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford additional 30 g (14%) of 9,12-dioxa-2,4-diazadispiro[4.2.4⁸.2⁵]]tetradecane-1,3-dione (TLC system: 10% Methanol in DCM; R_f: 0.4).

[0175] **Step 2: 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4⁸.2⁵]]tetradecane-1,3-dione**

[0176] Cs₂CO₃ (258.7 g, 796.1 mmol) was added to the solution of **73a** (150 g, 663.4 mmol) in MeCN (1.5 L) under argon atmosphere and the reaction mixture was stirred for 30 min. A solution of *p*-methoxybenzyl bromide (96 mL, 663.4 mmol) was added. The reaction mixture was stirred at RT for 48 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH₄Cl (1.0L) and the organic product was extracted with EtOAc (2x1.5L). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was washed with diethyl ether and pentane and dried under reduced pressure to afford 151 g (65%) of 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4⁸.2⁵]]tetradecane-1,3-dione as an off white solid (TLC system: 10% MeOH in DCM; R_f: 0.6).


[0177] **Step 3: 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxo-2,4-diazadispiro[4.2.4⁸.2⁵]} tetradecan-3-one**

[0178] AlCl_3 (144.3 g, 1082.6 mmol) was added to a solution of LiAlH_4 (2M in THF) (433 mL, 866.10 mmol) in THF (4.5 L) at 0°C under argon atmosphere and the resulting mixture was stirred at RT for 1 h. 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxo-2,4-diazadispiro[4.2.4⁸.2⁵]}tetradecane-1,3-dione (150g, 433.05mmol) was added at 0°C . The reaction mixture was stirred at RT for 16 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0°C , quenched with sat. aq. NaHCO_3 (500 mL) and filtered through celite pad. The filtrate was extracted with EtOAc (2x2.0 L). The combined organic layer was dried over anhydrous Na_2SO_4 and concentrated *in vacuo* to afford 120g (84%) of 2-[(4-methoxyphenyl)-methyl]-9,12-dioxo-2,4-diazadispiro[4.2.4⁸.2⁵]}tetradecan-3-one as an off-white solid. (TLC system: 10% MeOH in DCM, Rf: 0.5).

[0179] **Step 4: 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione**

[0180] A solution of 2-[(4-methoxyphenyl)-methyl]-9,12-dioxo-2,4-diazadispiro[4.2.4⁸.2⁵]}tetradecan-3-one (120 g, 361.03 mmol) in 6N aq. HCl (2.4 L) was stirred at 0°C for 2 h and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was extracted with DCM (2x2.0L). The aqueous layer was basified to pH 10 with 50% aq. NaOH and then extracted with DCM (2 x 2.0L). Combined organic extracts were dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The solid residue was washed with hexane and dried *in vacuo* to afford 90 g of 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione (**INT-966**) as an off-white solid (TLC system: 10% MeOH in DCM; Rf: 0.4) $[\text{M}+\text{H}]^+$ 289.11.

[0181] **Synthesis of INT-971: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one**




[0182] **Step 1: CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0183] In analogy to the method described for **INT-951 step 1** CIS-8-Dimethylamino-8-[3-(methoxymethoxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (**INT-968**) was converted into CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-(methoxymethoxy)phenyl)-1,3-diazaspiro[4.5]decan-2-one.

[0184] **Step 2: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one**

[0185] TFA (0.2mL) was added to the solution of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-methoxyphenyl)-1,3-diazaspiro[4.5]decan-2-one (300 mg, 0.57 mmol) in DCM (1.5 mL) at 0°C. The reaction mixture was stirred at 0°C for 3 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NaHCO₃ and the organic product was extracted with DCM (3x10mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. Purification of the residue by preparative TLC (3% MeOH in DCM as mobile phase) yielded 50 mg (18%) of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (**INT-971**) as an off white solid. (TLC system: 10% MeOH in DCM; Rf: 0.20) [M+H]⁺ 478.3

[0186] **Synthesis of INT-974: CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one**




[0187] **Step 1: 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile**

[0188] Dimethylamine hydrochloride (76.4 g, 936.4 mmol) was added to a solution of 3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione (**INT-966**) (90 g, 312.13 mmol) in MeOH (180 mL) at RT under argon atmosphere. The solution was stirred for 15 min and 40wt% aq. dimethylamine (780 mL) and KCN (48.76 g, 749.11 mmol) were sequentially added. The reaction mixture was stirred for 48 h and the completion of the reaction was monitored by NMR. The reaction mixture was diluted with water (1.0 L) and the organic product was extracted with ethyl acetate (2x2.0L). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 90g (85%) of 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile as an off white solid (TLC system: 10% MeOH in DCM; Rf: 0.35, 0.30).

[0189] **Step 2: CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one**


[0190] 3-Fluorophenylmagnesium bromide (1M in THF) (220 mL, 219.17 mmol) was added dropwise to a solution of 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (15 g, 43.83 mmol) in THF (300 mL) at 0°C under argon atmosphere. The reaction mixture was stirred for 16 h at RT. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0°C, quenched with sat. aq. NH₄Cl (200 mL) and the organic product was extracted with EtOAc (2x200mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The reaction was carried out in 4 batches (15 g x 2 and 5 g x 2) and the batches were combined for purification. Purification of the crude product by flash column chromatography on silica gel (230-400 mesh) (2 times) (0-20% methanol in DCM) eluent and subsequently by washing with pentane yielded 5.6 g (11%) of CIS-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (**INT-974**) as an off-white solid. (TLC system: 5% MeOH in DCM in presence of ammonia; R_f: 0.1). [M+H]⁺ 412.2

[0191] **Synthesis of INT-975: CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0192] KOtBu (1M in THF) (29.30mL, 29.30mmol) was added to the solution of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one **INT-976** (8.0 g, 29.30 mmol) in THF (160 mL) under argon atmosphere and the reaction mixture was stirred for 30 min. 4-Methoxybenzyl bromide (4.23 mL, 29.30 mmol) was added and stirring was continued at RT for 4 h. The reaction completion was monitored by TLC. The reaction mixture was diluted with sat. aq. NH₄Cl (150mL) and the organic product was extracted with EtOAc (2x150mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The reaction was carried out in 2 batches (8 g x 2) and the batches were combined for purification. Purification of the crude product by flash column chromatography on silica gel (0-10% methanol in DCM) and subsequently by washing with pentane yielded 11 g (47%) of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-975**) as a white solid. [M+H]⁺ 394.2

[0193] **Synthesis of INT-976: CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0194] **Step 1: 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2,4-dione**

[0195] In a sealed tube 4-dimethylamino-4-phenyl-cyclohexan-1-one (**INT-965**) (2 g, 9.22 mmol) was suspended in 40mL EtOH/H₂O (1:1 v/v) at RT under argon atmosphere. (NH₄)₂CO₃ (3.62 g, 23.04 mmol) and KCN (0.6 g, 9.22 mmol) were added. The reaction mixture was stirred at 60°C for 18h. The reaction mixture was cooled to 0°C and diluted with ice-water and filtered through a glass filter. The solid residue was dried under reduced pressure to afford 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2,4-dione (1.8 g, 86%) as an off white crystalline solid (TLC: 80% EtOAc in hexane; R_f: 0.25).


[0196] **Step 2: 8-(dimethylamino)-8-phenyl-1, 3-diazaspiro [4, 5] decan-2-one**

[0197] LiAlH₄ (2M in THF) (70 mL, 139.4 mmol) was added to the solution of 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2,4-dione (10 g, 34.8 mmol) in THF/Et₂O (2:1 v/v) (400 mL) at 0°C under argon atmosphere. The reaction mixture was stirred for 4 h at 60°C. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0°C, quenched with saturated Na₂SO₄ solution (100mL) and filtered through Celite pad. The filtrate was dried over anhydrous Na₂SO₄ and concentrated *in vacuo* to afford 5.7g (59%) of 8-(dimethylamino)-8-phenyl-1, 3-diazaspiro [4, 5] decan-2-one as an off white solid. (TLC system: 10% MeOH in DCM, R_f: 0.3).

[0198] **Step 3: CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0199] A mixture of CIS- and TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2-one (8g, 29.30mmol) was purified by preparative chiral SFC (column: Chiralcel AS-H, 60% CO₂, 40% (0.5% DEA in MeOH)) to get 5g of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-976**) as a white solid. [M+H]⁺ 274.2.

[0200] **Synthesis of INT-977: CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid; 2,2,2-trifluoro-acetic acid salt**




[0201] **Step 1: CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic acid tert-butyl ester**

[0202] A solution of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-975**) (5.0 g, 12.7 mmol) in THF (18 mL) was cooled to 0°C and treated with LDA solution (2M in THF/heptane/ether, 25.4 mL, 50.8 mmol). The resulting mixture was allowed to warm up to RT over 30 min. The solution was then cooled to 0°C again and tert-butyl-bromoacetate (5.63 mL, 38.1 mmol) was added. The reaction mixture was stirred at RT for 16 h, quenched with water and extracted with DCM (3x). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel provided CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic acid tert-butyl ester (4.4 g).

[0203] **Step 2: cis- 2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid trifluoroacetic acid salt**


[0204] CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5] decan-1-yl]-acetic acid tert-butyl ester (200 mg, 0.4 mmol) was dissolved in TFA (5 mL) and heated to reflux overnight. After cooling to RT all volatiles are removed *in vacuo*. The residue was taken up in THF (1 mL) and added dropwise to diethyl ether (20 mL). The resulting precipitate was filtered off and dried under reduced pressure to give CIS-2-(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid; 2,2,2-trifluoro-acetic acid salt (**INT-977**) (119 mg) as a white solid. [M+H]⁺ 332.2

[0205] **Synthesis of INT-978: CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide**



[0206] CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid (**INT-977**) trifluoroacetic acid salt (119 mg, 0.35 mmol) was dissolved in DCM (5 mL). Triethylamine (0.21 mL, 1.6 mmol), dimethylamine (0.54 mL, 1.1 mmol) and T3P (0.63 mL, 1.1 mmol) were sequentially added. The reaction mixture was stirred at RT overnight, then diluted with 1 M aq. Na_2CO_3 (5 mL). The aqueous layer was extracted with DCM (3x5mL), the combined organic layers were dried over Na_2SO_4 and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to yield CIS-2-(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide (**INT-978**) (39 mg) as a white solid. $[\text{M}+\text{H}]^+$ 359.2

[0207] **Synthesis of INT-982: CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0208] **Step 1: CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**


[0209] A solution of NaOH (2.85 g, 71.2 mmol) in DMSO (25 mL) was stirred at RT for 10 min. CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (**INT-975**) (7.00 g, 17.8 mmol) was added and stirring was continued for 15 min. 1-(Bromo-methyl)-1-methyl-cyclobutane (8.7 g, 53.4 mmol) was added at 0°C. The reaction mixture was heated to 60°C for 16 h. After cooling down to RT, water (100 mL) was added and the mixture was extracted with DCM (3x150 mL). The combined organic layers were washed with water (70 mL), brine (100 mL), dried over Na_2SO_4 and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel provided CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (6.5g) as a light yellow solid.

[0210] **Step 2: CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0211] To the solution of CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (6.66 g, 14.0 mmol) in DCM (65 mL) was added TFA (65 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was taken up in DCM (100 mL) and water (60 mL) and basified with 2M aq. NaOH to pH 10. The organic layer was separated and washed with brine (40 mL), dried over MgSO_4 , filtered and concentrated under reduced

pressure. Crystallization of the residue from EtOAc provided CIS-8-Dimethylamino-1-[(1-methylcyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (**INT-982**) (3.41 g) as an off-white solid. $[M+H]^+$ 356.3

[0212] **Synthesis of INT-984: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0213] **Step 1: CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0214] In analogy to the method described for **INT-951 step 1** CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-975**) was converted into CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one.

[0215] **Step2: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0216] In analogy to the method described for **INT-982 step 2** CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-984**).

[0217] **Synthesis of INT-986: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0218] **Step 1: CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0219] N-Iodosuccinimide (3.11 g, 13.92 mmol) was added to the solution of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[phenyl-methyl]-1,3-diazaspiro[4.5]decan-2-one (**INT-950**) (4 g, 9.28 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 80 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH~10 and the organic product was extracted with DCM (3x10 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The residue was stirred vigorously with a mixture of 10wt% aq. citric acid (5 mL) and DCM (10 mL) at RT for 10 min. The reaction mixture was basified with 5N aq. NaOH to pH~10 and extracted with DCM (3x10 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated *in vacuo* to give 3.5g (crude) of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as semi solid (TLC system: 10% MeOH in DCM; R_f: 0.60.).


[0220] **Step 2: CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0221] Sodium cyanoborohydride (1.56 g, 25.17 mmol, 3 equiv.) was added to the solution of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (3.5 g, 8.39 mmol), acetaldehyde (738 mg, 16.78 mmol, 2 equiv.) and acetic acid (0.5 mL) in methanol (20 mL). The reaction mixture was stirred at RT for 3 h, then quenched with sat. aq. NaHCO₃ and the organic product was extracted with DCM (3x50 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. Purification of the residue by flash column chromatography on silica gel (230-400 mesh) (20-25% ethyl acetate in petroleum ether) yielded 2.3g (62%) of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as a solid. (TLC system: 50% EtOAc in Pet. Ether; R_f: 0.65).

[0222] **Step 3: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-986)**


[0223] Sodium metal (1.18 g, 51.68 mmol, 10 equiv.) was added to liquid ammonia (~25 mL) at -78°C. The resulting mixture was stirred for 10min at -78°C. A solution of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (2.3 g, 5.16 mmol) in THF (25 mL) was added at -78 °C. The reaction mixture was stirred for 15min, then quenched with sat. aq. NH₄Cl, warmed to RT and stirred for 1h. The organic product was extracted with DCM (3x50 mL). The combined organic layer was washed with water, brine and concentrated under reduced pressure to afford 1.30 g (72%) of CIS-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-986**) as an off-white solid. (TLC system: 10% MeOH in DCM R_f: 0.15.). [M+H]⁺ 356.3

[0224] **Synthesis of INT-987: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0225] In analogy to the method as described for **INT-982 step 2** CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (**INT-952**) was converted into CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-987**).

[0226] **Synthesis of INT-988: CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0227] **Step 1: CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0228] Sodium hydroxide (78.06 mg, 4.0 equiv.) was suspended in DMSO (3.5 mL), stirred for 10 minutes, 8-(dimethylamino)-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-975**) (192.0 mg, 1.0 equiv.) was added, the reaction mixture was stirred for 5 min followed by addition of 2-(1-methoxycyclobutyl)ethyl 4-methylbenzenesulfonate (416.2 mg, 3.0 equiv.) in DMSO (1.5 mL). The resulting mixture was stirred overnight at 50°C. The reaction mixture was quenched with water and extracted with DCM (3x20 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue (283 mg yellow oil) was purified by column chromatography on silica gel (eluent DCM/EtOH 98/2 to 96/4) to give 8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one 163 mg (66%).

[0229] **Step 2: CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-988)**

[0230] In analogy to the method described for **INT-982 step 2** CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-988**). Mass: m/z 386.3 (M+H)⁺.

[0231] **Synthesis of INT-1008: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one**



[0232] **Step 1 and step 2: ethyl-(8-phenyl-1,4-dioxaspiro[4.5]dec-8-yl)-amine hydrochloride (INT-1004)**

A mixture of 1,4-dioxaspiro[4.5]decan-8-one (25.0 g, 160.25 mmol, 1.0 eq.) and 2M solution of EtNH₂ in THF (200 ml, 2.5 eq. 400.64 mmol) in EtOH (30 ml) was stirred at RT for 48h. The reaction mixture was concentrated under argon atmosphere and the residue was diluted with ether (60 ml), and a freshly prepared PhLi solution was added [prepared by addition of 2.5M n-BuLi in THF (70.5 ml, 1.1 eq. 176.27 mmol) to a solution of bromobenzene (27.675g, 1.1 eq. 176.275 mmol) in ether (100 ml) at -30 °C and stirred at RT for 1h). The reaction mixture was stirred at RT for 1.5h, quenched with saturated NH₄Cl solution (100 ml) at 0°C and extracted with ethyl acetate (2 x 750 ml). The combined organic layer was washed with water (3 x 350 ml), brine (300 ml), dried over Na₂SO₄ and concentrated under reduced pressure. The resulting residue was dissolved in ethyl methyl ketone (100 ml) and trimethylsilyl chloride (37.5 ml) was added at 0°C. The resulting mixture was stirred at RT for 16h. The precipitated solid was filtered off and washed with acetone followed by THF to get ethyl-(8-phenyl-1,4-dioxaspiro[4.5]dec-8-yl)-amine hydrochloride as an off white solid. This reaction was done in 2 batches of 25 g scale and the yield is given for 2 combined batches. Yield: 18 % (17.1 g, 57.575 mmol). LCMS: m/z 262.2 (M+H)⁺.

[0233] Step 3: 4-ethylamino-4-phenyl-cyclohexanone (INT-1005)

[0234] To a solution of ethyl-(8-phenyl-1,4-dioxo-spiro[4.5]dec-8-yl)-amine hydrochloride (10.1 g, 34.0 mmol, 1 eq.) in water (37.5 ml) was added conc. aq. HCl (62.5 ml) at 0°C and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with aq. NaOH (pH ~14) at 0°C and extracted with DCM (2x750 ml). Organic layer was washed with water (400 ml), brine (400 ml), dried over Na₂SO₄ and concentrated under reduced pressure to yield 4-ethylamino-4-phenyl-cyclohexanone which was used in the next step without further purification. This reaction was carried out in another batch of 15.1g scale and the yield is given for 2 combined batches. Yield: 92 % (17.0 g, 78.34 mmol).

[0235] Step 4: cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006 and INT-1007)

[0236] To a solution of 4-ethylamino-4-phenyl-cyclohexanone (17 g, 78.341 mmol, 1.0 eq.) in EtOH (250 ml) and water (200 ml) was added (NH₄)₂CO₃ (18.8 g, 195.85 mmol, 2.5 eq.) and the reaction mixture was stirred at RT for 15 min. KCN (5.09 g, 78.341 mmol, 1.0 eq.) was added and stirring was continued at 60 °C for 18 h. The reaction mixture was cooled down to RT. The precipitated solid was filtered off, washed with water (250 ml), EtOH (300 ml), hexane (200 ml) and dried under reduced pressure to yield *cis* and *trans* mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (13.0 g, 45.29 mmol, 58%) as a white solid. Yield: 58 % (13 g, 45.296 mmol). LC-MS: m/z [M+1]⁺ = 288.2.

[0237] Step 5: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006)


[0238] To a solution of *cis* and *trans* mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (12g) in MeOH-DCM (1:1, 960 ml) was added a solution of L-tartaric acid in MeOH (25 ml) and the resulting mixture stirred at RT for 2 h and then kept in refrigerator for 16 h. The precipitated solid was filtered off and washed with MeOH-DCM (1:5, 50 ml) to get tartrate salt of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (7.5 g) as a white solid. To this solid sat. aq. NaHCO₃ was added (pH~8) and the resulting mixture was extracted with 25% MeOH-DCM (2 x 800 ml). Combined organic layer was washed with water (300 ml), brine (300 ml), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was triturated with 20 % DCM-hexane and the resulting solid was dried under reduced pressure to afford CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione as white solid. This step was done in 2 batches (12 g & 2.4 g) and the yield is given for 2 combined batches. Yield: 31.2 % (5.0 g, 17.421 mmol). LC-MS: m/z [M+1]⁺ = 288.0.

[0239] Step 6: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1008)

[0240] To a slurry of LiAlH₄ (793 mg, 20.91 mmol, 3.0 eq.) in THF (15 ml) was added a suspension of CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (2.0 g, 6.97 mmol, 1.0 eq.) in THF (60 ml) at 0°C and the reaction mixture was heated to 65°C for 16 h. The reaction mixture was cooled to 0°C,

quenched with sat. aq. Na_2SO_4 (20 ml), stirred at RT for 1h and filtered through celite pad. The residue was washed with 15% MeOH-DCM (500 ml). The combined filtrate was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure to give crude product which was triturated with 15% DCM-Hexane to afford CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (**INT-1008**) (1.6 g, 5.86 mmol, 84%) as a white solid. Yield: 84 % (1.6 g, 5.86 mmol). LC-MS: m/z $[\text{M}+1]^+ = 274.2$.

[0241] **Synthesis of INT-1026: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0242] **Step 1: 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfonamide**

[0243] Titanium ethoxide (58.45 g, 256.4mmol) was added to a solution of 1,4-dioxaspiro[4.5]decan-8-one (20 g, 128.20 mmol) and 2-methylpropane-2-sulfonamide (15.51g, 128.20 mmol) in THF (200 mL) at RT and the reaction mixture was stirred at RT for 18h. The reaction mixture was cooled to 0°C and quenched by dropwise addition of sat. aq. NaHCO_3 (500 mL) over a period of 30 min. The organic product was extracted with EtOAc (3x100 mL). The combined organic extracts were dried over anhydrous Na_2SO_4 and concentrated *in vacuo* to afford 10 g (crude) of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfonamide as a white solid (TLC system: 30% Ethyl acetate in hexane; Rf: 0.30).

[0244] **Step 2: 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfonamide**

[0245] Phenylmagnesium bromide (1M in THF, 116 mL, 116 mmol) was added dropwise to a solution of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfonamide (10 g, 38.61 mmol) in THF (500 mL) at -10°C under argon atmosphere. The reaction mixture was stirred for 2h at -10°C to 0°C. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH_4Cl (50mL) at 0°C and the organic product was extracted with EtOAc (3x100 mL). The combined organic extracts were dried over anhydrous Na_2SO_4 and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel 230-400 mesh; 40-60% ethyl acetate in hexane) to yield 6.0 g (46%) of 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfonamide as a liquid (TLC system: 70% Ethyl acetate in hexane; Rf: 0.30).

[0246] **Step 3: 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride**

[0247] 2N solution of HCl in diethyl ether (17.80 mL, 35.60 mmol) was added to a solution of 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfonamide (6.0g, 17.80 mmol) in DCM (60 mL) at 0°C. The reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated *in vacuo*. The residue was washed with diethyl ether to yield 3g (crude) of 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride as a brown solid (TLC system: 5% MeOH in DCM; Rf: 0.10).

[0248] **Step 4: 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine**

[0249] Sodium cyanoborohydride (2.17 g, 33.45 mmol) was added to a solution of 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride (3.0 g, 11.15 mmol) and tetrahydrofuran-3-carbaldehyde (4.46 mL, 22.30 mmol) and acetic acid (0.05 mL) in methanol (30 mL) at 0°C. The reaction mixture was stirred at RT for 16h. The reaction mixture was concentrated *in vacuo* at 30°C and to the residue sat. aq. NaHCO₃ was added. The organic product was extracted with DCM (3x30 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and solvent was concentrated under reduced pressure to get 3g (crude) of 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine as a semi-solid (TLC system: 10% MeOH in DCM; Rf: 0.22).

[0250] **Step 5: N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine)**

[0251] Sodium cyanoborohydride (1.76 g, 28.39 mmol) was added to a solution of 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine (3.0 g, 9.46 mmol), 37% formaldehyde in water (7.70 mL, 94.60 mmol) and acetic acid (0.05 mL) in methanol (30 mL) at 0°C. The reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated *in vacuo* and to the residue sat. aq. NaHCO₃ was added. The organic product was extracted with DCM (3x30 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and solvent was concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel 230-400 mesh; 5-6% MeOH in DCM) to yield 2.50 g (83%) of N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine as a semi solid (TLC system: 10% MeOH in DCM; Rf: 0.25).

[0252] **Step 6: 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone**

[0253] 5% sulfuric acid in water (25 mL) was added to N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine (2.50 g, 7.55 mmol) at 0°C and the resulting mixture was stirred at RT for 24 h. The reaction mixture was quenched with sat. aq. NaHCO₃ and the organic product was extracted with DCM (2x50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated *in vacuo* to afford 2.0g (crude) of 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone as a thick liquid (TLC system: 10% MeOH in DCM, Rf: 0.20).

[0254] **Step 7: 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione**

[0255] 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone (1.50 g, 5.22 mmol) was suspended in 30 mL of EtOH:H₂O (1:1 v/v) at RT under argon atmosphere. (NH₄)₂CO₃ (1.9 g, 13.05 mmol) and KCN (0.34 g, 5.22 mmol) were added. The reaction mixture was heated to 70°C for 16 h. The reaction mixture was diluted with ice-water and the organic product was extracted with DCM (2x50 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated *in vacuo* to give 1.0 g (crude) of 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione as a solid (TLC system: 70% Ethyl acetate in hexane; R_f: 0.18).


[0256] **Step 8: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione**

[0257] Diastereomeric mixture of 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (1.0 g) was separated by reverse phase preparative HPLC to afford 400 mg of isomer 1 (CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione) and 60 mg of isomer 2 (TRANS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione) and 300 mg of mixture of both isomers. Reverse phase preparative HPLC conditions: mobile phase: 10mM ammonium bicarbonate in H₂O/acetonitrile, column: X-BRIDGE-C18 (150*30), 5µm, gradient (T/B%): 0/35, 8/55, 8.1/98, 10/98, 10.1/35, 13/35, flow rate: 25 ml/min, diluent: mobile phase+ THF.

[0258] **Step 9: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026)**

[0259] LiAlH₄ (1M in THF) (4.48 mL, 4.48 mmol) was added to a solution of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (isomer-1) (0.4 g, 1.12 mmol) in THF:Et₂O (2:1 v/v, 15 mL) at 0°C under argon atmosphere. The reaction mixture was stirred at 65°C for 16 h. The mixture was cooled to 0°C, quenched with sat. aq. Na₂SO₄ (1000 mL) and filtered through celite pad. The filtrate was dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel 230-400 mesh; 5-6% MeOH in DCM) to yield 0.3g (78%) of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026) as an off white solid. (TLC system: 10% MeOH in DCM, R_f: 0.2). LC-MS: m/z [M+1]⁺ = 344.2.

[0260] **Synthesis of INT-1031: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one**




[0261] **Step 1: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one**

[0262] In analogy to the method described for **INT-952** CIS-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (**INT-974**) was converted into CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one.

[0263] **Step 2: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one**

[0264] In analogy to the method described for **INT-982** step 2 1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one was converted into 1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one (**INT-1031**).

[0265] **Synthesis of INT-1037: 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile**



[0266] **Step 1: 9,12-dioxo-2,4-diazadispiro[4.2.4⁸.2⁵]]tetradecan-3-one**

[0267] Lithiumaluminiumhydride (2.2 equiv., 292 mmol) was suspended in THF (400 mL) and the suspension was cooled to 0°C. 8-(Dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (B, 75 mg, 0,261 mmol) (step 1 of **INT-965**) was added portionwise at 0°C. The reaction mixture was stirred 1.5 h at 0°C, then overnight at RT and then 2 h at 40°C. The reaction mixture was cooled down to 0°C, quenched carefully with sat. aq. Na₂SO₄, EtOAc (400 mL) was added and the resulting mixture was stirred for 2 h and then left without stirring for 2h at RT. The precipitate was filtered off and washed with EtOAc and MeOH. The resulting solid residue was suspended in methanol and stirred at RT overnight. The precipitate was filtered off and disposed. The filtrate was concentrated under reduced pressure, the residue was suspended thoroughly in water (50 mL) at 40 °C, the precipitate was filtered off and dried under reduced pressure to yield 9,12-dioxo-2,4-diazadispiro[4.2.4⁸.2⁵]]tetradecan-3-one (11.4 g, 41%). Mass: m/z 213.2 (M+H)⁺.


[0268] **Step 2: 1,3-diazaspiro[4.5]decane-2,8-dione**

[0269] In analogy to the method described for **INT-1003 step 3** 9,12-dioxo-2,4-diazadispiro[4.2.4⁸.2⁵]]tetradecan-3-one was treated with conc. aq. HCl to be converted into 1,3-diazaspiro[4.5]decane-2,8-dione. Mass: m/z 169.1 (M+H)⁺.

[0270] **Step 3: 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (INT-1037)**

[0271] In analogy to the method described for **INT-965 step 1** 1,3-diazaspiro[4.5]decane-2,8-dione was treated with dimethyl amine and potassium cyanide to be converted into 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (**INT-1037**). Mass: m/z 223.2 (M+H)⁺.


[0272] **Synthesis of INT-1038: CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one**



[0273] To the suspension of 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (200 mg, 0.90 mmol) in THF (4 mL) at RT was added dropwise 1M bromo(m-tolyl)magnesium in THF (4 equiv., 3.6 mmol, 3.6 mL) and the reaction mixture was stirred for 1 h at RT. Additional portion of 1M bromo(m-tolyl)magnesium in THF (1 equiv., 0.8 mL) was added. The reaction mixture was stirred at RT overnight, then quenched with methanol/water. Solid NH₄Cl and DCM were added to the resulting mixture and the precipitate was filtered off. The organic phase of the filtrate was separated and the aqueous phase was extracted with DCM (3x). The combined organic phases were dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (DCM/MeOH, 100/0

to 65/35) to yield CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (**INT-1038**) (81 mg, 31%). Mass: m/z 288.2 (M+H)⁺.

[0274] **Synthesis of INT-1052: CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0275] **Step 1: CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile**

[0276] NaH (60% in mineral oil) (1.76 g, 44.04 mmol) was added to the solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-983) (3.6 g, 11.01 mmol) in DMSO (150 mL) at RT under argon atmosphere. 2-Cyano-2-methylpropyl 4-methylbenzenesulfonate (113 mg, 0.45 mmol) was added to the reaction mixture in one portion. The reaction mixture was heated at 70 °C for 16 h. The reaction mixture was cooled to 0°C and quenched with water (20 mL). The organic product was extracted with EtOAc (2x200 mL). The combined organic extracts were dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 100-200 mesh, 0-10% MeOH in DCM) to get 2.1 g, 46% of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile as an off-white solid (TLC system: 5 % MeOH in DCM; R_f: 0.60).

[0277] **Step 2: CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanamide**


[0278] H₂O₂ (30% in water) (8 mL) was added to a solution of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (2.0 g, 4.90 mmol) in DMSO (50 mL) at RT under argon atmosphere. A solution of KOH (1.1 g, 19.6 mmol) in water (10 mL) was added dropwise to the reaction mixture. The reaction mixture was stirred at RT for 16h. The reaction mixture was diluted with water (300 mL) and the organic product was extracted with EtOAc (2 x 100 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 100-200 mesh, 0-5% MeOH in DCM) to get 0.44 g (21%) of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanamide as a gummy solid (TLC system: 5 % MeOH in DCM; R_f: 0.30) and 1.1 g of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-

diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile was also reisolated (TLC system: 5 % MeOH in DCM; Rf: 0.30).

[0279] Step 3: CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1052)


[0280] $\text{PhI}(\text{OCOCF}_3)_2$ (703.5 mg, 1.636 mmol) was added to a solution of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanamide (410 mg, 0.962 mmol) in mixture of acetonitrile (15 mL) and water (15 mL) at RT under argon atmosphere. The reaction mixture was stirred for 18h at RT. The reaction mixture was diluted with water (15 mL) and the aqueous layer was washed with EtOAc (2x20 mL). The water layer was basified with solid NaHCO_3 and the organic product was extracted with EtOAc (2x30 mL). The organic layer was dried over anhydr. Na_2SO_4 and solvent was concentrated under reduced pressure to afford 350 mg, 91% of CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as gummy solid (TLC system: 5 % MeOH in DCM; Rf: 0.15). Mass: m/z 399.3 ($\text{M}+\text{H}$)⁺.

[0281] Synthesis of INT-1054: CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one



[0282] To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (50 g, 230.1 mmol) in MeOH (400 mL) was added NH_4Cl (24.6 g, 460.8 mmol) followed by NH_4OH (400 mL) at RT and stirred for 15 min. NaCN (22.5 g, 460.83 mmol) was added to the reaction mixture and stirred for 16 h at RT. The reaction mixture was extracted with DCM (3x750 mL). Organic layer was washed with water (750 mL), brine (750 mL) and dried over Na_2SO_4 . The solvent was evaporated under reduced pressure. The residue was triturated with DCM/hexane to get crude 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (50 g, 90%) as off white solid which was used in next step without purification. Yield: 78 % (44 g, 181 mmol). Mass: m/z 244.2 ($\text{M}+\text{H}$)⁺.

[0283] Synthesis of INT-1055 and INT-1056: CIS- and TRANS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



[0284] **Step 1: N-(1-cyano-4-(dimethylamino)-4-phenylcyclohexyl)cyclobutanecarboxamide (CIS-/TRANS mixture)**

[0285] To a solution of 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (**INT-1054**) (5.0 g, 20.57 mmol, 1.0 eq.) in THF (100 mL) were added cyclobutanecarboxylic acid (2.50 g, 24.69 mmol, 1.2 eq), DIPEA (10.5 mL, 61.71 mmol, 3.0 eq) and T3P (18.38 mL, 30.85 mmol, 1.5 eq). The reaction mixture was stirred at RT for 16h, diluted with water (100 mL) and extracted with EtOAc (2x200 mL). Combined organic layer was washed with brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude cyclobutanecarboxylic acid (1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-amide as a light yellow sticky material which was used in the next step without further purification. Mass: m/z 326.3 (M+H)⁺.

[0286] **Step 2: 1-(aminomethyl)-N¹-(cyclobutylmethyl)-N⁴,N⁴-dimethyl-4-phenylcyclohexane-1,4-diamine (CIS/TRANS-mixture)**

[0287] To suspension of LiAlH₄ (2.81 g, 73.84 mmol, 6.0 eq.) in dry THF (25 mL) was added a solution cyclobutanecarboxylic acid (1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-amide (4.0 g, 12.3 mmol, 1.0 eq.) in dry THF (35 mL) dropwise at 0°C. The reaction mixture was stirred at RT for 16h, then quenched with sat. aq. Na₂SO₄ at 0°C, excess THF was added and the resulting mixture stirred at RT for 2h. The reaction mixture was filtered through celite and washed with THF (100 mL). Filtrate was concentrated under reduced pressure to get crude 1-aminomethyl-N-cyclobutylmethyl-N⁴,N⁴-dimethyl-4-phenyl-cyclohexane-1,4-diamine (3.0 g) as a light yellow sticky material which was used in the next step without further purification. Mass: m/z 316.4 (M+H)⁺.

[0288] **Step 3: N-((1-((cyclobutylmethyl)amino)-4-(dimethylamino)-4-phenylcyclohexyl)methyl)-2-methyl-2-(methylthio)propanamide (CIS/TRANS-mixture)**

[0289] To a solution of crude 1-aminomethyl-N-cyclobutylmethyl-N',N'-dimethyl-4-phenyl-cyclohexane-1,4-diamine (3.0 g, 9.23 mmol, 1.0 eq.) in THF (50 mL) were added 2-methyl-2-methylsulfanyl-propionic acid (1.23 g, 9.23 mmol, 1.0 eq), DIPEA (4.81 mL, 27.69 mmol, 3.0 eq) and T3P (8.3 mL, 13.84 mmol, 1.5 eq, 50% solution in EtOAc) at 0°C and the resulting mixture was stirred at RT for 16h. The reaction mixture was diluted with DCM (300 mL), washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude N-[1-(cyclobutylmethyl-amino)-4-dimethylamino-4-phenyl-cyclohexylmethyl]-2-methyl-2-methylsulfanyl-propionamide as a light yellow sticky material which was used in the next step without further purification. Mass: m/z 432.1 (M+H)⁺.


[0290] **Step 4: N¹-(cyclobutylmethyl)-N⁴,N⁴-dimethyl-1-(((2-methyl-2-(methylthio)propyl)amino)methyl)-4-phenylcyclohexane-1,4-diamine (CIS/TRANS-mixture)**

[0291] To a solution of crude N-[1-(cyclobutylmethyl-amino)-4-dimethylamino-4-phenyl-cyclohexylmethyl]-2-methyl-2-methylsulfanyl-propionamide (2.5 g, 5.8 mmol, 1.0 eq.) in THF (60 mL) was added BH₃xMe₂S (2.75 mL, 29.0 mmol, 5.0 eq.). The reaction mixture was stirred at RT for 16h, then quenched with MeOH (10 mL) and 2N HCl (10 mL) at 0°C and stirred at RT for 30 min. The resulting mixture was concentrated under reduced pressure, diluted with water (50 mL), basified with sat. aq. NaHCO₃ and extracted with DCM (2x250 mL). Combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure to get crude N-cyclobutylmethyl-N',N'-dimethyl-1-[(2-methyl-2-methylsulfanyl-propylamino)-methyl]-4-phenyl-cyclohexane-1,4-diamine as a light yellow sticky material which was used in the next step without further purification. Mass: m/z 418.4 (M+H)⁺.

[0292] **Step 5: CIS- and TRANS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1055 and INT-1056)**

[0293] To a solution of crude N-cyclobutylmethyl-N',N'-dimethyl-1-[(2-methyl-2-methylsulfanyl-propylamino)-methyl]-4-phenyl-cyclohexane-1,4-diamine (2.0 g, 4.79 mmol, 1.0 eq.) in toluene (30 mL) was added KOH (1.61 g, 28.77 mmol, 6.0 eq) in water (60 mL) at 0°C followed by addition of COCl₂ (5.84 L 16.76 mmol, 3.5 eq., 20% in toluene). The reaction mixture was stirred at RT for 16h, then basified with sat. aq. NaHCO₃ and extracted with DCM (2x200 mL). Combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by prep HPLC to get CIS-1-cyclobutylmethyl-8-dimethylamino-3-(2-methyl-2-methylsulfanyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-1055**) as peak 2 (45 mg) and TRANS-1-cyclobutylmethyl-8-dimethylamino-3-(2-methyl-2-methylsulfanyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-1056**) as peak 1 (300 mg). Mass: m/z 444.1 (M+H)⁺ (trans), m/z 444.0 (M+H)⁺ (cis).

[0294] **Synthesis of INT-1059: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0295] **Step 1: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione**

[0296] To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (250.0 g, 1.15 mol, 1.0 eq.) in EtOH (2.5 L) and water (2.1 L) was added $(\text{NH}_4)_2\text{CO}_3$ (276.2 g, 2.87 mol, 2.5 eq.) and the reaction mixture was stirred at RT for 15 min. KCN (74.92 g, 1.15 mol, 1.0 eq.) was added. The reaction mixture was stirred at 60°C for 18h and then filtered in hot condition to get white solid which was washed with water (2.5 L), ethanol (1 L) and hexane (2.5 L). The resulting solid was dried under reduced pressure to get CIS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (223 g, 0.776 mol, 65%) as a white solid. The filtrate was collected from multiple batches (~450 g) which contained a mixture of cis and trans isomers. The filtrate was concentrated under reduced pressure and solid obtained was filtered and washed with water (1 L) and hexane (1 L). Solid material was dried under reduced pressure to get ~100 g of a mixture of cis and trans (major) isomers. Crude material was partially dissolved in hot MeOH (600 mL) and cooled to RT, filtered through sintered funnel, washed with MeOH (200 mL) followed by ether (150 mL) and dried to get TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (50 g, 0.174 mmol, ~9-10%).

[0297] **Step 2: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059)**

[0298] In analogy to the method described for **INT-976 step 2** TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione was treated with LiAlH_4 to be converted into TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-1059**). Mass: m/z 274.2 ($\text{M}+\text{H}$)⁺.

[0299] **Synthesis of INT-1068 and INT-1069: CIS- and TRANS-8-(dimethylamino)-8-phenyl-1-(2,2,2-trifluoroethyl)-1,3-diazaspiro[4.5]decan-2-one**



[0300] **Step 1: 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile**

[0301] To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (50 g, 230.096 mmol) in MeOH (400 mL) was added NH_4Cl (24.6 g, 460.8 mmol) followed by NH_4OH (400 mL) at RT and the reaction mixture was stirred for 15 min. NaCN (22.5 g, 460.83 mmol) was added and the resulting mixture was stirred for 16 h at RT. The reaction mixture was extracted with DCM (3x750 mL). Combined organic layer was washed with water (750 mL), brine (750 mL), dried over Na_2SO_4 and concentrated under reduced pressure. The residue was triturated with DCM/hexane to get crude 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (50 g, 90%) as an off white solid which was used in next step without further purification. LC-MS: m/z $[\text{M}+\text{H}]^+ = 244.2$ (MW calc. 244.09).

[0302] **Step 2: N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoroacetamide**

[0303] To a solution of 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (5.0 g, 20.57 mmol, 1.0 eq.) in THF (100 mL) were added DIPEA (10.72 mL, 61.71 mmol, 3.0 eq), trifluoroacetic acid (1.89 mL, 24.69 mmol, 1.2 eq) and T3P (18.2 mL, 30.85 mmol, 1.5 eq) at 0°C . The reaction mixture was stirred at RT for 16h, then diluted with water (100 mL) and extracted with 10 % MeOH in DCM (2x250 mL). Combined organic layer was washed with brine (100 mL), dried over Na_2SO_4 and concentrated under reduced pressure to get crude N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoroacetamide as a light yellow sticky material which was used in the next step without further purification. LC-MS: m/z $[\text{M}+1]^+ = 339.9$ (MW calc. 339.36).


[0304] **Step 3: 1-aminomethyl-N',N'-dimethyl-4-phenyl-N-(2,2,2-trifluoroethyl)cyclohexane-1,4-diamine**

[0305] To suspension of LiAlH_4 (4.03 g, 106.19 mmol, 6.0 eq.) in dry THF (40 mL) was added N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoro-acetamide (6.0 g, 17.69 mmol, 1.0 eq.) in dry THF (100 mL) dropwise at 0°C . The reaction mixture was stirred at RT for 16 h, then quenched with sat. aq. Na_2SO_4 at 0°C , excess THF was added and the resulting mixture was stirred at RT for 2 h. The resulting suspension was filtered through celite and the filter cake was washed with 10% MeOH in DCM (150 mL). Combined filtrate was concentrated under reduced pressure to yield crude 1-aminomethyl-N',N'-dimethyl-4-phenyl-N-(2,2,2-trifluoro-ethyl)-cyclohexane-1,4-diamine (4.2 g, crude) as a light yellow sticky material which was directly used in the next step without further purification. LC-MS: m/z $[\text{M}+1]^+ = 330.0$ (MW calc. 329.40).

[0306] Step 4: CIS- and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1068 and INT-1069)

[0307] To a solution of 1-aminomethyl-N',N'-dimethyl-4-phenyl-N-(2,2,2-trifluoro-ethyl)-cyclohexane-1,4-diamine (4.2 g, 12.76 mmol, 1.0 eq.) in toluene (60 ml) was added KOH (4.29 g, 76.56 mmol, 6.0 eq.) in water (120 ml) at 0°C followed by addition of COCl_2 (15.6 ml, 44.66 mmol, 3.5 eq., 20% in toluene) at 0°C and stirred at RT for 16 h. Reaction mixture was basified with sat NaHCO_3 solution and extracted with DCM (2×200 ml). Combined organic layer was dried over Na_2SO_4 and concentrated under reduced pressure to get crude product which was purified by prep HPLC to get CIS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diazaspiro[4.5]decan-2-one (**INT-1068**) (1.5g) (major isomer, polar spot on TLC) and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diazaspiro[4.5]decan-2-one (**INT-1069**) as minor isomer (non-polar spot on TLC) (120 mg, 92.93% by HPLC) as off-white solids. CIS-isomer: LC-MS: m/z $[\text{M}+1]^+ = 356.2$ (MW calc. = 355.40). HPLC: 98.53%, Column: Xbridge C-18 (100 x4.6), 5μ , Diluent: MeOH, Mobile phase: A) 0.05% TFA in water; B) ACN flow rate: 1ml/min, $R_t = 5.17$ min. ^1H NMR ($\text{DMSO}-d_6$, 400 MHz), δ (ppm) = 7.43-7.27 (m, 5H), 6.84 (s, 1H), 3.30-3.25 (m, 4H), 2.66-2.63 (d, 2H, $J = 12.72$ Hz), 1.89 (s, 6H), 1.58-1.51 (m, 2H), 1.46-1.43 (m, 2H), 1.33-1.23 (m, 2H).

[0308] Synthesis of INT-1071: CIS-8-(dimethylamino)-8-phenyl-1-(2,2,2-trifluoroethyl)-1,3-diazaspiro[4.5]decan-2-one



[0309] **Step 1: tert-butyl CIS-2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate**

[0310] To a solution of CIS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (**INT-976**) (10.0 g, 36.63 mmol, 1.0 eq.) in dry THF (1.5 L) was added potassium tert-butoxide (7.14 mg, 36.63 mmol, 1.1 eq.) at RT. The reaction mixture was stirred for 30 min followed by addition of tert-butyl bromo acetate (4.51g, 40.293 mmol, 1.1 eq.). The reaction mixture was stirred at RT for 4 h, poured into ice-water and extracted with EtOAc (2x700 mL). The organic layer was washed with water (400 mL), brine (400 mL) and dried over Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (neutral alumina; 1% MeOH/Hexane) to yield CIS-(8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid tert-butyl ester (7 g, 18.06mmol, 49 %) as a white solid. LC-MS: m/z [M+1]⁺ = 387.9 (MW calc.=387.52).

[0311] **Step 2: mixture of CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]dec-3-yl)-acetic acid cyclopropylmethyl ester and CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]dec-3-yl)-acetic acid tert-butyl ester:**

[0312] To a solution of CIS-(8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid tert-butyl ester (2.0 g, 5.16 mmol, 1.0 eq.) in dry DMF (40 mL) was added 60 wt% NaH (413 mg, 10.33 mmol, 2 eq.) at RT. The reaction mixture was stirred for 30 min followed by addition of bromomethylcyclopropane (1.74 g, 12.91 mmol, 2.5 eq.). The reaction mixture was stirred at RT for 20 h, poured slowly into ice-water and extracted with EtOAc (2 x 400 mL). The organic layer was washed with water (2 x 200 mL), brine (200 mL) and dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by column chromatography (neutral alumina; 30% EA/Hexane) to yield a mixture of CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid cyclopropylmethyl ester and CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]dec-3-yl)-acetic acid tert-butyl ester (3:2) (1.1 g, 2.505 mmol, 48 %) as a light brown sticky liquid. LC-MS: m/z [M+1]⁺ = 440.0, 442.0 (MW calc.=439.59, 441.61).

[0313] **Step 3: CIS-2-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]dec-3-yl)-acetamide**

[0314]






[0315] To a mixture of CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]dec-3-yl)-acetic acid cyclopropylmethyl ester and CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]dec-3-yl)-acetic acid tert-butyl ester (2.0 g, 4.55 mmol, 1.0 eq.) in dry MeOH (5 mL) was added 7M NH₃ in MeOH (15 mL) and the reaction mixture was stirred in a sealed tube at 95°C for 48h. Solvent was evaporated under reduced pressure to get crude product which was purified by column chromatography (neutral alumina; 2% MeOH/DCM) to yield CIS-2-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetamide (1.2 g, 3.15 mmol, 68 %) as an off-white solid. LC-MS (Method 1): m/z [M+H]⁺ = 385.2 (MW calc. = 384.52).






[0316] **Step 4: CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl) acetonitrile (INT-1071)**






[0317] To a solution of CIS-2-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetamide (1.7 g, 4.42 mmol, 1.0 eq.) in dry DMF (40 mL) was added cyanuric chloride (2.4 g, 13.28 mmol, 3 eq.) at RT. The reaction mixture was stirred at RT for 1.5h, basified (pH~9) with sat. aq. NaHCO₃ and extracted with EtOAc (2x400 mL). The combined organic layer was washed with water (2x300 mL), brine (300 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by column chromatography (neutral alumina; 80% DCM/Hexane) to yield CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl) acetonitrile (1.1 g, 3.00mmol, 68 %) as an off-white solid. LC-MS: m/z [M+1]⁺ = 367.3 (MW calc.=366.50).





[0318] For **further intermediates** the synthesis in analogy to previously described methods is given in the following table. The syntheses of the building blocks and intermediates have either been described previously within this application or can be performed in analogy to the herein described methods or by methods known to the person, skilled in the art. Such a person will also know which building blocks and intermediates need to be chosen for synthesis of each exemplary compound.






Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-794	CIS-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-975	424.3
INT-796	CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-(3-methoxy-propyl)-1,3-diazaspiro[4.5]decan-2-one		INT-974	390.3
INT-797	CIS-8-(Ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-976	288.2
INT-949	CIS-8-Dimethylamino-1-ethyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-984	302.2
INT-950	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[phenyl-methyl]-1,3-diazaspiro[4.5]decan-2-one		INT-952	432.3

Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-954	4-Dimethylamino-4-(5-methyl-thiophen-2-yl)-cyclohexan-1-one		INT-965	238.1
INT-955	4-Dimethylamino-4-thiophen-2-yl-cyclohexan-1-one		INT-965	224.1
INT-956	1-(1-Methyl-1H-pyrazol-3-yl)-4-oxo-cyclohexane-1-carbonitrile		INT-958	204.1
INT-957	4-Oxo-1-pyrazin-2-yl-cyclohexane-1-carbonitrile		INT-958	202.1
INT-959	4-Dimethylamino-4-(1-methyl-1H-pyrazol-3-yl)-cyclohexan-1-one		INT-961	222.2






Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-960	4-Dimethylamino-4-pyrazin-2-yl-cyclohexan-1-one		INT-961	220.1
INT-962	4-Dimethylamino-4-(3-methoxyphenyl)-cyclohexan-1-one		INT-965	248.2
INT-963	CIS-3-Benzyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-975	364.2
INT-964	4-(Ethyl-methyl-amino)-4-phenyl-cyclohexan-1-one		INT-965	232.2
INT-967	CIS-8-Dimethylamino-8-[4-(methoxymethoxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one		INT-974	454.3

Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-968	CIS-8-Dimethylamino-8-[3-(methoxymethoxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one		INT-974	454.3
INT-969	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(4-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one		INT-971	478.3
INT-970	CIS-8-Dimethylamino-8-(4-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one		SC_2017	424.3
INT-972	CIS-8-Dimethylamino-8-(3-methoxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one		SC_2017	424.3
INT-973	CIS-8-Dimethylamino-8-(4-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one		INT-974	412.2





Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-979	CIS-8-Dimethylamino-1-(3-methoxy-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-984	346.2
INT-980	CIS-8-Dimethylamino-1-(2-methoxy-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-984	332.2
INT-981	CIS-8-Dimethylamino-8-phenyl-1-propyl-1,3-diazaspiro[4.5]decan-2-one		INT-984	316.2
INT-983	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-984	328.2





Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-985	CIS-1-(Cyclobutyl-methyl)-8-(methyl-propyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-986	370.3
INT-993	4-benzyl-4-(dimethylamino)cyclohexanone		INT-965	232.3
INT-994	CIS-8-benzyl-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one		INT-976	288.2
INT-995	TRANS-8-benzyl-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one		INT-976	288.2
INT-997	CIS-8-(dimethylamino)-8-(thiophen-2-yl)-1,3-diazaspiro[4.5]decan-2-one		INT-976	280.1

Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-998	TRANS-8-(dimethylamino)-8-(thiophen-2-yl)-1,3-diazaspiro[4.5]decan-2-one		INT-976	280.1
INT-999	4-(dimethylamino)-4-(1-methyl-1H-benzo[d]imidazol-2-yl)cyclohexanone		INT-965	272.2
INT-1000	CIS-8-(dimethylamino)-8-(1-methyl-1H-benzo[d]imidazol-2-yl)-1,3-diazaspiro[4.5]decan-2-one		INT-976	328.2
INT-1001	TRANS-8-(dimethylamino)-8-(1-methyl-1H-benzo[d]imidazol-2-yl)-1,3-diazaspiro[4.5]decan-2-one		INT-976	328.2
INT-1009	TRANS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one		INT-1008	274.2

Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-1024	CIS-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one		INT-977 (step 2)	292.2
INT-1025	CIS-8-(dimethylamino)-8-(4-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one		INT-974, INT-977 (step 2)	292.2
INT-1039	CIS-8-(dimethylamino)-8-(3-(trifluoromethoxy)phenyl)-1,3-diazaspiro[4.5]decan-2-one		INT-1038	358.2
INT-1040	(CIS)-8-(dimethylamino)-8-(3-(trifluoromethyl)phenyl)-1,3-diazaspiro[4.5]decan-2-one		INT-1038	342.2
INT-1041	(CIS)-8-(dimethylamino)-8-(3-methoxyphenyl)-1,3-diazaspiro[4.5]decan-2-one		INT-1038	304.2

Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-1042	(CIS)-8-(5-chlorothiophen-2-yl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one		INT-1038	314.1
INT-1043	(CIS)-8-(dimethylamino)-8-(3-fluoro-5-methylphenyl)-1,3-diazaspiro[4.5]decan-2-one		INT-1038	306.2
INT-1044	(CIS)-8-(3-chlorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one		INT-1038	308.2
INT-1047	(CIS)-8-(methyl(oxetan-3-ylmethyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-1026	330.5


Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-1050	(CIS)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one		SC_4054	357.3
INT-1051	(CIS)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-ylmethyl)-1,3-diazaspiro[4.5]decan-2-one		SC_4058	371.5
INT-1053	(CIS)-3-(2-amino-2-methylpropyl)-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-1052	429.3
INT-1061	TRANS-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-984	328.2

Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-1063	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one		INT-1031	346.2
INT-1066	TRANS-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		INT-987	342.3
INT-1070	CIS-8-(dimethylamino)-8-phenyl-1-(3,3,3-trifluoropropyl)-1,3-diazaspiro[4.5]decan-2-one		INT-1068	360.2
INT-1072	CIS-8-(dimethylamino)-1-((1-(1-hydroxycyclobutyl)methyl)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one	 HCl	SC_4054	441.3

Inter-mediate	Chemical Name	Chemical Structure	in analogy to method	m/z [M+H] ⁺
INT-1073	CIS-8-(dimethylamino)-1-((1-(1-hydroxycyclobutyl)methyl)-8-phenyl)-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one		SC_4054	429.3
INT-1074	CIS-8-(dimethylamino)-8-(3-fluorophenyl)-1-(((1-(1-hydroxycyclobutyl)methyl)-1,3-diazaspiro[4.5]decan-2-one		INT-1031	376.2


[0319] Synthesis of exemplary compounds

[0320] Synthesis of SC_4001: CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyramide




[0321] CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile (**SC_4012**) (201 mg, 0.5 mmol) was dissolved in DMSO (7 mL) and K_2CO_3 (136 mg, 1 mmol) and hydrogen peroxide (30% in water, 0.7 mL) were added. The resulting mixture was stirred at RT for 18h, then quenched with 2N aq. NaOH (5mL) and extracted with ethyl acetate (3x5mL). The combined organic layers were dried over Na_2SO_4 , concentrated *in vacuo* and purified by flash chromatography to yield CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyramide **SC_4001** (58 mg) as a white solid. $[M+H]^+$ 427.3

[0322] Synthesis of SC_4003: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one




[0323] In an oven dried flask, sodium hydroxide powder (28 mg, 0.7 mmol) was added to DMSO (0.25 mL) at RT. The mixture was stirred for 5 min, then CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-987**) (60 mg, 0.18 mmol) was added and the reaction mixture was stirred for 10 min at RT. 1-[2-(2-Bromo-ethoxy)ethoxy]-2-methoxy-ethane (120 mg, 0.53 mmol) was added and the resulting mixture was stirred for 30 min at RT and for 2 h at 60 °C. Water was added and the aqueous layer was extracted with DCM (3x10 mL). The combined organic layers were dried over Na_2SO_4 and concentrated *in vacuo*. The residue was purified by flash chromatography to yield CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4003**) (38 mg) as a white solid. $[M+H]^+$ 488.3

[0324] Synthesis of SC_4010: CIS-1-(Cyclobutyl-methyl)-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one




[0325] N-Iodosuccinimide (30 mg, 0.14 mmol) was added to a suspension of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4009**) (40 mg, 0.09 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 20 mL) at RT and the resultant mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH~10 and the organic product was extracted with DCM (3x10 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was stirred vigorously with a mixture of 10wt% aq. citric acid (5 mL) and DCM (10 mL) at RT for 10 min. The reaction mixture was basified with 5N aq. NaOH to pH~10 and extracted with DCM (3x10 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash chromatography and prep. HPLC to give 16 mg of CIS-1-(cyclobutyl-methyl)-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4010**). [M+H]⁺ 434.2

[0326] **Synthesis of SC_4012:** CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile




[0327] Potassium cyanide (131 mg, 2 mmol) and sodium iodide (202 mg, 1.4 mmol) were added to a solution of CIS-3-(3-chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4027**) (57mg, 1.4mmol) in DMSO (5mL) at RT and the resulting mixture was stirred at 90°C for 18h. The reaction mixture was quenched with water (5mL) and extracted with ethyl acetate (5x25mL). The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash chromatography to yield CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile (**SC_4012**) (38 mg) as a white solid. [M+H]⁺ 409.3

[0328] **Synthesis of SC_4013:** CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methyl-butryamide




[0329] CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyric acid methyl ester (**SC_4028**) (59 mg, 0.13 mmol) was treated with 2M methylamine in methanol (1.5 mL) and heated for 100 min at 100°C in a closed vessel. Volatiles were removed under a stream of nitrogen, the residue was taken up in 2M methylamine in methanol (1.5mL) and heated for 50 min at 120°C in a closed vessel. All volatiles were removed under a stream of nitrogen to afford the crude product, which was purified by column chromatography to yield 49 mg of CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methyl-butamide (**SC_4013**) as a white solid. $[M+H]^+$ 441.3

[0330] **Synthesis of SC_4025: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(tetrahydro-pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one**




[0331] KOtBu (1M in THF) (0.5 mL, 0.504 mmol) was added to a suspension of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-799**) (0.15 g, 0.42 mmol) in THF (4 mL) at 0°C. The reaction mixture was stirred for 10 min and a solution of 4-(bromomethyl)tetrahydro-2H-pyran (90 mg, 0.504 mmol) in THF (2 mL) was added. The reaction mixture was stirred at 70°C for 16h, then quenched with sat. aq. NH_4Cl (5mL) and extracted with ethyl acetate (2x20mL). The combined organic extracts were washed with water, brine, dried over anhydr. Na_2SO_4 and concentrated under reduced pressure. The residue was purified by preparative TLC to afford 0.044 g of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(tetrahydro-pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one (**SC_4025**) as an off-white solid (TLC system: 10% MeOH in DCM R_f : 0.52.). $[M+H]^+$ 456.3

[0332] **Synthesis of SC_4027: CIS-3-(3-Chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0333] Sodium hydride (60% suspension in mineral oil, 23 mg, 0.6 mmol) was added to a solution of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-987**) (100 mg, 0.3 mmol) in THF (3 mL) at 0°C and the resulting mixture was stirred for 30 min at 50°C. A solution of 1-bromo-3-chloropropane (0.14 mL, 1.5 mmol) in THF (0.7 mL) was added at 50°C and stirring was continued at 80°C for 18h. The reaction mixture was quenched with cold water (10 mL) and extracted with ethyl acetate (3x10mL). The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash chromatography to yield CIS-3-(3-chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4027**) (50 mg) as a white powder. [M+H]⁺ 418.3

[0334] **Synthesis of SC_4028:** CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyric acid methyl ester




[0335] CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile **SC_4012** (345mg, 0.85mmol) was dissolved in 5mL conc. HCl and stirred for 6h at 100°C. Volatiles were removed under reduced pressure to afford the crude product as hydrochloride salt. This salt was dissolved in MeOH /toluene and concentrated under reduced pressure. The latter dissolution/evaporation cycle was repeated, yielding 380 mg of CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro [4.5]decan-3-yl]-butyric acid methyl ester **SC_4028**. [M+H]⁺ 442.

[0336] **Synthesis of SC_4031:** CIS-3-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one




To the mixture of CIS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (**INT-976**) (3.5 g, 12.83 mmol, 1.0 eq.) and K_2CO_3 (3.54 g, 25.66 mmol, 2.0 eq.) in THF (200 ml) at 0 °C was added acetyl chloride (1.4 ml, 19.23 mmol, 1.5 eq.). The reaction mixture was stirred at RT for 3h, diluted with DCM (300 ml) and filtered through Celite. The filtrate was washed with sat. aq. $NaHCO_3$ (100 ml), water (100 ml) and brine (100 ml). The organic layer was dried over Na_2SO_4 and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel neutralized with ammonia, 5% MeOH/DCM) to yield CIS-3-acetyl-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (**SC-4031**) as an off white solid. Note: This reaction was done in two parallel batches of 3.5g scale and yield given for two combined batches. Yield: 63 % (5.1 g, 16.19 mmol). ^1H NMR (DMSO- d_6 , 400 MHz), δ (ppm) = 8.05 (bs, 1H), 7.36-7.25 (m, 5H), 3.44 (s, 2H), 2.31 (s, 5H, CH_3+CH_2), 1.92 (s, 6H), 1.83-1.76 (m, 4H), 1.39 (bs, 2H). Mass: m/z 316.1 $[M+H]^+$

[0337] **Synthesis of SC_4032: CIS-8-(dimethylamino)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0338] $KOtBu$ (1M in THF) (1.1 mL, 0.11 mmol) was added to the suspension of CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-976**) (0.3 g, 0.11 mmol) in THF (10 mL) at 0°C. The reaction mixture was stirred for 10 min and 1-bromo-2-(methylsulfonyl)ethane (0.16 g, 0.09 mmol) was added. The reaction mixture was stirred at 0°C for 4h, then quenched with sat. aq. NH_4Cl (15mL) and the organic product was extracted with DCM (3x20mL). The combined organic extracts were washed with brine, dried over anhydr. Na_2SO_4 and concentrated under reduced pressure. Purification of the residue by reverse phase preparative HPLC afforded 180mg (43%) of CIS-8-(dimethylamino)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4032**) as an off white solid (TLC system: 10% MeOH in DCM Rf: 0.3.). ^1H NMR (DMSO- d_6): δ 7.37-7.23 (m, 5H), 6.90 (br s, 1H), 3.43 (t, 2H), 3.26 (t, 2H), 3.10 (s, 2H), 2.95 (s, 3H), 2.32 (br m, 2H), 1.93 (s, 6H), 1.79-1.76 (m, 4H), 1.38-1.36 (m, 2H). Mass: m/z 380.2 $[M+H]^+$

[0339] **Synthesis of SC_4033: CIS-1-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0340] **Step 1: CIS-1-acetyl-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one.**

[0341] To a solution of CIS-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (**INT-975**) (19.5 g, 49.6 mmol, 1.0 eq.) in THF (180 ml) was added 2.5M solution of n-BuLi in hexane (39.7 ml, 99.23 mmol, 2.0 eq.) at 0 °C and the resulting mixture was stirred for 1h. A solution of acetyl chloride (7.7 g, 99.23 mmol, 2.0 eq.) in THF (20 ml) was added dropwise at 0 °C. The cooling bath was removed, the reaction mixture was stirred at RT for 16h, then cooled down to 0°C again, quenched with water and extracted with ethyl acetate (2x200 ml). The combined organic extracts were washed with brine (250 ml), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; 30% EtOAc/Hexane) to yield CIS-1-acetyl-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (6.1g, 14.02 mmol, 28%) as a light yellow sticky solid. Mass: m/z 436.3 [M+H]⁺

[0342] **Step 2: CIS-1-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4033).**

[0343] To a solution of CIS-1-acetyl-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (5.0 g, 11.5 mmol, 1.0 eq.) in acetonitrile (60 ml) was added a solution cerium(IV) ammonium nitrate (18.98 g, 34.5 mmol, 3.0 eq.) in water (60 ml) at 0 °C and the reaction mixture was stirred at RT for 2 h. The reaction mixture was quenched with aq. NaHCO₃ solution (50 ml) and extracted with ethyl acetate (2x100 ml). The combined organic layer was washed with brine (2 x 100 ml), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel neutralized with TEA; 2/3 v/v EtOAc/Hexane) to yield CIS-1-acetyl-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (**SC_4033**) as an off white solid. Yield: 61 % (4.9 g, 15.55 mmol). ¹HNMR (DMSO-d₆, 400 MHz), δ (ppm) = 7.57 (s, 1H), 7.33-7.23 (m, 5H), 3.21 (s, 2H), 3.03 (t, 2H, J = 12.78 Hz), 2.60 (d, 2H, J = 13.32 Hz), 2.32 (s, 3H), 1.89 (s, 6H), 1.37-1.32 (m, 4H). Mass: m/z 316.2 [M+H]⁺


[0344] **Synthesis of SC_4034: CIS--1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-(methanesulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0345] To a solution of CIS-8-dimethylamino-3-(2-methanesulfonyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (**SC_4032**) (150 mg, 0.395 mmol, 1.0 eq.) in dry DMF (5 ml) was added 60% NaH (47 mg, 1.18 mmol, 3.0 eq.) at RT and the reaction mixture was stirred for 20 min. Bromomethylcyclopropane (160 mg, 1.18 mmol, 3.0 eq.) was added and the reaction mixture was stirred for 16h. The reaction mixture was quenched with ice-water (20 ml) and extracted with EtOAc (2x20 ml). The combined organic layers were washed with water (20 ml) and brine (20 ml), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; 3% MeOH/DCM) to yield CIS-1-cyclopropylmethyl-8-dimethylamino-3-(2-methanesulfonyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (80 mg, 0.18 mmol, 47%) (**SC_4034**) as a white solid. ¹HNMR (CDCl₃, 400 MHz), δ (ppm) = 7.36-7.24 (m, 5H,

merged with CDCl₃), 3.65 (t, 2H, J = 6.46 Hz), 3.27 (t, 2H, J = 6.46 Hz), 3.23 (s, 2H), 3.04 (d, 2H, J = 6.7 Hz), 2.94 (s, 3H), 2.65-2.62 (m, 2H), 2.30-2.23 (m, 2H), 2.02 (s, 6H), 1.46-1.40 (m, 4H), 1.02-0.98 (m, 1H), 0.53-0.49 (m, 2H), 0.33-0.29 (2H). Mass: m/z 434.0 (M+H)⁺ (MW calc. = 433.61).

[0346] **Synthesis of SC_4037: CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one**




[0347] **Step 1: CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one**

[0348] CIS-8-(dimethylamino)-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-975**) (500 mg, 1.271 mmol) was dissolved in THF (8 mL) under nitrogen atmosphere and the solution was cooled down to -78 °C. [Bis(trimethylsilyl)amino]lithium (1M in THF, 1.5 equiv., 1.906 mmol, 1.9 mL) was added dropwise and the reaction mixture was stirred at -78 °C for 30 min, then at 0 °C for 30 min. The reaction mixture was cooled down to -78 °C again and the solution of p-toluenesulfonyl chloride (1.5 equiv., 1.906 mmol) in THF (5 mL) was added. The reaction mixture was stirred further 2.5 h at -78 °C and then the temperature was allowed to increase to RT overnight. The reaction mixture was quenched by the addition of sat. aq. NaHCO₃ (20 mL). The aqueous phase was extracted with EtOAc (3x40 mL). The combined organic extracts were washed with brine (30 mL), dried over MgSO₄ and concentrated under reduced pressure. Purification of the residue by flash chromatography on silica gel (elution with gradient DCM/EtOH 100/0 to 97/3) yielded 281 mg (40%) of CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one. ¹H NMR (600 MHz, DMSO) δ 7.90 – 7.84 (m, 2H), 7.47 – 7.40 (m, 2H), 7.42 – 7.27 (m, 4H), 7.27 – 7.22 (m, 1H), 7.15 – 7.06 (m, 2H), 6.92 – 6.83 (m, 2H), 4.16 (s, 2H), 3.72 (s, 3H), 3.24 (s, 2H), 2.99 (ddd, 2H), 2.70 – 2.62 (m, 2H), 2.42 (s, 3H), 2.01 (s, 6H), 1.56 – 1.49 (m, 2H), 1.31 (td, 2H). Mass: m/z 548.3 (M+H)⁺.

[0349] **Step 2: CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (SC_4037)**

In analogy to the method described for **INT-982** (step 2) CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one was reacted with trifluoroacetic acid to be converted into CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4037**). ¹HNMR (DMSO-*d*₆, 400 MHz), δ (ppm) = 7.82 (d, 2H, J = 8.0 Hz), 7.48 (s, 1H), 7.40 (d, 2H, J = 7.88 Hz), 7.35-7.24 (m, 5H), 3.27 (s, 2H), 2.97 (t, 2H, J = 11.88 Hz), 2.66 (d, 2H, J = 12.76 Hz), 2.39 (s, 3H), 2.0 (s, 6H), 1.60 (d, 2H, J = 11.04 Hz), 1.38 (t, 2H, J = 13.56 Hz). Mass: m/z 427.9 (M+H)⁺.

[0350] **Synthesis of SC_4038: CIS-8-(dimethylamino)-3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0351] **Step 1: CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-((tetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one**

[0352] NaH (60% in mineral oil) (84.03 mg, 2.101 mmol) was added to an ice cold solution of CIS-8-(methylamino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (**INT-799**) (500 mg, 1.401 mmol) in DMF (5 mL) under argon atmosphere and the resulting mixture was stirred for 2 min. The reaction mixture was allowed to warm up to RT and a solution of (tetrahydro-2H-thiopyran-4-yl)methyl 4-methylbenzenesulfonate (481.5 mg, 1.681 mmol) in DMF (4.8 mL) was added. The reaction mixture was stirred at RT for 16 h. The reaction progress was monitored by LCMS. The reaction mixture was diluted with water (50mL) and the organic product was extracted with EtOAc (3x40mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give 550 mg of crude product. The crude product was purified by prep-HPLC (column LUNA-PHENYL HEXYL-C18 (150*30mm) 5μm, detection at 215 nm, eluent 10mM ammonium bicarbonate in water/Acetonitrile gradient 45/55 to 2/98, flow rate: 25 ml/min) to afford 235mg (35%) of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-((tetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one as an off white solid (TLC system: 5% MeOH in DCM Rf: 0.63.). Mass: m/z 472.3 (M+H)⁺.

[0353] **Step 2: CIS-8-(dimethylamino)-3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4038)**


[0354] A solution of oxone (599.53 mg, 0.975 mmol) in water (6 mL) was added to a solution of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-((tetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one (230 mg, 0.488 mmol) in MeOH (8 mL) at RT under argon atmosphere. The reaction mixture was stirred for 16 h. The reaction progress was monitored by LCMS. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give 330 mg of crude product, which was purified by prep. HPLC (column LUNA-PHENYL HEXYL-C18 (150*30mm) 5μm, detection at 215 nm, eluent 10mM ammonium bicarbonate in water/Acetonitrile gradient 45/55 to 2/98, flow rate: 25 ml/min) to get 128 mg (52%) of CIS-8-(dimethylamino)-3-(4-(bromomethyl)-1-λ6-thiane-1,1-dione)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4038**) as an off white solid (TLC system: 10% MeOH in DCM Rf: 0.53). ¹H NMR (DMSO-d₆): δ 7.37-7.25 (m, 5H), 6.01 (s, 1H), 3.26 (s, 2H), 3.09-2.99 (m, 8H), 2.69-2.65 (m, 2H), 2.09-1.82 (m, 15H), 1.66-1.51 (m, 3H), 1.41-1.33 (m, 5H). Mass: m/z 504.2 (M+H)⁺.

[0355] **Synthesis of SC_4044: CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0356] NaH (0.14 g, 3.501 mmol, 60% dispersion in mineral oil) was added to a solution of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-799**) (0.25 g, 0.700 mmol) in THF (40 mL) at 0°C under argon atmosphere. The solution of 1,6-dioxaspiro[2.5]octane (0.479 g, 4.200 mmol) in THF (2mL) was added dropwise and the reaction mixture was stirred at 85°C for 16 h. The reaction mixture was cooled to 0°C and quenched with water (50mL). The organic product was extracted with ethyl acetate (2x50mL). Combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel 230-400mesh size, 0-60% EtOAc in pet ether as eluent) followed by reverse phase prep HPLC to get 0.180g of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one formiate. The product formiate salt was taken in water (20mL), basified with solid NaHCO₃ and extracted with ethyl acetate (2x20mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 0.130g (39%) of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4044**) as an off white solid. (TLC system: 5% MeOH in DCM; R_f: 0.3). ¹H NMR (DMSO-d₆): δ 7.37-7.34 (m, 4H), 7.27-7.26 (m, 1H), 6.04 (s, 1H), 4.51 (s, 1H), 3.61-3.56 (m, 4H), 3.43 (s, 2H), 3.09-3.05 (m, 4H), 2.70-2.67 (m, 2H), 2.07-1.82 (m, 12H), 1.63-1.61 (m, 1H), 1.51-1.30 (m, 9H). Mass: m/z 472.3 (M+H)⁺.


[0357] **Synthesis of SC_4049: CIS-(5s,8s)-3-(1-benzoylpiperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0358] Triethylamine (0.51 mL, 3.65 mmol) was added to a stirred solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (0.3g, 0.73mmol) in DCM (10 mL) at 0°C under argon atmosphere. After 10 min, acetyl chloride (86mg, 1.09mmol) was added dropwise at 0°C and the reaction mixture was stirred at RT for 16 h. The reaction mixture was quenched with sat. aq. NaHCO₃. The organic product was extracted with DCM (2x50mL), the combined organic layer was dried

over anhydr. Na_2SO_4 and concentrated under reduced pressure. The residue was purified by reverse phase prep. HPLC to afford 0.133 g (40%) of CIS-3-(1-acetylpiperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4049**) as a white solid. (TLC system: 10% MeOH in DCM; Rf: 0.55). ^1H NMR (DMSO- d_6): δ 7.36-7.33 (m, 2H), 7.28-7.25 (m, 3H), 4.70-4.67 (m, 1H), 3.98-3.81 (m, 2H), 3.12-3.04 (m, 5H), 2.65-2.57 (m, 3H), 2.26 (t, 2H), 2.06-2.04 (m, 9H), 1.79-1.70 (m, 2H), 1.50-1.39 (m, 6H), 1.02 (m, 1H), 0.53-0.50 (m, 2H), 0.34-0.31 (m, 2H). Mass: m/z 453.3 ($\text{M}+\text{H}$) $^+$.

[0359] **Synthesis of SC_4052: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(1-hydroxycyclohexyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0360] **Step 1: CIS-3-(2-(1-(benzyloxy)cyclohexyl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0361] In analogy to the method described for **SC_4034** CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-787**) was reacted with 2-(4-(benzyloxy)tetrahydro-2H-pyran-4-yl)ethyl 4-methylbenzenesulfonate to be converted into CIS-3-(2-(1-(benzyloxy)cyclohexyl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one. Mass: m/z 558.4 ($\text{M}+\text{H}$) $^+$.

[0362] **Step 2: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(1-hydroxycyclohexyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4052)**

[0363] Trifluoroacetic acid (20 mL) was added to CIS-3-(2-(1-(benzyloxy)cyclohexyl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.4 g, 0.71 mmol) at RT. The reaction mixture was stirred at RT for 16 h and then concentrated under reduced pressure. To the residue sat. aq. NaHCO_3 was added and the organic product was extracted with dichloromethane (3x150mL). The combined organic extract was dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by column chromatography (230-400mesh silica gel; 4-8% MeOH in DCM as eluent) and further by reverse phase prep HPLC to afford 0.112 g (40%) of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(1-hydroxycyclohexyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4052**) as a white solid. (TLC system: 10% MeOH in DCM; Rf: 0.45). ^1H NMR (DMSO- d_6): δ 7.37-7.32 (m, 4H), 7.27-7.23 (m, 1H), 4.25 (s, 1H), 3.62-3.49 (m, 4H), 3.17-3.13 (m, 2H), 3.09 (s, 2H), 3.01 (d, 2H), 2.66-2.63 (m, 2H), 2.05-2.02 (m, 1H), 1.97-1.91 (m, 9H), 1.80-1.65 (m, 4H), 1.53-1.43 (m, 5H), 1.38-1.35 (m, 6H). Mass: m/z 470.4 ($\text{M}+\text{H}$) $^+$.

[0364] **Synthesis of SC_4054: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one**




[0365] **Step 1: CIS-tert-butyl 4-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)piperidine-1-carboxylate**

[0366] In analogy to the method described for **SC_4044** CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-983**) was reacted with tert-butyl 4-(tosyloxy)piperidine-1-carboxylate to be converted into CIS-tert-butyl 4-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)piperidine-1-carboxylate. Mass: m/z 511.4 ($M+H$)⁺.

[0367] **Step 2: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4054)**

[0368] 4N HCl in dioxane (20 mL) was added to a solution of CIS-tert-butyl 4-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)piperidine-1-carboxylate (1.9 g, 3.7 mmol) in DCM (30 mL) at 0°C under argon atmosphere. The reaction was stirred at 0°C for 2 h and then concentrated under reduced pressure to get CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride as gummy, which was triturated with diethyl ether to get CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (**SC_4054**) as an off-white solid. (TLC system: 10% MeOH in DCM; R_f: 0.15). ¹H NMR (DMSO-d₆): δ 7.37-7.32 (m, 4H), 7.28-7.23 (m, 1H), 3.58-3.50 (m, 2H), 3.10 (s, 2H), 2.94-2.89 (m, 4H), 2.66-2.62 (m, 2H), 2.46-2.41 (m, 2H), 2.13 (t, 2H), 1.97 (s, 6H), 1.49-1.41 (m, 6H), 1.32-1.29 (m, 2H), 0.93-0.88 (m, 1H), 0.46-0.42 (m, 2H), 0.25-0.24 (m, 2H). Mass: m/z 411.3 ($M+H$)⁺.

[0369] **Synthesis of SC_4055: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-hydroxy-2-methylpropyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0370] **Step 1: tert-butyl 2-(CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate**

[0371] In analogy to the method described for **SC_4027** CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-983**) was reacted with tert-butyl bromoacetate to be converted into tert-butyl 2-(CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate. Mass: m/z 442.3 (M+H)⁺.

[0372] **Step 2: methyl CIS-2-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate**


[0373] 4M HCl in dioxane (8 mL) was added to tert-butyl CIS-2-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate (800 mg, 1.81 mmol) in DCM (6 mL) at 0°C. The reaction mixture was stirred at RT for 16h and then concentrated under reduced pressure. The residue was suspended in DCM and the resulting mixture was concentrated under reduced pressure again. The residue was washed with diethyl ether (5mL) to give CIS-2-(8-(dimethylamino)-3-oxo-8-phenyl-2-azaspiro[4,5]decan-2-yl)acetic acid hydrochloride which was dissolved in methanol (10mL) and refluxed for 2h. The reaction mixture was cooled down to RT and concentrated under reduced pressure. The residue was partitioned between EtOAc and sat. aq. NaHCO₃. The organic layer was separated and washed with water, brine, dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel 100-200 mesh, 0-3% MeOH in DCM) yielded 500 mg (56%) of methyl CIS-2-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate as a solid. (TLC system: 10% MeOH in DCM Rf: 0.20). Mass: m/z 400.3 (M+H)⁺.

[0374] **Step 3: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-hydroxy-2-methylpropyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4055)**

[0375] Methylmagnesium bromide (3M in Et₂O, 2.1 mL, 6.25 mmol) was added to a solution of methyl CIS-2-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate (500 mg, 1.25


mmol) in THF (10 mL) at 0°C. The reaction mixture was warmed to RT and stirred for 2 h. The reaction mixture was quenched with sat. aq. NH₄Cl and the organic product was extracted with DCM (3x25mL). The combined organic extracts were washed with water, brine, dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. Purification of the resulting residue by column chromatography (silica gel 100-200 mesh, 0-3% MeOH in DCM) followed by preparative HPLC yielded 80 mg (16%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-hydroxy-2-methylpropyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4055**) as a solid. (TLC system: 10% MeOH in DCM Rf: 0.20). ¹H NMR (DMSO d₆): δ 7.36-7.33 (m, 4H), 7.26-7.24 (m, 1H), 4.39 (s, 1H), 3.30 (m, 2H), 2.95-2.91 (m, 4H), 2.69-2.66 (m, 2H), 2.18-2.13 (m, 2H), 1.97 (s, 6H), 1.37-1.31 (m, 4H), 1.03 (s, 6H), 0.92-0.91 (m, 1H), 0.46-0.43 (m, 2H), 0.26-0.23 (m, 2H). Mass: m/z 400.3 (M+H)⁺.

[0376] **Synthesis of SC_4056: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyrimidin-5-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one**




[0377] CsCO₃ (1.27 g, 3.90 mmol) was added to a solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (**SC_4054**) (0.4 g, 0.97 mmol), XanthPhos (85 mg, 0.146 mmol), Pd₂(dba)₃ (89 mg, 0.097 mmol) and 5-bromopyrimidine (0.31 g, 1.95 mmol) in 1,4-dioxane (20 mL). The mixture was purged with argon for 5 min and then stirred for 16 h at 120°C. The reaction mixture was cooled to RT and concentrated under reduced pressure. The residue was diluted with DCM (20 mL), filtered through a pad of celite and concentrated under reduced pressure. The crude product was purified by flash chromatography (silica gel 230-400 mesh size, 5-10% methanol in DCM as eluent) to afford 0.4g of the desired product, which was further purified by reverse phase prep HPLC to afford 172mg (36%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyrimidin-5-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (**SC_4056**) as off-white solid. (TLC system: 10% MeOH in DCM; Rf: 0.35). ¹H NMR (CDCl₃): δ 8.64 (s, 1H), 8.34 (s, 2H), 7.36-7.33 (m, 2H), 7.29-7.27 (m, 2H), 7.24 (m, 1H), 4.00-3.96 (m, 1H), 3.78-3.76 (m, 2H), 3.09-3.06 (m, 4H), 2.96-2.90 (m, 2H), 2.66-2.63 (m, 2H), 2.30-2.24 (m, 2H), 2.04 (s, 6H), 1.83-1.81 (m, 2H), 1.73-1.61 (m, 2H), 1.45-1.40 (m, 4H), 1.04-1.01 (m, 1H), 0.54-0.50 (m, 2H), 0.35-0.32 (m, 2H). Mass: m/z 489.3 (M+H)⁺.

[0378] **Synthesis of SC_4057: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyrimidin-5-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one**



[0379] Triethylamine (0.23 mL, 1.70 mmol) was added to a solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (**SC_4054**) (0.35 g, 0.85 mmol) and phenylboronic acid (0.21 g, 1.70 mmol) in acetonitrile (15 mL). Copper(II) acetate (155 mg, 0.85 mmol) was added and the reaction mixture was stirred at 100°C for 24 h. The reaction mixture was cooled to RT, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (3% MeOH/DCM) to give 100mg of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-phenylpiperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one, which was further purified by reverse phase prep HPLC to afford 38mg (9%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-phenylpiperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (**SC_4057**) as an off-white solid. (TLC system: 10% MeOH in DCM; R_f: 0.65). ¹H NMR (DMSO-d₆): δ 7.36-7.33 (m, 2H), 7.29-7.27 (m, 2H), 7.24-7.21 (m, 3H), 6.91 (d, 2H), 6.81 (t, 1H), 3.95-3.91 (m, 1H), 3.72-3.69 (m, 2H), 3.11-3.06 (m, 4H), 2.84-2.79 (m, 2H), 2.65-2.62 (m, 2H), 2.26 (t, 2H), 2.04 (s, 6H), 1.79-1.70 (m, 4H), 1.45-1.40 (m, 4H), 1.05-1.01 (m, 1H), 0.53-0.51 (m, 2H), 0.34-0.32 (m, 2H). Mass: m/z 487.4 (M+H)⁺.


[0380] **Synthesis of SC_4064: CIS-3-((1-aminocyclopropyl)methyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0381] To a solution titanium isopropoxide (0.89 mL, 3.0 mmol, 2 eq.) in dry THF (15 mL) was added EtMgBr (3 M in Et₂O) (2 mL, 6.0 mmol, 4 eq.) at -78 °C and the resulting mixture was stirred for 1.5h at -78°C. A solution of CIS-(1-cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]dec-3-yl)-acetonitrile (**INT-1071**) (550 mg, 1.50 mmol, 1.0 eq.) in THF (5 mL) was added dropwise at -78°C. The reaction mixture was stirred at same temperature for 10 min, then warmed to RT and stirred for 1.5h. The reaction mixture was cooled again to -78°C, BF₃·Et₂O (0.37 mL, 3.0 mmol, 2 eq.) was added and the resulting mixture was stirred at -78°C for 10 min and at RT for 1.5h. The reaction mixture was basified (pH~ 9-10) with 10wt% aq. NaOH, stirred for 30 min and extracted with EtOAc (2x250 mL). The combined organic layer was washed with water (2x150 mL), brine (200 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by column chromatography (neutral alumina; 2.5% MeOH/DCM) to yield

CIS-3-(1-amino-cyclopropylmethyl)-1-cyclopropylmethyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4064) as off white solid. This step was done in two batches of 550 mg scale and yield is given for combined batches. Yield: 16 % (200 g, 0.25 mmol). LC-MS: m/z $[M+H]^+ = 397.1$ (MW calc. = 396.57). ^1H NMR (DMSO- d_6 , 400 MHz), δ (ppm) = 7.35-7.25 (5H), 3.24 (s, 2H), 3.00 (s, 2H), 2.92 (d, 2H, $J = 6.48$ Hz), 2.68-2.65 (m, 2H), 2.19-2.07 (m, 2H), 1.97 (s, 6H), 1.75 (bs, 2H), 1.43-1.36 (m, 4H), 0.93 (bs, 1H), 0.46-0.36 (m, 6H), 0.25-0.23 (m, 2H).

[0382] **Synthesis of SC_4071: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(3-hydroxyoxetan-3-yl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0383] **Step 1: 2-(3-(benzyloxy)oxetan-3-yl)acetaldehyde**

[0384] To a stirred solution of 3-allyl-3-(benzyloxy)oxetane (10.0 g, 49.01 mmol, prepared from 3-allyl-3-hydroxyoxetane and benzyl bromide) in acetone (300 mL) and water (200 mL) was added potassium osmate(VI) dihydrate (0.61 g, 1.66 mmol). The reaction mixture was cooled to 0°C and sodium periodate (41.93 g, 916.07 mmol) was added portionwise over a period of 15 min. The reaction mixture was allowed to stir for 1 h at 0°C. The reaction mixture was filtered and the filter cake was washed with acetone (300 mL). The combined filtrate was concentrated under reduced pressure and the aqueous layer was extracted with dichloromethane (2x300 mL). The combined organic layer was washed with water (2x200 mL), brine (300 mL), dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 230-400 mesh size 30-40% EtOAc in Pet. ether as eluent) to afford 2-(3-(benzyloxy)oxetan-3-yl)acetaldehyde (4.5 g, 43%) as a liquid. (TLC system: 40% EtOAc in Pet. ether; R_f : 0.4).

[0385] **Step 2: 2-(3-(benzyloxy)oxetan-3-yl)ethanol**

[0386] To a cold stirred solution of 2-(3-(benzyloxy)oxetan-3-yl)ethanol (4.50 g, 21.84 mmol) in methanol (50 mL) was added portionwise NaBH₄ (1.24 g, 32.76 mmol). The reaction mixture was stirred at 0°C for 1h. The reaction mixture was quenched with water (30 mL), concentrated under reduced pressure and the residue was taken in DCM (150 mL). The organic layer was washed with water (100 mL) and brine (100mL), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure to get 5.0 g of crude 2-(3-(benzyloxy)oxetan-3-yl)ethanol which was used in the next step without further purification.

[0387] **Step 3: 2-(3-(benzyloxy)oxetan-3-yl)ethyl 4-methylbenzenesulfonate**

[0388] To a stirred solution of 2-(3-(benzyloxy)oxetan-3-yl)ethanol (5.0 g, 24.03 mmol) in DCM (15mL) were added triethylamine (13.4 mL, 96.15 mmol) and DMAP (0.29 g, 2.40 mmol). The reaction mixture was cooled to 0°C and tosyl chloride (9.13 g, 48.07mmol) was added to the reaction mixture portionwise. The reaction mixture was stirred at RT for 16 h, then diluted with sat. aq. NaHCO₃ and the organic product was extracted with DCM (200 mL). The organic layer was dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (230-400mesh silica gel; 20-40% EtOAc in Pet. ether as eluent) to afford 2-(3-(benzyloxy)oxetan-3-yl)ethyl 4-methylbenzenesulfonate (4.0 g, 50 % over 2 steps) as an off-white solid.

[0389] **Step 4: CIS-3-(2-(3-(benzyloxy)oxetan-3-yl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**


[0390] NaH (0.29 g, 7.33 mmol, 60% dispersion in mineral oil) was added to a solution of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**INT-987**) (0.50 g, 1.46 mmol) in DMF (15 mL) at RT under argon atmosphere and the resuting mixture was stirred for 10 min. 2-(3-(Benzyloxy)oxetan-3-yl)ethyl 4-methylbenzenesulfonate (1.58 g, 4.39 mmol) was added and the reaction mixture was stirred at 120°C for 16 h. The reaction progress was monitored by LCMS. The reaction mixture was cooled to 0°C and quenched with sat. aq. NaHCO₃ (50mL). The organic product was extracted with DCM (2x100mL), the combined organic phase was dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by flash chromatography (silica gel 230-400 mesh size 2-5% methanol in DCM as eluent) to afford 0.40 g (51%) of CIS-3-(2-(3-(benzyloxy)oxetan-3-yl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as a brown oil. (TLC system: 10% MeOH in DCM; R_f: 0.6).

[0391] **Step 5: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(3-hydroxyoxetan-3-yl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4071)**


[0392] CIS-3-(2-(3-(benzyloxy)oxetan-3-yl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.38 g, 0.71 mmol) in THF (4 mL) was added to sodium metal (0.32 g, 14.31 mmol) in liquid ammonia (5 mL) at -78°C. The reaction mixture was stirred for 20 min at -78°C, then quenched with saturated NH₄Cl solution and the organic product was extracted with EtOAc (2x20 mL). The combined organic layer was dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was

purified by flash chromatography (silica gel 230-400 mesh 2-5% methanol in DCM as eluent) to afford 0.155g (49%) of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(3-hydroxyoxetan-3-yl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (**SC_4071**) as an off-white solid. (TLC system: 5% MeOH in DCM; Rf: 0.4). ¹H NMR (DMSO-d₆): δ 7.36-7.32 (m, 4H), 7.26-7.23 (m, 1H), 5.62 (s, 1H), 4.38-4.31 (m, 4H), 3.14-3.10 (m, 4H), 3.01 (d, 2H), 2.64-2.63 (m, 2H), 2.49 (m, 1H), 2.02-1.96 (m, 10H), 1.87-1.77 (m, 6H), 1.39 (t, 2H), 1.28 (d, 2H). Mass: m/z 442.3 (M+H)⁺.

[0393] **Synthesis of SC_4072: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-methyl-2-(2-oxopyrrolidin-1-yl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**




[0398] **Synthesis of SC_4080: CIS-8-(dimethylamino)-8-phenyl-3-(1-phenylpiperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one**



[0399] KOtBu (94.26 mg, 0.840 mmol) was added to a solution of CIS-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (**INT-1050**) (0.25 g, 0.70 mmol), bromobenzene (109.9 mg, 0.70 mmol), BINAP (65.38 mg, 0.105 mmol) and Pd₂(dba)₃ (96.15 mg, 0.105 mmol) in toluene (40 mL). The mixture was purged with argon for 5 min and stirred for 16 h at 90°C. The reaction mixture was cooled to RT and diluted with DCM (20 mL), filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by flash chromatography (silica gel 230-400 mesh, 5-10% methanol in DCM as eluent) followed by reverse phase prep. HPLC to afford 57 mg (18%) of CIS-8-(dimethylamino)-8-phenyl-3-(1-phenylpiperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (**SC_4080**) as an off-white solid. (TLC system: 10% MeOH in DCM; R_f: 0.40). Reverse prep HPLC condition: mobile phase: 10mM ammonium bicarbonate in H₂O/acetonitrile; column: INERTSIL-ODS(250*19mm) 5μm; gradient (%B): 0/65, 8/80, 8.1/98, 12/98, 12.1/65, 15/65; flow rate: 18 ml/min; diluent: ACN+THF+MeOH+H₂O. ¹H NMR (DMSO-d₆): δ 7.36-7.30 (m, 4H), 7.23 (t, 1H), 7.18-7.14 (m, 2H), 6.90 (d, 2H), 6.72 (t, 2H), 3.72-3.69 (m, 2H), 3.65-3.60 (m, 1H), 3.01 (s, 2H), 2.70-2.65 (m, 2H), 2.28 (br s, 2H), 1.93 (s, 6H), 1.78 (br m, 4H), 1.68-1.60 (m, 2H), 1.57-1.55 (m, 2H), 1.34-1.31 (m, 2H). Mass: m/z 433.3 (M+H)⁺.

[0400] **Synthesis of SC_4084: CIS-1-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)pyrrolidine-2,5-dione**



[0401] **Step 1: CIS-4-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-ylamino)-4-oxobutanoic acid**


[0402] Succinic anhydride (233.3 mg, 2.330 mmol) was added to a stirred solution of CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.58 g,

1.457 mmol) in DCM (15 mL) at RT under argon atmosphere. The reaction mixture was stirred at RT for 4 h and then concentrated under reduced pressure to yield 440 mg of crude CIS-4-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-ylamino)-4-oxobutanoic acid as an off-white solid (TLC system: 5% MeOH in DCM; Rf: 0.35).

[0403] **Step 2: CIS-1-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)pyrrolidine-2,5-dione (SC_4084)**

[0404] Acetyl chloride (2.2 mL) was added to a solution of CIS-4-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-ylamino)-4-oxobutanoic acid (0.44 g, 0.883 mmol) in EtOAc (30 mL) at 0°C under argon atmosphere. The reaction mixture was stirred at 80°C for 16h. The reaction mixture was cool to RT, concentrated under reduced pressure, quenched with sat. aq. NaHCO₃ and the organic product was extracted with EtOAc (2x30 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 230-400 mesh, 0-8% MeOH in DCM) followed by reverse phase prep HPLC to get 50 mg (9%) of CIS-1-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)pyrrolidine-2,5-dione (SC_4084) as a white solid (TLC system: 5 % MeOH in DCM; Rf: 0.30). Reverse prep HPLC condition: mobile phase: 10mM ammonium bicarbonate in H₂O/acetonitrile; column: INERTSIL-ODS(250*19mm) 5µm; gradient (%B): 0/80, 9/90, 9.1/80, 12/80; flow rate: 18 ml/min; diluent: ACN+THF+H₂O. ¹H NMR (DMSO-d₆): δ 7.35-7.34 (m, 4H), 7.27-7.24 (m, 1H), 3.34 (s, 2H), 3.19 (s, 2H), 2.87 (d, 2H), 2.66-2.64 (m, 2H), 2.43 (s, 4H), 2.13-2.08 (m, 2H), 1.97 (s, 6H), 1.51 (s, 6H), 1.37-1.32 (m, 4H), 0.89-0.87 (m, 1H), 0.45-0.42 (m, 2H), 0.27-0.24 (m, 2H). Mass: m/z 481.3 (M+H)⁺.

[0405] **Synthesis of SC_4096: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyridazin-4-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one**



[0406] **Step 1: CIS-3-(1-(6-chloropyridazin-4-yl)piperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**


[0407] DIPEA (0.566 g, 4.3 mmol) was added to a solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4054) (0.6 g, 1.4 mmol) and 3,5-dichloropyridazine (310 mg, 2.10 mmol) in N-methyl-2-pyrrolidone (30 mL). The reaction mixture was purged with argon for 10 min and stirred for 16 h at 80°C. The reaction mixture was quenched with water and extracted

with EtOAc (3x20 mL). The combined organic layer was concentrated under reduced pressure and the crude product was purified by flash chromatography (silica gel 230-400 mesh size, 5-10% methanol in dichloromethane as eluent) to afford 250 mg of CIS-3-(1-(6-chloropyridazin-4-yl)piperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as a light brown solid. (TLC system: 10% MeOH in DCM; Rf: 0.35).

[0408] Step 2: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyridazin-4-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4096)

[0409] 10% Pd-C (125 mg) was added to a solution of CIS-3-(1-(6-chloropyridazin-4-yl)piperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.25 g, 0.47 mmol) and triethylamine (96 mg, 0.95 mmol) in ethanol. The resultant mixture was hydrogenated under balloon pressure for 4h. The reaction mixture was diluted with EtOH (10 mL); filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography (silica gel 230-400 mesh, 5-10% methanol in DCM as eluent) and further purified by reverse phase prep HPLC to afford 85 mg (17%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyridazin-4-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4096) as an off-white solid. (TLC system: 10% MeOH in DCM; Rf: 0.35). Reverse prep HPLC condition: column X-BRIDGE C18 (4.6x150mm) 3.5 μ m; mobile phase: 10mM ammonium acetate in water (A)/acetonitrile (B); gradient time(min)/% B : 0/5, 1.2/5, 3/55, 5/70, 7/95, 10/95, 12/100, 14/5, 16/5; flow rate : 1 ml/min; diluent: (acetonitrile/water). ¹H NMR (DMSO): δ 8.92 (m, 1H), 8.55-8.54 (m, 1H), 7.34-7.30 (m, 4H), 7.24-7.21 (m, 1H), 6.91-6.89 (m, 1H), 4.09-4.07 (d, 2H), 3.84 (m, 1H), 3.09 (s, 2H), 2.95-2.90 (m, 4H), 2.62-2.59 (d, 2H), 2.12-2.09 (t, 2H), 1.96 (s, 6H), 1.60-1.56 (m, 4H), 1.42-1.39 (m, 2H), 1.31-1.28 (m, 2H), 0.91 (m, 1H), 0.46-0.43 (m, 2H), 0.26-0.23 (m, 2H). Mass: m/z 489.4 (M+H)⁺.


[0410] Synthesis of SC_4091: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-methyl-2-(methylsulfonyl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one



[0411] To a solution of 1-cyclobutylmethyl-8-dimethylamino-3-(2-methyl-2-methylsulfonyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (45 mg, 0.1 mmol, 1.0 eq) in THF/H₂O (6 mL, 5:1) was added oxone (119 mg, 0.19 mmol, 1.9 eq.) at 0°C. The reaction mixture was stirred at RT for 16 h, then quenched with sat. aq. NaHSO₃, diluted with EtOAc (50 mL) and washed with sat. aq. NaHCO₃ (25 mL). Organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (neutral alumina; 1.5% MeOH in DCM) to yield 1-cyclobutylmethyl-8-dimethylamino-3-(2-methanesulfonyl-2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4091) (100 mg, 0.17 mmol,

94%) as an off-white solid. ^1H NMR at 100°C (DMSO- d_6 , 400 MHz), δ (ppm) = 7.33-7.24 (m, 5H), 3.41 (s, 2H), 3.29 (s, 2H), 3.10 (d, 2H, J = 7.04 Hz), 2.87 (s, 3H), 2.63-2.56 (m, 3H), 2.12-2.01 (m, 10H), 1.83-1.81 (m, 4H), 1.47-1.27 (m, 10H). Mass: m/z 576.0 ($M+H$) $^+$.

[0412] **Synthesis of SC_4098: TRANS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**



[0413] **Step 1: TRANS-8-(dimethylamino)-3-(2-(methylthio)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione**

[0414] In analogy to the method described for **SC_4034** TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (step 1 of **INT-1059**) was reacted with 1-bromo-2-methylsulfanyl-ethane to be converted into TRANS-8-(dimethylamino)-3-(2-(methylthio)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione. Mass: m/z 362.2 ($M+H$) $^+$.

[0415] **Step 2: TRANS-8-(dimethylamino)-3-(2-(methylthio)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one**

[0416] To a slurry of LiAlH_4 (315 mg, 8.31 mmol, 6.0 eq.) in THF (10 mL) was added a solution of TRANS-8-dimethylamino-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (500 mg, 1.38 mmol, 1.0 eq.) in THF (10 mL) at 0°C under argon atmosphere and the reaction mixture was stirred at reflux for 16h. The reaction mixture was cooled to 0 °C and quenched with sat. aq. Na_2SO_4 (10 mL). The resulting suspension was stirred at RT for 30 min. The reaction mixture was filtered through celite and filter cake was washed with 10% MeOH in DCM (30 mL). The combined filtrate was dried over anhydr. Na_2SO_4 and concentrated under reduced pressure and residue was dissolved in HCOOH (15 mL) and NaBH_4 (314 mg, 8.31 mmol, 6.0 eq.) was added portionwise at 0°C. The reaction mixture was stirred at RT for 3h, then basified with sat. aq. NaHCO_3 up to pH~8 and extracted with EtOAc (2x50 mL). Combined organic layer was washed with brine (30 mL), dried over Na_2SO_4 and concentrated under reduced pressure to get crude TRANS-8-dimethylamino-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (400 mg, 1.29 mmol, 83%) as a brown solid which was used in the next step without further purification. LC-MS: m/z [$M+1$] $^+$ = 348.4 (MW calc. 347.52).


[0417] **Step 3: TRANS-8-dimethylamino-1-(1-hydroxy-cyclobutylmethyl)-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one**

[0418] To a solution of TRANS-8-dimethylamino-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (450 mg, 1.29 mmol, 1.0 eq.) in DMSO (10 mL) was added NaOH (363 mg, 9.07 mmol, 7.0 eq.) at RT. The reaction mixture was heated to 60°C for 30 min, then cooled to RT and 1-oxa-spiro[2.3]hexane (435 mg, 5.18 mmol, 4.0 eq.) was added. The reaction mixture was stirred at 60°C for 48 h, then quenched with ice water (25 mL), extracted with EtOAc (2x50 mL). Combined organic layer was washed with brine (25 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to get the crude product which was purified by column chromatography (neutral alumina; 4% MeOH/DCM) to yield TRANS-8-dimethylamino-1-(1-hydroxy-cyclobutylmethyl)-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (120 mg, 0.27 mmol, 21%) as a brown liquid. LC-MS: m/z [M+1]⁺ = 432.0 (MW calc. 431.64).

[0419] **Step 4: TRANS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4098)**

[0420] In analogy to the method described for step 2 of SC_4038 TRANS-8-dimethylamino-1-(1-hydroxy-cyclobutylmethyl)-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one was reacted with oxone to be converted into TRANS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4098). Mass: m/z 464.3 (M+H)⁺. ¹HNMR (DMSO-d₆, 400 MHz), δ (ppm) = 7.39-7.28 (m, 5H), 5.35 (s, 1H), 3.59-3.56 (m, 2H), 3.42-3.34 (m, 4H), 2.97-2.95 (m, 3H), 2.66 (s, 2H), 2.67 (bs, 2H), 2.59-2.56 (m, 2H), 2.00 (s, 6H), 1.77-.163 (m, 6H), 1.50-1.27 (m, 5H), 1.05-0.98 (m, 1H).

[0421] **Synthesis of SC_5063: CIS-2,2-dimethyl-3-(8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)propanenitrile**



[0422] **Step 1: CIS-3-(8-(dimethylamino)-1-(methoxymethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile**

[0423] To a solution of CIS-3-(8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-2,2-dimethylpropionitrile (**SC_5062**) (1.8 g, 5.08 mmol, 1.0 eq.) in THF (20 ml) was added NaH (95%, 366 mg, 15.25 mmol, 3.0 eq.) at 0°C and the reaction mixture was stirred for 20 min at RT. A solution of methoxymethyl chloride (0.57 ml, 7.62 mmol, 1.5 eq.) in THF (5 ml) was added at 0°C and the resulting mixture was stirred at RT for 16h. The reaction mixture was diluted with water (20 ml) and extracted with EtOAc (2x50 ml). The combined organic layers were washed with water (50 ml) and brine (50 ml), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (neutral alumina; 0.2% MeOH/DCM) to yield CIS-3-(8-(dimethylamino)-1-(methoxymethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (700 mg, 1.75 mmol, 34%) as an off-white sticky solid.. LC-MS: m/z [M+H]⁺ = 399.3 (MW calc. = 398.54).

[0424] **Step 2: CIS-3-(1-(methoxymethyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile**

[0425] To a solution of CIS-3-(8-(dimethylamino)-1-(methoxymethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (700 mg, 1.75 mmol, 1.0 eq.) in acetonitrile (20 ml) and THF (10 ml) was added N-iodosuccinimide (590 mg, 2.63 mmol, 1.5 eq.) at 0°C and the mixture was stirred at RT for 3h. The reaction mixture was diluted with water (20 ml) and 1N aq. NaOH (5 ml) and extracted with DCM (2x30 ml). The combined organic layers were washed with brine (40 ml), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure to give CIS-3-(1-(methoxymethyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (350 mg, 0.911 mmol, 52 %) which was used directly for next step without further purification. LC-MS: m/z [M+H]⁺ = 385.2 (MW calc. = 384.52).

[0426] **Step 3: CIS-2,2-dimethyl-3-(8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)propanenitrile (SC_5063)**

[0427] To a solution of CIS-3-(1-(methoxymethyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (400 mg, 1.04 mmol, 1.0 eq.) in MeOH (10 ml) was added 2M aq. HCl (30 ml) at 0°C and the mixture was stirred at RT for 16h. The reaction mixture was basified with 2M aq. NaOH and extracted with DCM (2x25 ml). The combined organic layers were washed with brine (30 ml), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure to give CIS-2,2-dimethyl-3-(8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)propanenitrile (**SC_5063**) (300 mg, 0.882 mmol, 84 %) which was 95.72% pure according to HPLC. LC-MS: m/z [M+H]⁺ = 341.27 (MW calc. = 340.46). ¹HNMR (DMSO-d₆, 400 MHz), δ (ppm) = 7.42-7.19 (m, 5H), 6.78 (bs, 1H), 3.36 (s, 2H), 3.18 (s, 2H), 1.96-1.85 (m, 7H), 1.66 (bs, 2H), 1.46-1.43 (m, 2H), 1.25 (s, 6H).

For **further exemplary compounds** the last synthesis step in analogy to previously described methods is given in the following table. The syntheses of the building blocks and intermediates have either been described previously within this application or can be performed in analogy to the herein described methods or by methods known to the person, skilled in the art. Such a person will also know which building blocks and intermediates need to be chosen for synthesis of each exemplary compound.

Example	Chemical Name	Reactant I	Reactant II	in analogy to method	m/z [M+H] ⁺
SC_4002	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	19-bromo-2,5,8,11,14,17-hexaaxanonadecane	SC_4003	620.4
SC_4004	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	22-bromo-2,5,8,11,14,17,20-heptaaxadocosane	SC_4003	664.4
SC_4005	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	16-bromo-2,5,8,11,14-pentaaxahexadecane	SC_4003	576.4
SC_4006	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(2-methoxy-ethoxy)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	1-bromo-2-(2-methoxyethoxy)ethane	SC_4003	444.3
SC_4007	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	1-bromo-2-methoxyethane	SC_4003	400.3
SC_4008	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	13-bromo-2,5,8,11-tetraoxatridecane	SC_4003	532.4
SC_4009	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	1-bromo-2-(methylsulfonyl)ethane	SC_4025	448.3
SC_4011	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	1-bromo-2-(methylsulfonyl)ethane	SC_4025	464.3
SC_4014	CIS-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-1-propionitrile	INT-799	3-bromo-2,2-dimethylpropanenitrile	SC_4025	423.3
SC_4017	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	25-bromo-2,5,8,11,14,17,20,23-octaaxacosane	SC_4003	708.5

Example	Chemical Name	Reactant I	Reactant II	in analogy to method	m/z [M+H] ⁺
	(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one		octaoxapentacosane		
SC_4018	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-methyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	Methyl iodide	SC_4025	356.3
SC_4021	CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	SC_4011	---	SC_4010	450.2
SC_4022	CIS-3-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile	SC_4029	---	SC_4010	397.3
SC_4024	CIS-2-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile	SC_4030	---	SC_4010	383.2
SC_4026	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	4-(2-bromoethyl)morpholine	SC_4025	471.3
SC_4029	CIS-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile	INT-799	3-bromopropanenitrile	SC_4025	411.3
SC_4030	CIS-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile	INT-799	2-bromoacetonitrile	SC_4025	397.3

Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4035	CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-1-(oxetan-3-yl-methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	SC_4032	toluene-4-sulfonic acid oxetan-3-ylmethyl ester	SC_4034	¹ H NMR (DMSO-d ₆ , 400 MHz), δ (ppm) = 7.34-7.25 (m, 5H), 4.59 (t, 2H, 6.64 Hz) 4.35 (bs, 2H), 3.48 (bs, 2H), 3.21 (s, 2H), 3.13 (bs, 1H), 2.95 (s, 3H), 2.67-2.65 (m, 2H), 1.97 (s, 8H), 1.41-1.30 (m, 4H).	450.1

Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4036	CIS-8-Dimethylamino-1-(3-methoxypropyl)-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	SC_4032	1-bromo-3-methoxy-propane	SC_4034	¹ H NMR (CDCl ₃ , 400 MHz): δ (ppm) = 7.35-7.25 (m, 5H, merged with CDCl ₃), 3.64 (t, 2H, J = 6.32 Hz), 3.44 (t, 2H, J = 6.08 Hz), 3.34 (s, 3H), 3.28-3.19 m, 6H), 2.95 (s, 3H), 2.64-2.61 (m, 2H), 2.22-2.16 (m, 2H), 2.01 (s, 6H), 1.89-1.86 (m, 2H), 1.29-1.27 (m, 4H).	452.3
SC_4039	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	1,6-dioxaspiro[2.5]octane	SC_4027	¹ H NMR (DMSO-d ₆): δ 7.37-7.31 (m, 4H), 7.26-7.23 (m, 1H), 4.52 (s, 1H), 3.60-3.56 (m, 4H), 3.28 (s, 2H), 3.03-3.01 (m, 4H), 2.68-2.65 (m, 2H), 2.49-2.46 (m, 1H), 2.06-1.92 (m, 10H), 1.82-1.65 (m, 4H), 1.49-1.44 (m, 2H), 1.34-1.31 (m, 6H).	456.3
SC_4040	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-tetrahydro-pyran-4-yl-1,3-diazaspiro[4.5]decan-2-one	INT-983	tetrahydro-2H-pyran-4-yl 4-methylbenzenesulfonate	SC_4027	¹ H NMR (DMSO-d ₆): δ 7.34-7.25 (m, 5H), 3.86-3.84 (m, 2H), 3.76-3.70 (m, 1H), 3.35 (m, 2H), 3.13 (s, 2H), 2.91 (d, 2H), 2.66-2.62 (m, 2H), 2.14 (t, 2H), 1.97 (s, 6H), 1.66-1.58 (m, 2H), 1.46-1.23 (m, 6H), 0.91 (m, 1H), 0.44 (m, 2H), 0.24 (m, 2H).	412.3
SC_4041	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	1-oxa-6-thiaspiro[2.5]octane (step 1)	SC_4027 (for step 1), SC_4038 (for step 2)	¹ H NMR (DMSO-d ₆): δ 7.37-7.23 (m, 5H), 5.02 (s, 1H), 3.27 (s, 2H), 3.17-3.03 (m, 6H), 2.97-2.94 (m, 2H), 2.68-2.65 (m, 2H), 2.54-2.46 (m, 1H), 2.07-1.92 (m, 10H), 1.87-1.84 (m, 4H), 1.80-1.66 (m, 4H), 1.34-1.31 (m, 4H).	504.3
SC_4042	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-tetrahydro-pyran-4-yl-1,3-diazaspiro[4.5]decan-2-one	INT-799	tetrahydro-2H-pyran-4-yl 4-methylbenzenesulfonate	SC_4027	¹ H NMR (DMSO-d ₆): δ 7.37-7.23 (m, 5H), 6.05 (s, 1H), 3.87-3.84 (m, 2H), 3.74-3.73 (m, 1H), 3.36-3.35 (m, 2H), 3.24 (s, 2H), 3.07 (s, 2H), 2.66-2.63 (m, 2H), 2.06-1.83 (m, 12H), 1.65-1.58 (m, 3H), 1.48-1.32 (m, 7H).	442.3
SC_4043	CIS-1-[[8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]-cyclobutane-1-carbonitrile	SC_4032	toluene-4-sulfonic acid 1-cyano-cyclobutylmethyl ester	SC_4034	¹ H NMR (DMSO-d ₆ , 400 MHz): δ (ppm) = 7.33-7.32 (m, 2H), 7.25 (s, 3 H), 3.69-3.66 (t, 2H, J=5), 3.41 (s, 2H), 3.30-3.25 (m, 4H), 2.95 (s, 3H), 2.67-2.64 (d, 2H, J=13.4), 2.45 (bs, 4H), 2.19-2.08 (m, 4H), 2.02 (s, 6H), 1.46-1.39 (m, 2H).	473.2

Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4045	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	1-oxa-6-thiaspiro[2.5]octane (step 1)	SC_4044 (for step 1), step 2 of SC_4038 (for step 2)	¹ H NMR (DMSO-d6): δ 7.37-7.25 (m, 5H), 5.93 (s, 1H), 5.01 (s, 1H), 3.41 (s, 2H), 3.16-3.09 (m, 6H), 2.98-2.95 (m, 2H), 2.70-2.66 (m, 2H), 2.06-2.03 (m, 4H), 1.97 (s, 6H), 1.89-1.87 (m, 6H), 1.64-1.61 (m, 1H), 1.45-1.31 (m, 5H).	520.3
SC_4046	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(1,1-dioxo-thian-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-983	tetrahydro-2H-thiopyran-4-yl 4-methylbenzenesulfonate (step 1)	SC_4044 (for step 1), step 2 of SC_4038 (for step 2)	¹ H NMR (DMSO-d6): δ 7.37-7.26 (m, 5H), 4.08-4.02 (m, 1H), 3.17-3.03 (m, 8H), 2.67-2.63 (m, 2H), 2.32-2.04 (m, 12H), 1.46-1.39 (m, 4H), 1.02-0.99 (m, 1H), 0.54-0.50 (m, 2H), 0.34-0.30 (m, 2H).	460.3
SC_4047	CIS-8-Dimethylamino-3-(1,1-dioxo-thian-4-yl)-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	tetrahydro-2H-thiopyran-4-yl 4-methylbenzenesulfonate (step 1)	SC_4044 (for step 1), step 2 of SC_4038 (for step 2)	¹ H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.23 (m, 1H), 5.94 (s, 1H), 3.97-3.91 (m, 1H), 3.33-3.31 (m, 2H), 3.27 (s, 2H), 3.07 (s, 2H), 3.02-2.99 (m, 2H), 2.64-2.61 (m, 2H), 2.12-2.02 (m, 6H), 1.97 (s, 6H), 1.88-1.85 (m, 4H), 1.66-1.61 (m, 1H), 1.50-1.29 (m, 5H).	490.3
SC_4049	CIS-3-(1-Benzoyl-piperidin-4-yl)-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	SC_4054	benzoyl chloride	SC_4048	¹ H NMR (CDCl3): δ 7.40-7.34 (m, 7H), 7.30-7.27 (m, 3H), 4.79 (m, 1H), 4.06-4.00 (m, 1H), 3.78 (br m, 1H), 3.90-3.05 (m, 5H), 2.80-2.77 (br m, 1H), 2.65 (d, 2H), 2.27 (t, 2H), 2.05 (s, 6H), 1.82-1.62 (m, 3H), 1.46-1.41 (m, 5H), 1.04-0.99 (m, 1H), 0.53-0.50 (m, 2H), 0.33-0.30 (m, 2H).	515.4
SC_4050	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one	SC_4054	isonicotinoyl chloride hydrochloride	SC_4048	¹ H NMR (CDCl3): δ 8.67-8.66 (m, 2H), 7.36-7.35 (m, 2H), 7.30-7.27 (m, 3H), 7.25-7.24 (m, 2H), 4.80-4.77 (m, 1H), 4.06-4.01 (m, 1H), 3.65-3.62 (m, 1H), 3.14-3.05 (m, 5H), 2.82 (t, 1H), 2.67-2.65 (m, 2H), 2.28 (m, 2H), 2.05 (s, 6H), 1.86-1.84 (m, 1H), 1.71-1.62 (m, 2H), 1.46-1.39 (m, 5H), 1.03-0.99 (m, 1H), 0.53-0.50 (m, 2H), 0.34-0.33 (m, 2H).	516.3
SC_4051	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-983	1,6-dioxaspiro[2.5]octane	SC_4044	¹ H NMR (DMSO-d6): δ 7.37-7.33 (m, 4H), 7.27-7.23 (m, 1H), 4.54 (s, 1H), 3.60-3.53 (m, 4H), 3.32 (m, 2H), 3.03 (s, 2H), 2.91 (d, 2H), 2.67 (d, 2H), 2.15 (t, 2H), 1.97 (s, 6H), 1.49-1.44 (m, 2H), 1.40-1.31 (m, 6H), 0.95-0.90 (m, 1H), 0.46-0.43 (m, 2H), 0.30-0.21 (m, 2H).	442.3

Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4053	CIS-3-[(1-Acetyl-piperidin-4-yl)-methyl]-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	SC_4058	acetyl chloride	SC_4048	¹ H NMR (DMSO d6): δ 7.35-7.34 (m, 4H), 7.25 (m, 1H), 4.31-4.28 (m, 1H), 3.77-3.74 (m, 1H), 3.15 (s, 2H), 2.97-2.90 (m, 5H), 2.68-2.64 (m, 2H), 2.19-2.13 (m, 2H), 1.97-1.95 (m, 9H), 1.76 (m, 1H), 1.59-1.52 (m, 2H), 1.43-1.31 (m, 4H), 1.03-0.87 (m, 3H), 0.45-0.44 (m, 2H), 0.25-0.24 (m, 2H).	467.3
SC_4058	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-(piperidin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one	INT-983	tert-butyl 4-((tosyloxy)methyl)piperidine-1-carboxylate (step 1)	SC_4034 (for step 1), step 2 of SC_4054 (for step 2)	¹ H NMR (DMSO d6): δ 7.37-7.34 (m, 4H), 7.27-7.23 (m, 1H), 3.13 (s, 2H), 2.91-2.87 (m, 6H), 2.67-2.64 (m, 2H), 2.39-2.33 (m, 2H), 2.18-2.12 (m, 2H), 1.97 (s, 6H), 1.58-1.54 (m, 1H), 1.47-1.30 (m, 6H), 0.98-0.88 (m, 3H), 0.46-0.42 (m, 2H), 0.26-0.22 (m, 2H).	425.3
SC_4059	CIS-3-(1-Benzoyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-976	tert-butyl 4-(tosyloxy)piperidine-1-carboxylate (step 1), benzoyl chloride (step 3)	SC_4054 (for steps 1,2), SC_4048 (for step 3)	¹ H NMR (DMSO d6): δ 7.42-7.23 (m, 10H), 6.67 (br s, 1H), 4.51 (m, 1H), 3.75 (m, 1H), 3.54 (m, 1H), 3.05 (s, 3H), 2.75 (m, 1H), 2.34 (m, 2H), 1.93 (s, 6H), 1.77 (m, 4H), 1.55-1.35 (m, 6H).	461.3
SC_4060	CIS-8-Dimethylamino-8-phenyl-1,3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one	INT-976	isonicotinoyl chloride hydrochloride	SC_4054 (for steps 1,2), SC_4048 (for step 3)	¹ H NMR (DMSO d6): δ 8.64-8.62 (m, 2H), 7.37-7.32 (m, 6H), 7.26-7.23 (m, 1H), 6.67 (br s, 1H), 4.50 (d, 1H), 3.80-3.73 (m, 1H), 3.40-3.37 (m, 1H), 3.11-3.05 (m, 3H), 2.78 (t, 1H), 2.36-2.33 (m, 2H), 1.93 (s, 6H), 1.80-1.65 (m, 4H), 1.61-1.52 (m, 3H), 1.49-1.35 (m, 3H).	462.3
SC_4061	CIS-3-(1-Acetyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-976	acetyl chloride	SC_4054 (for steps 1,2), SC_4048 (for step 3)	¹ H NMR (DMSO-d6): δ 7.36-7.23 (m, 5H), 6.68 (br, s, 1H), 4.40 (d, 1H), 3.80 (d, 1H), 3.69 (m, 1H), 3.05-2.99 (m, 3H), 2.32 (m, 3H), 1.95-1.92 (m, 9H), 1.78-1.76 (m, 4H), 1.50-1.46 (m, 3H), 1.33-1.30 (m, 3H).	399.3
SC_4062	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-983	1-oxa-6-thiaspiro[2.5]octane (step 1)	SC_4044 (for step 1), step 2 of SC_4038 (for step 2)	¹ H NMR (DMSO-d6): δ 7.37-7.33 (m, 4H), 7.27-7.24 (m, 1H), 5.04 (s, 1H), 3.30 (m, 2H), 3.15-3.07 (m, 4H), 2.97-2.92 (m, 4H), 2.69-2.66 (m, 2H), 2.18-2.13 (m, 2H), 1.97 (s, 6H), 1.87-1.84 (m, 4H), 1.38-1.31 (m, 4H), 0.94-0.91 (m, 1H), 0.47-0.43 (m, 2H), 0.26-0.24 (m, 2H).	490.3

Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4063	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	tert-butyl bromoacetate (step 1), methylmagnesium bromide (step 3)	SC_4055	¹ H NMR (DMSO d6): δ 7.37-7.33 (m, 4H), 7.26-7.23 (m, 1H), 6.11 (s, 1H), 4.41 (s, 1H), 3.42 (s, 2H), 3.09 (s, 2H), 2.98 (s, 2H), 2.70-2.67 (m, 2H), 2.07-2.02 (m, 4H), 1.97 (s, 6H), 1.91-1.83 (m, 3H), 1.63-1.61 (m, 1H), 1.45-1.42 (m, 2H), 1.36-1.32 (m, 3H), 1.04 (s, 6H).	430.3
SC_4066	CIS-8-Dimethylamino-1,3-bis(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-976	1-bromo-2-methylsulfonyl-ethane	SC_4003	¹ H NMR (600 MHz, DMSO) δ 7.40 – 7.32 (m, 4H), 7.30 – 7.23 (m, 1H), 3.52 (t, 2H), 3.46 – 3.31 (m, 1H), 3.27 (s, 2H), 3.05 (s, 3H), 2.97 (s, 3H), 2.72 – 2.63 (m, 2H), 2.11 – 2.01 (m, 2H), 1.99 (s, 6H), 1.45 – 1.36 (m, 4H).	380.2
SC_4067	CIS-N-[1-[[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-methyl]-cyclopropyl]-acetamide	SC_4064	acetyl chloride	SC_4048	[0375] ¹ H NMR (DMSO-d6, 400 MHz), δ (ppm) = 7.98 (s, 1H), 7.36-7.25 (m, 5H), 3.25 (s, 2H), 3.12 (s, 2H), 2.89 (d, 2H, J = 6.48 Hz), 2.67-2.64 (m, 2H), 2.16-2.07 (m, 2H), 1.97 (s, 6H), 1.67 (s, 3H), 1.44-1.36 (m, 4H), 0.91 (bs, 1H), 0.62-0.42 (m, 6H), 0.25-0.23 (m, 2H).	439.1
SC_4068	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-[(1-pyrimidin-5-yl-piperidin-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one	SC_4058	5-bromo-2-(trifluoromethyl)pyrimidine	SC_4056	¹ H NMR (DMSO d6): δ 8.52 (s, 1H), 8.45 (s, 2H), 7.37-7.33 (m, 4H), 7.27-7.23 (m, 1H), 3.83-3.80 (m, 2H), 3.17 (s, 2H), 2.96-2.75 (m, 4H), 2.73-2.65 (m, 4H), 2.16 (m, 2H), 1.98 (s, 6H), 1.65 (m, 1H), 1.65-1.63 (m, 2H), 1.40-1.32 (m, 4H), 1.20-1.17 (m, 2H), 0.94 (m, 1H), 0.46-0.44 (m, 2H), 0.26-0.24 (m, 2H).	503.4
SC_4069	CIS-8-Dimethylamino-8-phenyl-3-[(1-pyrimidin-5-yl-piperidin-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one	INT-1051	5-bromopyrimidine	SC_4056	¹ H NMR (DMSO d6): δ 8.52 (s, 1H), 8.45 (s, 2H), 7.37-7.33 (m, 4H), 7.26-7.23 (m, 1H), 6.72 (broad s, 1H), 3.82-3.79 (m, 2H), 3.18 (s, 2H), 2.90-2.89 (m, 2H), 2.72-2.69 (m, 2H), 2.30 (m, 2H), 1.92 (s, 6H), 1.79-1.69 (m, 5H), 1.64-1.61 (m, 2H), 1.35 (m, 2H), 1.20-1.12 (m, 2H).	449.3
SC_4070	CIS-8-Dimethylamino-8-phenyl-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one	INT-1050	5-bromopyrimidine	SC_4056	¹ H NMR (DMSO-d6): δ 8.52 (s, 1H), 8.46 (s, 2H), 7.36-7.30 (m, 4H), 7.24-7.22 (m, 1H), 6.71 (br s, 1H), 3.90-3.88 (m, 2H), 3.71-3.67 (m, 1H), 3.00 (s, 2H), 2.84-2.79 (m, 2H), 2.28 (br s, 2H), 1.92 (s, 6H), 1.78 (br m, 4H), 1.66-1.55 (m, 4H), 1.34-1.33 (m, 2H).	435.3

Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4072	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[2-methyl-2-(2-oxo-pyrrolidin-1-yl)-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-1052	4-chlorobutanoyl chloride (step 1)	SC_4048 (step 1), procedure described (step 2)	¹ H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.24 (m, 1H), 3.40-3.36 (m, 4H), 3.16 (s, 2H), 2.92 (d, 2H), 2.69-2.66 (m, 2H), 2.19-2.07 (m, 4H), 1.97 (s, 6H), 1.79-1.75 (m, 2H), 1.37-1.29 (m, 4H), 1.26 (s, 6H), 0.93-0.92 (m, 1H), 0.47-0.42 (m, 2H), 0.27-0.24 (m, 2H).	467.3
SC_4073	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[2-(1,1-dioxo-[1,2]thiazolidin-2-yl)-2-methyl-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-1052	3-chloropropane-1-sulfonyl chloride (step 1)	SC_4072	¹ H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.24 (m, 1H), 3.34-3.27 (m, 4H), 3.16-3.13 (m, 4H), 2.93 (d, 2H), 2.67-2.64 (m, 2H), 2.16-2.05 (m, 4H), 1.97 (s, 6H), 1.40-1.36 (m, 4H), 1.29 (s, 6H), 0.93-0.92 (m, 1H), 0.46-0.44 (m, 2H), 0.26-0.24 (m, 2H).	503.3
SC_4074	CIS-8-Dimethylamino-1-[1-(1-hydroxy-cyclobutyl)-methyl]-3-[2-(4-hydroxy-tetrahydro-pyran-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	2-(4-(benzyloxy)tetrahydro-2H-pyran-4-yl)ethyl 4-methylbenzenesulfonate	SC_4052	¹ H NMR (DMSO-d6): δ 7.37-7.34 (m, 4H), 7.27-7.24 (m, 1H), 6.17 (s, 1H), 4.28 (br s, 1H), 3.61-3.51 (m, 4H), 3.25 (s, 2H), 3.22-3.18 (m, 2H), 3.07 (s, 2H), 2.68-2.65 (m, 2H), 2.06-2.03 (m, 4H), 1.97 (s, 6H), 1.91-1.83 (m, 2H), 1.64-1.61 (m, 1H), 1.57-1.50 (m, 2H), 1.47-1.29 (m, 9H).	486.4
SC_4075	CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(4-hydroxy-1,1-dioxo-thian-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-987	4-allyl-4-(benzyloxy)tetrahydro-2H-thiopyran	SC_4071	¹ H NMR (DMSO-d6): δ 7.37-7.23 (m, 5H), 4.76 (s, 1H), 3.16-3.10 (m, 6H), 3.01 (d, 2H), 2.91-2.88 (m, 2H), 2.67-2.63 (m, 2H), 2.02-1.82 (m, 14H), 1.80-1.65 (m, 5H), 1.58 (m, 2H), 1.42-1.35 (m, 2H), 1.28-1.26 (m, 2H).	518.3
SC_4076	CIS-3-[1-(Acetyl-piperidin-4-yl)-methyl]-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-1051	acetyl chloride	SC_4048	¹ H NMR (DMSO d6): δ 7.37-7.23 (m, 5H), 6.72 (b s, 1H), 4.30-4.27 (m, 1H), 3.76-3.73 (m, 1H), 3.03 (s, 2H), 2.96-2.91 (m, 1H), 2.86-2.81 (m, 2H), 2.44 (m, 1H), 2.32 (m, 2H), 1.95-1.92 (m, 9H), 1.79-1.68 (m, 5H), 1.58-1.50 (m, 2H), 1.36-1.34 (m, 2H), 1.05-1.01 (m, 1H), 0.98-0.92 (m, 1H).	413.3
SC_4077	CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	SC_4032	2-chloro-1-pyrrolidin-1-yl-ethanone	SC_4003	¹ H NMR (600 MHz, DMSO) δ 7.38 – 7.30 (m, 4H), 7.29 – 7.22 (m, 1H), 3.79 (s, 2H), 3.53 – 3.48 (m, 5H), 3.35 – 3.27 (m, 5H), 2.96 (s, 3H), 2.67 – 2.59 (m, 2H), 1.98 – 1.87 (m, 10H), 1.77 (p, 2H), 1.44 – 1.34 (m, 4H).	491.3

Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4078	TRANS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-1059	1-bromo-2-methylsulfonyl-ethane	SC_4003	¹ H NMR (DMSO-d ₆ , 400 MHz at 100 °C), δ (ppm) = 7.35-7.24 (m, 5H), 6.43 (s, 1H), 3.50 (t, 2H, J = 6.46 Hz), 3.31-3.22 (m, 4H), 2.95 (3H, merged with DMSO-water), 2.17 (bs, 2H), 1.99 (bs, 8H), 1.72 (bs, 2H), 1.45-1.39 (m, 2H).	380.2
SC_4079	CIS-8-Dimethylamino-1-[(1-hydroxycyclobutyl)-methyl]-3-[2-(4-hydroxy-1,1-dioxo-thian-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	4-allyl-4-(benzyloxy)tetrahydro-2H-thiopyran	SC_4071	¹ H NMR (DMSO-d ₆): δ 7.37-7.33 (m, 4H), 7.27-7.24 (m, 1H), 6.13 (br s, 1H), 3.26 (s, 2H), 3.20-3.11 (m, 4H), 3.07 (s, 2H), 2.92-2.89 (m, 2H), 2.68-2.65 (m, 2H), 2.05-2.01 (m, 4H), 1.97 (s, 6H), 1.89-1.85 (m, 8H), 1.64-1.60 (m, 3H), 1.43-1.32 (m, 4H).	534.3
SC_4081	CIS-N-[2-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl]-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-acetamide	INT-1052	acetyl chloride	SC_4048	¹ H NMR (CDCl ₃ , 400 MHz), δ (ppm) = 7.53 (s, 1H), 7.36-7.28 (m, 5H), 3.28 (s, 2H), 3.08-3.04 (m, 4H), 2.66-2.63 (m, 2H), 2.31-2.25 (m, 2H), 2.03 (s, 6H), 1.87 (s, 3H), 1.51-1.41 (m, 4H), 1.35 (s, 6H), 1.02 (bs, 1H), 0.53-0.51 (m, 2H), 0.33-0.32 (m, 2H).	441.3
SC_4082	CIS-N-[2-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl]-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-methanesulfonic acid amide	INT-1052	methanesulfonyl chloride	SC_4048	¹ H NMR (CDCl ₃ , 400 MHz), δ (ppm) = 7.34-7.25 (m, 5H), 6.16 (s, 1H), 3.31 (s, 2H), 3.10-3.05 (m, 4H), 2.97 (s, 3H), 2.67-2.63 (m, 2H), 2.32-2.25 (m, 2H), 2.03 (s, 6H), 1.51-1.43 (m, 4H), 1.37 (s, 6H), 1.01-0.99 (m, 1H), 0.52-0.50 (m, 2H), 0.32 (m, 2H).	477.2
SC_4083	CIS-8-Dimethylamino-1-[(1-hydroxycyclobutyl)-methyl]-3-[2-(3-hydroxyoxetan-3-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	3-(benzyloxy)-3-vinylloxetane	SC_4071	¹ H NMR (DMSO-d ₆): δ 7.36-7.33 (m, 4H), 7.26-7.25 (m, 1H), 6.12 (s, 1H), 5.65 (s, 1H), 4.39 (d, 2H), 4.33 (d, 2H), 3.29 (s, 2H), 3.17-3.14 (m, 2H), 3.08 (s, 2H), 2.68-2.65 (m, 2H), 2.07-2.02 (m, 4H), 1.97 (s, 6H), 1.91-1.86 (m, 4H), 1.69-1.59 (m, 1H), 1.43-1.40 (m, 4H), 1.38-1.31 (m, 1H).	458.3
SC_4085	CIS-N-[2-[8-Dimethylamino-1-[(1-hydroxycyclobutyl)-methyl]-2-oxo-8-phenyl]-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-acetamide	INT-1053	acetyl chloride	SC_4048	¹ H NMR (DMSO-d ₆ , 400 MHz), δ (ppm) = 7.48 (s, 1H), 7.32 (m, 5H), 5.95 (s, 1H), 3.29-3.26 (m, 4H), 3.06 (s, 2H), 2.65-2.62 (m, 2H), 2.05-1.99 (m, 4H), 1.93 (s, 6H), 1.85-1.82 (m, 2H), 1.67 (s, 3H), 1.60-1.59 (m, 1H), 1.43-1.26 (m, 5H), 1.13 (m, 6H).	471.3

Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4086	CIS-N-[2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl]-1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl-methanesulfonic acid amide	INT-1053	methanesulfonyl chloride	SC_4048	¹ H NMR (DMSO-d ₆ , 400 MHz): δ (ppm) = 7.35-7.25 (m, 5H), 6.90 (s, 1H), 5.95 (s, 1H), 3.44 (s, 2H), 3.14 (s, 2H), 3.10 (s, 2H), 2.92 (s, 3H), 2.68-2.66 (m, 3H), 2.08-2.03 (m, 4H), 1.97 (s, 6H), 1.88-1.85 (m, 2H), 1.47-1.31 (m, 7H), 1.21 (s, 6H).	507.1
SC_4087	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyridin-3-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one	SC_4054	3-bromopyridine	SC_4056	¹ H NMR (DMSO d ₆): δ 8.26 (d, 1H), 7.93 (m, 1H), 7.35-7.27 (m, 4H), 7.25-7.23 (m, 2H), 7.17-7.15 (m, 1H), 3.80 (d, 2H), 3.77-3.68 (m, 1H), 3.29-3.27 (m, 1H), 3.13 (s, 2H), 2.91 (d, 2H), 2.77 (t, 2H), 2.64-2.62 (m, 1H), 2.14 (t, 2H), 1.97 (s, 6H), 1.72-1.68 (m, 2H), 1.61-1.59 (m, 2H), 1.44 (t, 2H), 1.32 (d, 2H), 0.94-0.90 (m, 1H), 0.47-0.44 (m, 2H), 0.28-0.25 (m, 2H).	488.4
SC_4088	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-(2-methylsulfonyl-ethyl)-1,3-diazaspiro[4.5]decan-2-one	INT-1063	1-bromo-2-methylsulfonyl-ethane	SC_4032	¹ H NMR (600 MHz, DMSO) δ 7.44 – 7.36 (m, 1H), 7.18 (d, 1H), 7.15 (dt, 1H), 7.10 (td, 1H), 3.51 (t, 2H), 3.32 (t, 2H), 3.23 (s, 2H), 2.96 (s, 3H), 2.93 (d, 2H), 2.68 – 2.60 (m, 2H), 2.18 – 2.10 (m, 2H), 2.00 (s, 6H), 1.45 – 1.33 (m, 4H), 0.93 (tdd, 1H), 0.50 – 0.41 (m, 2H), 0.31 – 0.22 (m, 2H).	452.2
SC_4089	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyridin-4-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one	SC_4054	4-bromopyridine	SC_4056	¹ H NMR (DMSO d ₆): δ 8.09-8.08 (d, 2H), 7.33-7.30 (m, 4H), 7.24-7.23 (m, 1H), 6.77-76 (d, 2H), 3.98-3.96 (d, 2H), 3.80 (m, 1H), 3.09 (s, 2H), 2.91-2.84 (m, 4H), 2.62-2.59 (m, 2H), 2.15-2.10 (m, 2H), 1.94 (m, 6H), 1.59-1.56 (m, 4H), 1.42-1.37 (m, 2H), 1.33-1.29 (m, 2H), 0.91-0.90 (m, 1H), 0.46-0.43 (m, 2H), 0.26 (m, 2H).	488.4
SC_4090	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-methyl-2-(2-oxo-pyrrolidin-1-yl)-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-1053	4-chlorobutanoyl chloride (step 1)	SC_4072	¹ H NMR (DMSO-d ₆): δ 7.37-7.32 (m, 4H), 7.27-7.25 (m, 1H), 6.03 (s, 1H), 3.43 (s, 2H), 3.39 (t, 2H), 3.27 (s, 2H), 2.09 (s, 2H), 2.69-2.66 (m, 2H), 2.12 (t, 2H), 2.07-2.03 (m, 4H), 1.96 (s, 6H), 1.90-1.86 (m, 2H), 1.84-1.76 (m, 2H), 1.63-1.61 (m, 1H), 1.45-1.43 (m, 2H), 1.41 (m, 3H), 1.35-1.31 (m, 6H).	497.4











Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4092	TRANS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methyl-2-methylsulfonyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-1056	-	SC_4091	¹ H NMR (DMSO-d ₆ , 400 MHz), δ (ppm) = 7.44-7.29 (m, 5H), 3.38 (s, 2H), 3.34 (s, 2H), 2.94 (s, 3H), 2.87 (s, 3H), 2.64 (d, 2H, J = 12.24 Hz), 2.60 (d, 2H, J = 7.24 Hz), 2.10-2.06 (m, 1H), 1.90 (s, 6H), 1.73-1.49 (m, 6H), 1.42-1.33 (m, 6H), 1.27 (s, 6H).	476.3
SC_4093	CIS-8-Dimethylamino-3-[2-(1,1-dioxo-[1,2]thiazolidin-2-yl)-2-methyl-propyl]-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-799	3-chloropropane-1-sulfonyl chloride (step 1)	SC_4072	¹ H NMR (DMSO-d ₆): δ 7.37-7.32 (m, 4H), 7.27-7.23 (m, 1H), 6.01 (s, 1H), 3.42 (s, 2H), 3.36-3.31 (m, 2H), 3.18-3.13 (m, 4H), 3.10 (s, 2H), 2.68-2.64 (m, 2H), 2.10-2.03 (m, 6H), 1.96 (s, 6H), 1.90-1.84 (m, 2H), 1.70-1.60 (m, 1H), 1.47-1.44 (m, 2H), 1.41-1.35 (m, 3H), 1.32 (s, 6H).	533.3
SC_4094	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one	INT-1063	1,6-dioxaspiro[2.5]octane	SC_4044	¹ H NMR (DMSO-d ₆): δ 7.34-7.29 (m, 1H), 7.06-7.04 (m, 1H), 6.99-6.95 (m, 2H), 4.43 (s, 1H), 3.82-3.78 (m, 2H), 3.74-3.71 (m, 2H), 3.28 (s, 2H), 3.14 (s, 2H), 3.06 (d, 2H), 2.59 (d, 2H), 2.26 (t, 2H), 2.05 (s, 6H), 1.58-1.49 (m, 4H), 1.47-1.42 (m, 4H), 1.02 (m, 1H), 0.54-0.51 (m, 2H), 0.33-0.31 (m, 2H)	460.3
SC_4095	CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one	INT-1072	5-bromopyrimidine	SC_4056		519.3
SC_4097	CIS-2-[8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-N,N-dimethyl-acetamide	SC_4032	2-chloro-N,N-dimethyl-acetamide	SC_4003	¹ H NMR (600 MHz, DMSO) δ 7.35 (d, 4H), 7.29 – 7.22 (m, 1H), 3.86 (s, 2H), 3.51 (t, 2H), 3.32 (t, 2H), 3.29 (s, 2H), 3.03 (s, 3H), 2.97 (s, 3H), 2.84 (s, 3H), 2.64 (d, 2H), 2.02 – 1.86 (m, 8H), 1.44 – 1.35 (m, 4H).	465.3
SC_4099	CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one	INT-1073	5-bromopyrimidine	SC_4056		507.3













Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4100	CIS-1-(cyclopropylmethyl)-8-(3-fluorophenyl)-8-(methylamino)-3-(2-(methylsulfonyl)ethyl)-1,3-diazaspiro[4.5]decan-2-one	SC_4088		SC_4010		438.2
SC_4101	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-983	1-oxaspiro[2.3]hexane	SC_4044		
SC_4102	CIS-8-(dimethylamino)-8-(3-fluorophenyl)-3-((4-hydroxy-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1-((1-hydroxycyclobutyl)methyl)-1,3-diazaspiro[4.5]decan-2-one	INT-1074	1-oxa-6-thiaspiro[2.5]octane (step 1)	SC_4044 (for step 1), step 2 of SC_4038 (for step 2)		
SC_4103	CIS-8-(dimethylamino)-8-(3-fluorophenyl)-1-((1-hydroxycyclobutyl)methyl)-3-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one	INT-1074	1,6-dioxaspiro[2.5]octane	SC_4044		
SC_4104	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-(3-fluorophenyl)-3-((4-hydroxy-1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one	INT-1063	1-oxa-6-thiaspiro[2.5]octane (step 1)	SC_4044 (for step 1), step 2 of SC_4038 (for step 2)		
SC_4105	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(oxetan-3-ylmethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-983	3-(bromomethyl)oxetane	SC_4032		













Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4106	CIS-8-(dimethylamino)-8-phenyl-3-((S)-1-(thiophen-3-yl)propan-2-yl)-1,3-diazaspiro[4.5]decan-2-one	INT-976	(R)-1-(thiophen-3-yl)propan-2-yl methanesulfonate	SC_4032		398.2
SC_4107	CIS-8-(dimethylamino)-8-phenyl-1,3-bis((1-(trifluoromethyl)cyclopropyl)methyl)-1,3-diazaspiro[4.5]decan-2-one	INT-976	(1-(trifluoromethyl)cyclopropyl)methyl 4-methylbenzenesulfonate	SC_4032		
SC_4108	CIS-8-(dimethylamino)-1,3-bis((1-fluorocyclopropyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-976	(1-fluorocyclopropyl)methyl 4-methylbenzenesulfonate	SC_4032		
SC_4109	CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-((3-(hydroxymethyl)oxetan-3-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-983	(3-(bromomethyl)oxetan-3-yl)methanol	SC_4032		
SC_4110	CIS-3-((3-aminooxetan-3-yl)methyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one	INT-983	tert-butyl (3-(bromomethyl)oxetan-3-yl)carbamate	SC_4034 (for step 1), step 2 of SC_4054 (for step 2)		
SC_4111	CIS-3-(8-(dimethylamino)-1-((1-fluorocyclopropyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile	INT-983	(1-cyanocyclobutyl)methyl 4-methylbenzenesulfonate	SC_4032		













Example	Chemical name	Reactant I	Reactant II	in analogy to method	¹ H NMR data	m/z (M+H) ⁺
SC_4112	CIS-3-(8-(dimethylamino)-1-((1-fluorocyclopropyl)methyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile	INT-976	2-cyano-2-methylpropyl 4-methylbenzenesulfonate (step 1), (1-fluorocyclopropyl)methyl 4-methylbenzenesulfonate (step 2)	SC_4032 (step 1), SC_4034 (step 2)		
SC_5061	CIS-3-[8-(Ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile	INT-797	3-bromo-2,2-dimethyl-propionitrile	step 1 of INT-897	¹ HNMR (DMSO-d ₆ , 400 MHz, at 100 °C), δ (ppm) = 7.34-7.21 (m, 5H), 6.70 (bs, 1H), 3.28 (s, 2H), 3.19 (s, 2H), 2.32-2.24 (m, 4H), 2.06 (s, 3H), 1.87-1.82 (m, 4H), 1.45-1.37 (bs, 2H), 1.27 (s, 6H), 0.93 (t, 3H, 6.8 Hz).	369.2
SC_5062	CIS-3-(8-(Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethyl-propionitrile	INT-976	3-bromo-2,2-dimethyl-propionitrile	step 1 of INT-897	¹ HNMR (DMSO-d ₆ , 400 MHz), δ (ppm) = 7.35-7.24 (m, 5H), 7.03 (bs, 1H), 3.25 (s, 2H), 3.15 (s, 2H), 2.32 (bs, 2H), 1.92 (s, 6H), 1.82 (bs, 4H), 1.38 (bs, 2H), 1.24 (s, 6H).	355.2
SC_5065	CIS-3-[8-(Ethyl-methyl-amino)-1-methyl-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile	SC_5061	methyl iodide	step 1 of INT-953	¹ HNMR (DMSO-d ₆ , 400 MHz), δ (ppm) = 7.34-7.22 (m, 5H), 3.38 (s, 2H), 3.21 (s, 2H), 2.71-2.64 (m, 5H), 2.19-2.16 (m, 4H), 1.96 (s, 3H), 1.37-1.30 (m, 4H), 1.25 (s, 6H), 0.98 (t, 3H, J = 6.48 Hz).	383.2
SC_5068	CIS-3-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethyl-propionitrile	INT-1008	3-bromo-2,2-dimethyl-propionitrile	step 1 of INT-897	¹ HNMR (DMSO-d ₆ , 400 MHz), δ (ppm) = 7.42 (d, 12H, J = 7.32 Hz), 7.30 (t, 2H, J = 7.20 Hz), 7.17 (t, 1H, J = 7.12 Hz), 6.78 (s, 1H), 3.35 (s, 2H), 3.17 (s, 2H), 2.05 (m, 7H), 1.67-1.43 (m, 4H), 1.25 (s, 6H), 0.91 (t, 3H, J = 6.78 Hz).	355.1
SC_5080	TRANS-3-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile	INT-1059	3-bromo-2,2-dimethyl-propionitrile (step 1), cyclopropylmethylbromide (step 2)	step 1 of INT-897 (for step 1), step 1 of INT-953 (for step 2)	¹ HNMR at 20 °C (DMSO-d ₆ , 400 MHz), δ (ppm) = 7.44-7.28 (m, 5H), 3.46 (s, 2H), 3.23 (s, 2H), 2.72-2.66 (m, 2H), 2.57-2.55 (m, 2H), 1.91 (s, 6H), 1.55-1.45 (m, 6H), 1.27 (s, 6H), 0.51 (bs, 1H), 0.19-0.14 (m, 2H), (-0.22)-(-0.26) (m, 2H).	409.2











[0428] Chemical Structure of all examples













 SC_4001	 SC_4002
 SC_4003	 SC_4004
 SC_4005	 SC_4006
 SC_4007	 SC_4008
 SC_4009	 SC_4010













 SC_4011	 SC_4012
 SC_4013	 SC_4014
 SC_4017	 SC_4018
 SC_4021	 SC_4022
 SC_4024	 SC_4025
 SC_4026	 SC_4027













 SC_4028	 SC_4029
 SC_4030	 SC_4031
 SC_4032	 SC_4033
 SC_4034	 SC_4035
 SC_4036	 SC_4037
 SC_4038	 SC_4039













 SC_4040	 SC_4041
 SC_4042	 SC_4043
 SC_4044	 SC_4045
 SC_4046	 SC_4047
 SC_4048	 SC_4049
 SC_4050	 SC_4051










SC_4050	
 SC_4052	 SC_4053
 SC_4054	 SC_4055
 SC_4056	 SC_4057
 SC_4058	 SC_4059
 SC_4060	 SC_4061

 SC_4062	 SC_4063
 SC_4064	 SC_4066
 SC_4067	 SC_4068
 SC_4069	 SC_4070
 SC_4071	 SC_4072
 SC_4073	 SC_4074

 SC_4075	 SC_4076
 SC_4077	 SC_4078
 SC_4079	 SC_4080
 SC_4081	 SC_4082
 SC_4083	 SC_4084
 SC_4085	 SC_4086

 SC_4087	 SC_4088
 SC_4089	 SC_4090
 SC_4091	 SC_4092
 SC_4093	 SC_4094
 SC_4095	 SC_4096
 SC_4097	 SC_4098

 SC_4099	 SC_4100
 SC_4101	 SC_4102
 SC_4103	 SC_4104
 SC_4105	 SC_4106
 SC_4107	 SC_4108
 SC_4109	 SC_4110

SC_4111 	SC_4112 
SC_5061 	SC_5062 
SC_5063 	SC_5065 
SC_5068 	SC_5075 
SC_5080 	

[0429] **Pharmacological investigations**

[0430] Functional investigation on the human mu-opioid receptor (hMOP), human kappa-opioid receptor (hKOP), human delta-opioid receptor (hDOP), and human nociceptin/orphanin FQ peptide receptor (hNOP)

[0431] *Human mu-opioid peptide (hMOP) receptor binding assay*

[0432] The hMOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.052 mg/ml bovine serum albumin (Sigma-Aldrich Co., St. Louis, MO). The final assay volume (250 µl/well) included 1 nM of [N-allyl-2,3-³H]naloxone as ligand (PerkinElmer Life Sciences, Inc. Boston, MA, USA), and either test compound in dilution series or 25 µM unlabelled naloxone for determination of unspecific binding. The test compound was diluted with 25 % DMSO in H₂O to yield a final 0.5 % DMSO concentration, which also served as a respective vehicle control. The assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd., Buckinghamshire, UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences, Inc. Boston, MA, USA). After incubation for 90 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC₅₀) values reflecting 50% displacement of [³H]naloxone-specific receptor binding were calculated by nonlinear regression analysis and K_i values were calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).

[0433] ***Human kappa-opioid peptide (hKOP) receptor binding assay***

[0434] The hKOP receptor binding assay is run as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.076 mg BSA/ml. The final assay volume of 250 µl per well includes 2 nM of [³H]U69,593 as ligand, and either test compound in dilution series or 100 µM unlabelled naloxone for determination of unspecific binding. The test compound is diluted with 25% DMSO in H₂O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well. The assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 µl final assay volume per well) which has been preloaded for 15 minutes at room temperature with hKOP receptor membranes (14.8 µg/250 µl final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 90 minutes at room temperature. After this incubation, the microtiter plates are sealed with a topseal and centrifuged for 20 minutes at 500 rpm. The signal rate is measured after a short delay of 5 minutes by means of a 1450 Microbeta Trilux β-counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC₅₀) values reflecting 50% displacement of [³H]U69,593-specific receptor binding are calculated by nonlinear regression analysis and K_i values are calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).

[0435] ***Human delta-opioid peptide (hDOP) receptor binding assay***

[0436] The hDOP receptor binding assay is performed as homogeneous SPA-assay using the assay buffer 50 mM TRIS-HCl, 5 mM MgCl₂ (pH 7.4). The final assay volume (250 µl/well) includes 1 nM of [Tyrosyl-3,5-³H]2-D-Ala-deltorphan II as ligand, and either test compound in dilution series or 10 µM unlabelled naloxone for determination of unspecific binding. The test compound is diluted with 25% DMSO in H₂O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well. The assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 µl final assay volume per well) which has been preloaded for 15 minutes at room temperature with hDOP receptor membranes (15.2 µg/250 µl final assay

volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 120 minutes at room temperature and centrifuged for 20 minutes at 500 rpm. The signal rate is measured by means of a 1450 Microbeta Trilux β -counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC₅₀) values reflecting 50% displacement of [Tyrosyl-3,5-³H]2-D-Ala-deltorphin II-specific receptor binding are calculated by nonlinear regression analysis and K_i values are calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).

[0437] ***Human nociceptin/orphanin FQ peptide (hNOP) receptor binding assay***

[0438] The hNOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl, 10mM MgCl₂, 1 mM EDTA (pH 7.4). The final assay volume (250 μ l/well) included 0.5 nM of [leucyl-³H]nociceptin as ligand (PerkinElmer Life Sciences, Inc. Boston, MA, USA), and either test compound in dilution series or 1 μ M unlabelled nociceptin for determination of unspecific binding. The test compound was diluted with 25 % DMSO in H₂O to yield a final 0.5 % DMSO concentration, which also served as a respective vehicle control. The assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd., Buckinghamshire, UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences, Inc. Boston, MA, USA).

[0439] After incubation for 60 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux β -counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC₅₀) values reflecting 50% displacement of [³H]nociceptin-specific receptor binding were calculated by nonlinear regression analysis and K_i values were calculated by using the Cheng-Prusoff equation. (Cheng and Prusoff, 1973).

Example	hNOP Ki [nM]	hMOP Ki [nM] or % μ inhibition at 1M
SC_4001	2.3	80.5
SC_4002	28	755
SC_4003	7.7	39.5
SC_4004	44	305
SC_4005	19	64.5
SC_4006	3.6	16
SC_4007	2.6	58
SC_4008	7.3	69.8
SC_4009	1.1	37.4
SC_4010	9.5	87
SC_4011	13	210
SC_4012	1.6	99.7

Example	hNOP Ki [nM]	hMOP Ki [nM] or % μ inhibition at 1M
SC_4013	5.8	40.5
SC_4014	2.1	84
SC_4017	45	375
SC_4018	1.3	19.7
SC_4021	83	636.7
SC_4022	140	555
SC_4024	155	285
SC_4025	26	206
SC_4026	57	643
SC_4031	119	1430
SC_4032	345	8530
SC_4033	-	15%@1 μ M

Example	hNOP Ki [nM]	hMOP Ki [nM] or % μinhibition at 1M
SC_4034	11	245
SC_4035	69	1580
SC_4036	8	210
SC_4037	815	185
SC_4038	69	1290
SC_4039	3	165
SC_4040	19	270
SC_4041	4	125
SC_4042	11	290
SC_4043	4	124
SC_4044	19	1065
SC_4045	17	415
SC_4046	15	655
SC_4047	8	265
SC_4048	46	805
SC_4049	11	220
SC_4050	19	255
SC_4051	21	770
SC_4052	3	175
SC_4053	34	1350
SC_4054	26	1305
SC_4055	54	1865
SC_4056	10	1755
SC_4057	3	1050
SC_4058	15	540
SC_4059	710	9%@1μM
SC_4060	1170	5%@1μM
SC_4061	710	9%@1μM
SC_4062	27	1810
SC_4063	15	2910
SC_4064	5	495
SC_4066	40	3045
SC_4067	12	615
SC_4068	13	985
SC_4069	140	6900
SC_4070	140	8%

Example	hNOP Ki [nM]	hMOP Ki [nM] or % μinhibition at 1M
SC_4071	1	63
SC_4072	10	255
SC_4073	6	300
SC_4074	12	460
SC_4075	1	39
SC_4076	235	17%
SC_4077	75	3230
SC_4078	125	74
SC_4079	6	415
SC_4080	145	4145
SC_4081	10	765
SC_4082	10	270
SC_4083	10	235
SC_4084	118	2465
SC_4085	3	495
SC_4086	6	570
SC_4087	12	535
SC_4088	6	935
SC_4089	64	275
SC_4090	6	520
SC_4091	0.4	76
SC_4092	16	17
SC_4093	17	1000
SC_4094	23	1980
SC_4095	8	630
SC_4096	36	330
SC_4097	114	4355
SC_4098	395	96
SC_5061	705	6%@1μM
SC_5062	84	2925
SC_5063	690	4%@1μM
SC_5065	0%@1μM (DOP 40%)	13%@1μM
SC_5068	0%@1μM (KOP	8%@1μM

Example	hNOP Ki [nM]	hMOP Ki [nM] or % inhibition at 1M
	40%)	
SC_5075	10	305
SC_5080	24	230

[0440] **Protocol for [³⁵S]GTPγS functional NOP/MOP/KOP/DOP assays**

[0441] Cell membrane preparations of CHO- K1 cells transfected with the human MOP receptor (Art.-No. RBHOMM) or the human DOP receptor (Art.-No. RBHODM), and HEK293 cells transfected with the human NOP receptor (Art.-No. RBHORLM) or the human KOP receptor (Art.-No. 6110558) are available from PerkinElmer (Waltham, MA). Membranes from CHO-K1 cells transfected with the human nociceptin/orphanin FQ peptide (hNOP) receptor (Art.-No. 93-0264C2, DiscoverX Corporation, Fremont, CA) are also used. [³⁵S]GTPγS (Art.-No. NEG030H; Lot-No. #0112, #0913, #1113 calibrated to 46.25 TBq/mmol) is available from PerkinElmer (Waltham, MA).

[0442] The [³⁵S]GTPγS assays are carried out essentially as described by Gillen et al (2000). They are run as homogeneous scintillation proximity (SPA) assays in microtiter luminescence plates, where each well contains 1.5 mg of WGA-coated SPA-beads. To test the agonistic activity of test compounds on recombinant hNOP, hMOP, hDOP, and hKOP receptor expressing cell membranes from CHO-K1 or HEK293 cells, 10 or 5 μg membrane protein per assay are incubated with 0.4 nM [³⁵S]GTPγS and serial concentrations of receptor-specific agonists in buffer containing 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl₂, 1 mM EDTA, 1 mM dithiothreitol, 1.28 mM NaN₃, and 10 μM GDP for 45 min at room temperature. The microtiter plates are then centrifuged for 10 min at 830 to sediment the SPA beads. The microtiter plates are sealed and the bound radioactivity [cpm] is determined after a delay of 15 min by means of a 1450 Microbeta Trilux (PerkinElmer, Waltham, MA).


[0443] The unstimulated basal binding activity (UBS_{obs} [cpm]) is determined from 12 unstimulated incubates and is set as 100% basal binding. For determination of the potency and the efficacy, the arithmetic mean of the observed total [³⁵S]GTPγS binding (TB_{obs} [cpm]) of all incubates (duplicates) stimulated by the receptor-specific agonists (i.e. N/OFQ, SNC80, DAMGO, or U69,593) are transformed in percent total binding (TB_{obs} [%]) relative to the basal binding activity (i.e. 100% binding). The potency (EC₅₀) of the respective agonist and its maximal achievable total [³⁵S]GTPγS binding (TB_{calc} [%]) above its calculated basal binding (UBS_{calc} [%]) are determined from its transformed data (TB_{obs} [%]) by means of nonlinear regression analysis with XLfit for each individual concentration series. Then the difference between the calculated unstimulated [³⁵S]GTPγS binding (UBS_{calc} [%]) and the maximal achievable total [³⁵S]GTPγS binding (TB_{calc} [%]) by each tested agonist is determined (i.e. B1_{calc} [%]). This difference (B1_{calc} [%]) as a measure of the maximal achievable enhancement of [³⁵S]GTPγS binding by a given agonist is used to calculate the relative efficacy of test compounds versus the maximal achievable enhancement by a receptor-specific full agonist, e.g. N/OFQ (B1_{calc-N/OFQ} [%]) which is set

as 100% relative efficacy for the hNOP receptor. Likewise, the percentage efficacies of test compounds at the hDOP, hMOP, or hKOP receptor are determined versus the calculated maximal enhancement of [³⁵S]GTPγS binding by the full agonists SNC80 ($B_{1\text{calc-SNC80}}$ [%]), DAMGO ($B_{1\text{calc-DAMGO}}$ [%]) and U69,593 ($B_{1\text{calc-U69,593}}$ [%]) which are set as 100% relative efficacy at each receptor, respectively.

[0444] The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the appended claims and equivalents thereof.

Patent claims:

1. A compound according to general formula (I)



wherein

R¹ and **R²** independently of one another mean

-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH₃, -CN and -CO₂CH₃;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH₃, -CN and -CO₂CH₃; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -OH, -OCH₃, -CN and -CO₂CH₃; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted;

or

R¹ and **R²** together with the nitrogen atom to which they are attached form a ring and mean -(CH₂)₃₋₆-; -(CH₂)₂-O-(CH₂)₂-; or -(CH₂)₂-NR^A-(CH₂)₂-, wherein **R^A** means -H or -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br and -I;

R³ means

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

R⁴ means

-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said -C₁-C₆-alkyl is optionally connected through -C(=O)-, -C(=O)O-, or -S(=O)₂-;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH₂-, or -S(=O)₂-;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH₂-, or -S(=O)₂-;

a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6-14-membered aryl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH₂-, or -S(=O)₂-; or

a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5-14-membered heteroaryl moiety is optionally connected through -C(=O)-, -C(=O)O-, -C(=O)O-CH₂-, or -S(=O)₂-;

R⁵ means


-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or

a moiety according to general formula (X);



R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ independently of one another mean -H, -F, -Cl, -Br, -I, -OH, or -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted;

wherein "mono- or polysubstituted" means that one or more hydrogen atoms are replaced by a substituent independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -**R²¹**, -C(=O)**R²¹**, -C(=O)OR²¹, -C(=O)NR²¹**R²²**, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, =O, -OR²¹, -OC(=O)**R²¹**, -OC(=O)OR²¹, -OC(=O)NR²¹**R²²**, -NO₂, -NR²¹**R²²**, -NR²¹-(CH₂)₁₋₆-C(=O)**R²²**, -NR²¹-(CH₂)₁₋₆-C(=O)OR²², -NR²³-(CH₂)₁₋₆-C(=O)NR²¹**R²²**, -NR²¹C(=O)**R²²**, -NR²¹C(=O)-OR²², -NR²³C(=O)NR²¹**R²²**, -NR²¹S(=O)₂**R²²**, -SR²¹, -S(=O)**R²¹**, -S(=O)₂**R²¹**, -S(=O)₂OR²¹, and -S(=O)₂NR²¹**R²²**;

wherein

R²¹, R²² and R²³ independently of one another mean

-H;

-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, and -O-C₁-C₆-alkyl;

a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, -C₁-C₆-alkyl and -O-C₁-C₆-alkyl;

a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched,

saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, -C₁-C₆-alkyl and -O-C₁-C₆-alkyl;

a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, -C₁-C₆-alkyl and -O-C₁-C₆-alkyl;

a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -NH₂, -C₁-C₆-alkyl and -O-C₁-C₆-alkyl;

or **R**²¹ and **R**²² within -C(=O)NR²¹R²², -OC(=O)NR²¹R²², -NR²¹R²², -NR²³-(CH₂)₁₋₆-C(=O)NR²¹R²², -NR²³C(=O)NR²¹R²², or -S(=O)₂NR²¹R²² together with the nitrogen atom to which they are attached form a ring and mean -(CH₂)₃₋₆-; -(CH₂)₂-O-(CH₂)₂-; or -(CH₂)₂-NR^B-(CH₂)₂-, wherein **R**^B means -H or -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br and -I;







or a physiologically acceptable salt thereof.











2. The compound according to claim 1, wherein **R**¹¹, **R**¹², **R**¹³, **R**¹⁴, **R**¹⁵, **R**¹⁶, **R**¹⁷, **R**¹⁸, **R**¹⁹, and **R**²⁰ independently of one another mean -H, -F, -OH, or -C₁-C₆-alkyl.
3. The compound according to claim 1 or 2, wherein **R**¹ means -H; and **R**² means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
4. The compound according to claim 1 or 2, wherein **R**¹ means -CH₃; and **R**² means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
5. The compound according to claim 1 or 2, wherein **R**¹ means -H or -CH₃; and wherein **R**² means -CH₂-cycloalkyl, -CH₂-cyclobutyl, -CH₂-cyclopentyl, -CH₂-oxetanyl or -CH₂-tetrahydrofuryl.
6. The compound according to claim 1 or 2, wherein **R**¹ and **R**² together with the nitrogen atom to which they are attached form a ring and mean -(CH₂)₃₋₆-.
7. The compound according to any of the preceding claims, wherein **R**³ means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
8. The compound according to any of claims 1 to 6, wherein **R**³ means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted.






9. The compound according to any of claims 1 to 6, wherein **R³** means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
10. The compound according to any of the preceding claims, wherein **R⁴** means -H.
11. The compound according to any of claims 1 to 9, wherein **R⁴** means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
12. The compound according to any of claims 1 to 9, wherein **R⁴** means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
13. The compound according to any of claims 1 to 9, wherein **R⁴** means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
14. The compound according to any of claims 1 to 9, wherein **R⁴** means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
15. The compound according to any of claims 1 to 9, wherein **R⁴** means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
16. The compound according to any of the preceding claims, wherein **R⁵** means -H.
17. The compound according to any of claims 1 to 15, wherein **R⁵** means -C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl and -S(=O)₂C₁-C₄-alkyl.
18. The compound according to any of claims 1 to 15, wherein **R⁵** means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, -C₁-C₄-alkyl, -C₁-C₄-alkyl-OH, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)C₁-C₄-alkyl, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -NH₂, -NHC₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NC₁-C₄-alkylC(=O)C₁-C₄-alkyl, -

$S(=O)C_1-C_4$ -alkyl and $-S(=O)_2C_1-C_4$ -alkyl; wherein said 3-12-membered cycloalkyl moiety is optionally connected through $-C_1-C_6$ -alkylene-, linear or branched, saturated or unsaturated, unsubstituted.

19. The compound according to any of claims 1 to 15, wherein R^5 means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, $-C_1-C_4$ -alkyl, $-C_1-C_4$ -alkyl-OH, $-O-C_1-C_4$ -alkyl, $-O-(CH_2CH_2-O)_{1-30}-H$, $-O-(CH_2CH_2-O)_{1-30}-CH_3$, $-C(=O)OH$, $-C(=O)C_1-C_4$ -alkyl, $-C(=O)OC_1-C_4$ -alkyl, $-C(=O)NH_2$, $-C(=O)NHC_1-C_4$ -alkyl, $-C(=O)N(C_1-C_4-alkyl)_2$, $-NH_2$, $-NHC_1-C_4$ -alkyl, $N(C_1-C_4-alkyl)_2$, $-NHC(=O)-C_1-C_4$ -alkyl, $-NC_1-C_4$ -alkyl $C(=O)C_1-C_4$ -alkyl, $-S(=O)C_1-C_4$ -alkyl and $-S(=O)_2C_1-C_4$ -alkyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through $-C_1-C_6$ -alkylene-, linear or branched, saturated or unsaturated, unsubstituted.
20. The compound according to any of the preceding claims, which has a structure according to any of general formulas (II-A) to (VIII-C):







wherein in each case


R¹, **R²**, **R³**, **R⁴**, and **R⁵** are defined as in any of the preceding claims,






















R^C means -H, -OH, -F, -CN or -C₁-C₄-alkyl;




















R^D means -H or -F;



















or a physiologically acceptable salt thereof.



21. The compound according to any of the preceding claims, wherein **R⁵** is selected from the group consisting of:











22. The compound according to any of the preceding claims, wherein

R¹ means -H or -CH₃;

R² means -C₁-C₆-alkyl, linear or branched, saturated, unsubstituted;

R³ means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -CN, -CH₃, -CH₂CH₃, -CH₂F, -CHF₂, -CF₃, -OCF₃, -OH, -OCH₃, -C(=O)NH₂, C(=O)NHCH₃, -C(=O)N(CH₃)₂, -NH₂, -NHCH₃, -N(CH₃)₂, -NHC(=O)CH₃, -CH₂OH, SOCH₃ and SO₂CH₃; or

R⁴ means

-H;

-C₁-C₆-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, =O, -S(=O)₂-C₁-C₄-alkyl and -O-C₁-C₄-alkyl;

3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl, wherein said 3-6-membered cycloalkyl is connected through -C₁-C₆-alkylene;

3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl is optionally connected through -C₁-C₆-alkylene-, unsubstituted or substituted with =O;

6-14-membered aryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, -OH, and -O-C₁-C₄-alkyl; wherein said 6-14-membered aryl is optionally connected through -C₁-C₆-alkylene- or -S(=O)₂-;

R⁵ means

-H;


-C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, =O, -OH, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)C₁-C₄-alkyl, -C(=O)OC₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl, -S(=O)₂C₁-C₄-alkyl, -NH₂, -NH-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NH-S(=O)₂C₁-C₄-alkyl; or

3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, =O, -OH, -C₁-C₄-alkyl, -C₁-C₄-alkyl-OH, -NH₂, -NH-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NHS(=O)₂-C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)C₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl, -S(=O)₂C₁-C₄-alkyl, -phenyl, -C(=O)-phenyl, -C(=O)-pyridyl, -pyridyl, -thiazolyl, -N-methyldiazolyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered cycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or

3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of -F, -Cl, -Br, -I, -CN, =O, -OH, -C₁-C₄-alkyl, -NH₂, -NH-C₁-C₄-alkyl, -N(C₁-C₄-alkyl)₂, -NHC(=O)-C₁-C₄-alkyl, -NHS(=O)₂-C₁-C₄-alkyl, -O-C₁-C₄-alkyl, -O-(CH₂CH₂-O)₁₋₃₀-H, -O-(CH₂CH₂-O)₁₋₃₀-CH₃, -C(=O)OH, -C(=O)OC₁-C₄-alkyl, -C(=O)C₁-C₄-alkyl, -C(=O)NH₂, -C(=O)NHC₁-C₄-alkyl, -C(=O)N(C₁-C₄-alkyl)₂, -S(=O)C₁-C₄-alkyl, -S(=O)₂C₁-C₄-alkyl, -phenyl, -C(=O)-phenyl, -C(=O)-pyridyl, -pyridyl, -thiazolyl, -N-methyldiazolyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through -C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; and

R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ mean -H.


23. The compound according to any of the preceding claims, which has a structure according to general formula (I')



wherein **R¹ to R⁵, R¹⁰ to R²⁰** are defined as in any of the preceding claims,

or a physiologically acceptable salt thereof.

24. The compound according to any of the preceding claims, which has a structure according to general formula (IX)



wherein

R^C means -H or -OH;

R^3 means -phenyl or -3-fluorophenyl;

R^5 means

C_1 - C_6 -alkyl, linear or branched, saturated, unsubstituted or monosubstituted with -OH, -CN, -NH₂, -NHC(=O) C_1 - C_4 -alkyl, -NHS(=O)₂- C_1 - C_4 -alkyl, or -S(=O)₂- C_1 - C_4 -alkyl; or

3-6-membered heterocycloalkyl, saturated, unsubstituted or substituted with -OH; wherein said 3-6-membered heterocycloalkyl is optionally connected through -CH₂- or -(CH₂)₂;

or a physiologically acceptable salt thereof.

25. The compound according to claim 24, wherein the 3-6-membered heterocycloalkyl is selected from the group consisting of oxetan-1-yl, tetrahydrofuran-2-yl and tetrahydropyran-2-yl.
26. The compound according to any of the preceding claims, which is selected from the group consisting of
- CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyramide;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(2-methoxy-ethoxy)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-(Cyclobutyl-methyl)-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile;
- CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methyl-butyramide;
- CIS-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-methyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-3-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile;
- CIS-2-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile;
- CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(tetrahydro-pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;
- CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-3-(3-Chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;
- CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyric acid methyl ester;

CIS-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile;

CIS-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile;

CIS-3-Acetyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

CIS-1-Acetyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-1-(oxetan-3-yl-methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-1-(3-methoxy-propyl)-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-8-phenyl-1-(p-tolylsulfonyl)-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-3-[(1,1-dioxo-thian-4-yl)-methyl]-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-tetrahydro-pyran-4-yl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-tetrahydro-pyran-4-yl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-[[8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]-cyclobutane-1-carbonitrile;

CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(1,1-dioxo-thian-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-3-(1,1-dioxo-thian-4-yl)-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-3-(1-Acetyl-piperidin-4-yl)-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-3-(1-Benzoyl-piperidin-4-yl)-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(4-hydroxy-tetrahydro-pyran-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-3-[(1-Acetyl-piperidin-4-yl)-methyl]-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-piperidin-4-yl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-hydroxy-2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-phenyl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one;

CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(piperidin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one;

CIS-3-(1-Benzoyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

CIS-8-Dimethylamino-8-phenyl-3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one;

CIS-3-(1-Acetyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;


CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;

CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one;


and the physiologically acceptable salts thereof.

27. The compound according to any of the preceding claims for use in the treatment of pain.
28. A medicament comprising a compound according to any of the preceding claims.

29. A compound according to general formula (IIIa) or (IIIb),



(IIIa)



(IIIb)

wherein

R¹, **R²** and **R³** are defined as in any of the preceding claims; and

PG is a protecting group;

or a physiologically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2017/025008

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D235/02 A61K31/4166 A61P25/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BIGNAN G C ET AL: "Recent advances towards the discovery of ORL-1 receptor agonists and antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 15, no. 4, 1 January 2005 (2005-01-01), pages 357-388, XP002393017, ISSN: 1354-3776, DOI: 10.1517/13543776.15.4.357 page 378, left-hand column - page 380, right-hand column; figure 15 -----	1-29
A	WO 2009/118168 A1 (GRUENENTHAL GMBH [DE]; NOLTE BERT [DE]; SCHROEDER WOLFGANG [DE]; LINZ) 1 October 2009 (2009-10-01) cited in the application page 137 - page 140; claims 1,8-10 ----- -/-	1-29



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 February 2017

Date of mailing of the international search report

28/02/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Härtinger, Stefan

INTERNATIONAL SEARCH REPORT

International application No

PCT/EP2017/025008

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2004/043967 A1 (GRUENENTHAL GMBH [DE]; HINZE CLAUDIA [DE]; AULENBACHER OTTO [DE]; SUND) 27 May 2004 (2004-05-27) cited in the application page 66 - page 75; claims 1,16-18 -----	1-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2017/025008

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2009118168	A1	01-10-2009	AR	074615	A1	02-02-2011
			AU	2009228642	A1	01-10-2009
			CA	2719735	A1	01-10-2009
			CN	102046595	A	04-05-2011
			CN	103183630	A	03-07-2013
			CN	103214376	A	24-07-2013
			CO	6251240	A2	21-02-2011
			EC	SP10010533	A	30-11-2010
			EP	2260021	A1	15-12-2010
			EP	2502907	A1	26-09-2012
			EP	2518052	A1	31-10-2012
			ES	2464102	T3	30-05-2014
			HK	1149257	A1	15-08-2014
			IL	219529	A	30-06-2015
			IL	219530	A	31-08-2015
			JP	5674635	B2	25-02-2015
			JP	5674722	B2	25-02-2015
			JP	5674723	B2	25-02-2015
			JP	2011517668	A	16-06-2011
			JP	2012188457	A	04-10-2012
			JP	2012254987	A	27-12-2012
			KR	20100136521	A	28-12-2010
			KR	20120075499	A	06-07-2012
			KR	20120075500	A	06-07-2012
			NZ	588779	A	29-06-2012
			NZ	600207	A	27-09-2013
			NZ	600210	A	30-08-2013
			PE	13132012	A1	07-10-2012
			PE	13142012	A1	07-10-2012
			PE	16892009	A1	21-11-2009
			RU	2010143438	A	10-05-2012
			RU	2012120387	A	27-11-2013
			RU	2012120389	A	27-11-2013
			US	2009247530	A1	01-10-2009
			US	2012202810	A1	09-08-2012
			US	2013197095	A1	01-08-2013
			US	2014357634	A1	04-12-2014
			WO	2009118168	A1	01-10-2009
			ZA	201007647	B	28-03-2012

WO 2004043967	A1	27-05-2004	AR	041932	A1	01-06-2005
			AR	074529	A2	26-01-2011
			AT	441650	T	15-09-2009
			AU	2003296563	A1	03-06-2004
			AU	2010200219	A1	11-02-2010
			BR	0315296	A	30-08-2005
			CA	2505555	A1	27-05-2004
			CN	1735619	A	15-02-2006
			CN	101693714	A	14-04-2010
			CO	5580765	A2	30-11-2005
			CY	1110558	T1	29-04-2015
			DE	10252667	A1	27-05-2004
			DK	1560835	T3	04-01-2010
			DK	2062898	T3	28-10-2013
			EC	SP055786	A	11-08-2005
			EP	1560835	A1	10-08-2005
			EP	2062898	A2	27-05-2009
			EP	2116544	A2	11-11-2009

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP2017/025008

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EP 2233487 A1	29-09-2010
		ES 2333956 T3	03-03-2010
		ES 2438269 T3	16-01-2014
		ES 2587013 T3	20-10-2016
		ES 2587185 T3	21-10-2016
		HK 1080478 A1	12-03-2010
		HK 1130491 A1	24-01-2014
		IL 168473 A	31-10-2012
		IL 203141 A	30-04-2012
		JP 4728645 B2	20-07-2011
		JP 5442565 B2	12-03-2014
		JP 5539821 B2	02-07-2014
		JP 2006508114 A	09-03-2006
		JP 2010006815 A	14-01-2010
		JP 2010270155 A	02-12-2010
		JP 2011016829 A	27-01-2011
		KR 20050074579 A	18-07-2005
		KR 20090129521 A	16-12-2009
		MX PA05004959 A	02-08-2005
		NO 331776 B1	26-03-2012
		NO 331818 B1	10-04-2012
		NZ 540575 A	30-11-2007
		PE 08302004 A1	17-11-2004
		PL 215227 B1	29-11-2013
		PL 217804 B1	29-08-2014
		PT 1560835 E	10-12-2009
		PT 2062898 E	22-10-2013
		RU 2354656 C2	10-05-2009
		SI 1560835 T1	29-01-2010
		SI 2062898 T1	29-11-2013
		US 2006004034 A1	05-01-2006
		US 2009156626 A1	18-06-2009
		US 2009163716 A1	25-06-2009
		US 2010240897 A1	23-09-2010
		US 2011319440 A1	29-12-2011
		US 2015322080 A1	12-11-2015
		WO 2004043967 A1	27-05-2004
		ZA 200504725 B	30-08-2006
